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Abstract 
Colorectal cancer (CRC) is the third most common cancer worldwide with over a 
million new cases each year. Eighty percent of CRC cases have no genetic 
predisposition and result from a series of epigenetic and genetic alterations, 
referred to as ‘sporadic’ CRC. Diets rich in red or processed meats (containing 
dietary carcinogens) as well as bowel inflammation are a major risk factors for 
disease, however the underlying mechanisms are not yet well understood. 
Upregulation of pro-inflammatory cytokines and cytochrome P450 (CYP450) 
enzymes that activate dietary carcinogens as well as microRNA (miRNA) 
dysregulation have been observed in CRC tissue. Interleukin-6 (IL6) is a 
multifunctional cytokine thought to play numerous roles in tumour progression 
including activation of tumour-promoting signalling pathways, epigenetic gene 
regulation and alteration of DNA repair mechanisms; thus presence of IL6 may 
be key to promoting CRC tumour progression. I hypothesised that elevated 
levels of IL6 in the tumour microenvironment (TME) could alter miRNA 
expression and induce local activation of dietary carcinogens, thereby 
stimulating epigenetic and genetic changes that promote CRC. The current 
project investigated this hypothesis using a mechanistic approach with in vitro 
cell culture techniques. Phenotypic changes in response to IL6 treatment were 
observed and the underlying causes were determined by performing genetic and 
epigenetic studies. The findings from this project identified three potential 
mechanisms of IL6-mediated CRC promotion, which involve miRNAs, STAT3 
signalling and DNA methylation. First, IL6 promoted dietary carcinogen-
mediated DNA damage by inducing CYP450 expression. Second, IL6 stimulated 
CRC cell proliferation, migration and invasion through gene and miRNA 
Abstract 
 - 3 - 
expression changes. Third, IL6- mediated CRC-immune cell crosstalk in the 
TME resulting in the maintenance of IL6 secretion. Taken together, these data 
suggest that IL6 plays multiple roles in promoting CRC. Understanding these 
molecular events could lead to better prevention and therapeutic strategies. 
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1.1 Colorectal cancer, a lifestyle disease? 
Colorectal cancer (CRC) is the term used to describe a cancer originating in the 
epithelium lining of the large intestine, which is divided into two parts: colon 
and rectum (Figure 1.1 A).  The large intestine is the final part of the digestive 
tract measuring approximately 1.5 meters in the human adult. Its role is to 
absorb vitamins and water from solid food waste prior to excreting the 
unwanted excess as stools. The epithelium lining of the large intestine is 
composed of a series of crypts each containing stem cells at their base, which 
divide and differentiate while moving along the crypt into various epithelial cell 
types: colonocytes, mucous-secreting goblet cells, peptide hormone-secreting 
endocrine cells and the antibacterial protein-secreting Paneth cells (Figure 1.1 
B). Once at the top of the crypt, these differentiated cells undergo apoptosis and 
are shed by the colon. On average, 1x1010 colon epithelial cells are discarded 
each day and to replace these, transient cells must proliferate rapidly, thus 
increasing the possibility for cell division errors leading to mutations and higher 
risk of cancer development (Humphries & Wright 2008; Tomasetti & Vogelstein 
2015). An accumulation of these events is thought to result in aberrant cell 
growth and tumour formation. 
Chapter 1 
	   -23- 
 
Figure 1.1 Large intestine and crypt architecture. (A) Diagram of large 
intestine with percentage of the colorectal cancer case occurrence at each site, 
adapted from Cancer Research UK, 2014. (B) Colonic crypt structure, adapted 
from Humphries & Wright 2008. 
CRC is the third most common cancer worldwide; occurrence rates are highest 
in Australia/New Zealand while Western Africa has the lowest rates (Midgley & 
Kerr 1999). Migration from low occurrence countries to countries with a 
Western culture increases incidence rates. CRC thus appears to be linked to 
Western culture, suggesting lifestyle plays an important role in disease risk 
(Haggar & Boushey 2009). In the UK alone, around 41,000 new cases of CRC 
were diagnosed in 2011 with a male to female ratio of 13:10, making it the fourth 
most common cancer in the country. The disease accounts for 10% of all cancer 
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deaths in the UK and 8% worldwide (Cancer Research UK 2014), and thus 
presents a major global health burden. As for the majority of cancers, early 
diagnosis is key to patient survival. While 5-year survival rate for local stage 
disease is high (90%), this rate drops to 12% when disease has metastasised 
(Cancer Research UK 2014). More importantly, overall CRC survival rates have 
not seen any significant improvement in the last 20 years highlighting the need 
for better preventive measures and diagnosis techniques, which currently rely 
on colonoscopies and faecal occult tests. Further understanding of the specific 
mechanisms involved in carcinogenesis is key to developing novel strategies to 
improve patient outcome. 
Most cases of CRC (around 90%) start off as a benign growth on the intestinal 
wall called a polyp or adenoma, which if left untreated can become cancerous 
over time through a series of genetic and epigenetic changes, a process known 
as carcinogenesis (Figure 1.2). In the multi-step model proposed by Vogelstein 
and co-workers (Fearon & Vogelstein 1990), cellular transformation from 
normal to malignant requires a succession of changes in different gene 
activities, each conferring a selective advantage to the transformed cell resulting 
in clonal expansion and tumour formation. Most human cancers are thought to 
be caused by 2-8 changes that develop over 20-30 years (Vogelstein et al. 2013). 
Genes involved in this process regulate key cellular events such as division, DNA 
repair and apoptosis. These can either be aberrantly activated (conversion of 
proto-oncogenes to oncogenes) or inappropriately silenced (tumour-suppressor 
genes) depending on the functional outcome of their deregulation. Regulation of 
these gene activities may occur by point-mutation, gene amplification, 
chromosome loss or epigenetic mechanisms.  
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Figure 1.2 Vogelstein’s multi-step genetic model for sporadic 
colorectal cancer development. APC mutation resulting in Wnt activation 
in transient proliferating cells leads to dysplasia. Further genetic alterations in 
KRAS and Smad2/4 leads to further adenoma growth. Loss of p53 function 
results in carcinoma and further genetic changes leads to tumour metastasis. 
Adapted from Rajagopalan, Nowak, Vogelstein, & Lengauer 2003. 
The inactivation of tumour-suppressor genes is believed to predominate over 
the activation of oncogenes (Fearon & Vogelstein 1990). Indeed, an early event 
in colorectal tumourigenesis is thought to be the loss-of-function mutation of 
the adenomatous polyposis coli (APC) gene (in 85% of cases), which leads to 
the formation of polyps. Further alterations are required for the polyps to 
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progress to malignancy. These include activation of the KRAS oncogene and p53 
tumour-suppressor gene inactivation through mutation. KRAS mutation in a 
single allele suffices to promote activity and appears in 50% of CRC tumours 
(Hanahan & Weinberg 2000; Fearon & Vogelstein 1990), while p53 mutation 
confers resistance to apoptosis (Hollstein et al. 1991; Fearon & Vogelstein 1990). 
The latter occurs not only in CRC but also in the majority of solid tumours 
(Hollstein et al. 1991). This multi-step genetic model for CRC initiation was first 
established by the pioneering works of Professor Bert Vogelstein and colleagues 
in the 1980s (Fearon & Vogelstein 1990; Cho & Vogelstein 1992; Cummins et al. 
2006). Once established, the primary tumour is thought to undergo further 
genetic and epigenetic alterations resulting in tumour progression and 
metastasis (Fearon & Vogelstein 1990).  More recently, a study by Tomasetti 
and Vogelstein demonstrated a strong positive correlation between number of 
stem cell divisions in a particular tissue and lifetime risk of cancer in that tissue, 
suggesting that the majority of mutations required for cancer development 
result from errors in DNA replication, with the rest of the mutations being 
caused by hereditary or environmental factors (Tomasetti & Vogelstein 2015).  
Risk factors for CRC are various and genetic predisposition accounts for only 
6% of cases (Rustgi 2007). The two major subtypes of hereditary CRC are 
hereditary non-polyposis colorectal cancer (also known as Lynch syndrome) 
and familial adenomatous polyposis, each caused by germline mutations in 
genes involved in the DNA mismatch-repair pathway and APC respectively 
(Midgley & Kerr 1999). However, the vast majority of CRC cases arise 
sporadically. While DNA replication errors are the primary source of de novo or 
non-inherited genetic changes responsible for cancer (Tomasetti & Vogelstein 
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2015), environmental factors also contribute to generating mutations in the cells 
lining the colorectal epithelial wall (Fearon & Vogelstein 1990). An astounding 
90% of CRC cases occur in individuals aged above 50 years (Haggar & Boushey 
2009), highlighting age as a key factor for disease, which supports Vogelstein’s 
multi-step progressive model for colorectal carcinogenesis. Nonetheless, other 
risk factors for disease linked to lifestyle are modifiable such as lack of physical 
activity, obesity with abdominal fatness, type 2 diabetes, cigarette smoking, and 
most importantly dietary habits (Tenesa & Dunlop 2009), thus making disease 
prevention possible, at least in theory.  
Diets rich in animal fat and processed meat are thought to strongly promote 
development of CRC as well as high consumption of alcohol, while dietary fibre 
and fruit/vegetable intake are believed to prevent disease (Midgley & Kerr 1999; 
Chao et al. 2005). In addition, it is estimated that changes in nutritional 
practices could reduce CRC incidence by up to 70% (Haggar & Boushey 2009), 
further highlighting the critical contribution of diet to disease risk and the 
potential to exploit this understanding for preventing disease. 
Diet may also contribute to colonic inflammation, another important risk factor 
for disease. Western-style diets, characterised by high-fat and low fibre content, 
have been shown to induce oxidative stress, macrophage recruitment and 
secretion of inflammatory proteins in the colon (Erdelyi et al. 2009). 
Furthermore, individuals with a chronic bowel inflammation such as 
inflammatory bowel disease (IBD) including ulcerative colitis and Crohn’s 
disease are 70% more susceptible to getting CRC than healthy individuals 
(Feagins et al. 2009). This risk is increased with duration of IBD and extent of 
inflammation. Mechanisms underlying the link between IBD and development 
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of CRC remain unclear. However, production of reactive oxygen species and 
increased levels of pro-inflammatory cytokines are thought to be involved with 
aberrant interleukin-6 (IL6) signalling playing a key role in IBD pathogenesis 
(Scheller et al. 2006; Li et al. 2010). This is evidenced through reports of 
antibody-mediated inhibition of IL6 being sufficient to suppress chronic colonic 
inflammation in Crohn’s disease (Ito et al. 2004). IL6 has also been implicated 
in promoting cancer development and progression, further corroborating its 
potential involvement in sporadic CRC. 
Interestingly, non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin 
have been reported to reduce CRC risk by 40-50% (Smalley et al. 1999; 
Williams et al. 1997). More recently, large-scale epidemiological studies led by 
Professor Peter Rothwell have reported that daily intake of aspirin not only 
decreases the risk of cancer development, it also reduces the risk of metastasis 
and cancer-related mortality (Rothwell et al. 2011; Rothwell, Wilson, et al. 
2012; Rothwell, Price, et al. 2012; Algra & Rothwell 2012). Importantly, these 
benefits were not only observed with long-term aspirin use, but were also 
detected as from 3 years onward, demonstrating that short-term use can be 
beneficial as well (Rothwell, Price, et al. 2012). Furthermore, these studies 
found that CRC risk was the most markedly reduced by daily aspirin intake 
(Rothwell, Wilson, et al. 2012; Algra & Rothwell 2012), further highlighting the 
importance of inflammation in CRC development.  
Therefore, even though a multitude of factors are involved in CRC development, 
environment does appear to play a significant role. Importantly, some of the 
lifestyle-linked factors are preventable, however prevention in order to be 
effective requires a profound understanding of the mechanisms involved. 
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1.2 Dietary carcinogens and cytochrome P450 enzymes, mediators 
of CRC carcinogenesis? 
As the colon is part of the digestive system, it is particularly susceptible to 
carcinogens present in the diet and over the last few decades, numerous 
epidemiological studies have reported a significant correlation between high 
consumption of red and processed meats, known sources of dietary carcinogens, 
to increased incidence of CRC (Chao et al. 2005). The method of cooking the 
meats, such as frying at high temperatures and formation of a heavily browned 
surface, has also been shown to increase risk of CRC. Commonly occurring 
dietary carcinogens include benzo[a]pyrene (BaP) and 2-amino-1-methyl-6-
phenylimidazo[4,5-b]pyridine (PhIP) (Creton et al. 2007; Irigaray et al. 2006). 
These compounds are considered carcinogenic due to their ability to form DNA 
adducts, resulting in DNA damage and mutations. They are known as pro-
carcinogens as they require metabolic activation to their respective DNA-
damaging agents by cytochrome P450 (CYP) enzymes (Figure 1.3; Gooderham 
et al. 2007; Lodovici et al. 2004).  
BaP is a five-ring polycyclic aromatic hydrocarbon generated during the 
combustion of organic compounds and is commonly found in motor fumes, 
cigarette smoke and cooked meats (Lodovici et al. 2004). It is thought to be 
involved in tobacco- and diet-associated cancers due to its mutagenic potential. 
Like many carcinogens, it is activated into its genotoxic compound, 7,8-diol-
9,10-epoxy BaP, by CYP1 A1, A2 and B1 (Figure 1.3). The activated molecule 
covalently binds DNA at the N2 atoms in guanine residues thus disrupting the 
double-helical structure, which results in DNA damage including double-strand 
breaks, deletions and points mutations (Lodovici et al. 2004; Trushin et al. 
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2012). Furthermore, BaP exposure has been shown to induce an inflammatory 
response as well as promote cell proliferation through gene expression changes 
(Albert et al. 1996; Volkov & Kobliakov 2011; Ouyang et al. 2007; Hockley et al. 
2007). It is thought that 7,8-diol-9,10-epoxy BaP can alter gene expression by 
activating a number of transcription factors including NFκB, AP1 and the aryl 
hydrocarbon receptor (AhR) pathway (Ouyang et al. 2007; Hockley et al. 2007).  
PhIP is the most abundant heterocyclic amine found primarily in meats cooked 
at high temperatures, particularly fish, chicken and beef (Murray et al. 1993). As 
with BaP, it is activated by CYP1 A1, A2 and B1 enzymes into its mutagenic 
compound, N-hydroxy PhIP (Figure 1.3; Gooderham et al. 2001; Buonarati & 
Felton 1990). N-hydroxy PhIP can then be esterified by sulphur transferase or 
acetyl transferase. This activated PhIP can intercalate DNA and covalently bind 
the C8 atom in guanine residues resulting in DNA adducts and mutations 
(Buonarati & Felton 1990). Interestingly, epidemiological studies have found 
correlations between meat consumption, PhIP intake, and colon, breast and 
prostate cancers (Chao et al. 2005; Sinha et al. 2005; Cross et al. 2005; Sinha et 
al. 2000), and PhIP-DNA adducts have been detected in these tissues (Tang et 
al. 2007; Malfatti et al. 2006; Zhu et al. 2003), supporting its role as a mutagen 
in these tissue types. It has also been shown to induce breast cancer cell 
invasion (Lauber & Gooderham 2011) and have oestrogenic activity 
(Papaioannou et al. 2014; Lauber et al. 2004). PhIP can also activate tumour-
promoting signalling pathway MAPK/ERK, resulting in increased cell 
proliferation and migration (Creton et al. 2007; Gooderham et al. 2007; Lauber 
et al. 2004; Lauber & Gooderham 2007).  
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While the ability for these dietary carcinogens to induce DNA damage is thought 
to be primarily associated with cancer initiation stages, their ability to alter key 
cellular signalling pathways is linked to promoting tumour progression (Ouyang 
et al. 2007). Therefore, these compounds are involved in all cancer stages. 
 
 
Figure 1.3 Dietary pro-carcinogens BaP and PhIP activation 
pathways. BaP is metabolised by CYP1A/1B to generate 7,8-epoxy BaP, which 
is converted into 7,8-diole BaP. The latter is again metabolised by CYP1A/1B to 
form the genotoxic product 7,8-diol-9,10-epoxy BaP. CYP1A/1B enzymes 
metabolise PhIP into N-hydoxy PhIP, which is converted into acetoxy and 
sulphonyloxy esters by sulphur/acetyl transfecrases. Adapted from Gooderham 
et al. 2001 and Trushin et al. 2012. 
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The CYP450 superfamily of enzymes is subdivided into 18 families. There are 57 
active CYP450 genes in the human genome (Sim & Ingelman-Sundberg 2010). 
CYP450 enzymes catalyse oxidative reactions and display a broad substrate 
specificity allowing them to metabolise a variety of endogenous substrates, 
drugs and xenobiotics resulting in either their bioactivation or deactivation. The 
first three families (CYP1-3) are responsible for metabolising exogenous 
chemicals, whereas the other CYP450 families generally metabolise endogenous 
substrates (Sim & Ingelman-Sundberg 2010). While most CYP450s are 
primarily expressed in the human liver, CYP2E1, CYP1B1 and CYP1A1 (known to 
activate dietary carcinogens) are found in CRC tissue (Patel et al. 2014; 
McFadyen et al. 2004; Murray et al. 1997). CYP450 enzymes have been 
implicated in cancer development and progression and are overexpressed in a 
variety of cancers including CRC (Murray et al. 1997; Gooderham et al. 2007; 
Braeuning et al. 2011; Kasai et al. 2013; Rodriguez & Potter 2013), suggesting 
they play an important role in CRC carcinogenesis.  
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1.3 The tumour microenvironment and its role in CRC progression. 
Tumours are surrounded by a variety of non-tumour cell types, which secrete 
signalling molecules into the tumour microenvironment (TME) including 
growth factors, chemokines and cytokines that activate key transcription factors 
to promote tumour progression. These non-tumour cells are genetically stable 
compared to cancer cells and are thus less likely to acquire resistance to 
therapy, making them attractive therapeutic targets (Mbeunkui & Johann 
2009). Understanding the complex intercellular interactions within the 
microenvironment is crucial for the development of cancer therapies that target 
the TME.  
Tumours are thought to reorganise their extracellular matrix (ECM) by 
secreting ECM degrading proteinases to allow tumour cells to proliferate and 
invade surrounding tissues (Lu et al. 2012; Pickup et al. 2014). The ECM is a 
complex network of proteins including proteoglycans and fibrous proteins such 
as collagen (Alberts et al. 2002). The composition of these different elements 
varies depending on tissue type and defines tissue structure. Organisation of the 
ECM is an important feature of the TME and ECM stiffness is characteristic of 
tumours (Lu et al. 2012). Its plasticity means it can readily be reorganised by 
tumour-secreted proteins, and as it also acts as a barrier for cell invasion, its 
remodelling is an essential step in cancer growth and metastasis (Lu et al. 2012; 
Pickup et al. 2014). Proteins that mediate this remodelling are secreted by 
tumour cells and include matrix metalloproteinases (MMPs), cathepsins and 
sulphatases (Azzam et al. 1993; Mott & Werb 2004; Gonzalez-Villasana et al. 
2015; Che et al. 2015; Yang et al. 2011; Mohamed & Sloane 2006). These 
proteinases can also target non-ECM proteins such as growth factors and 
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cytokines making their role within the microenvironment complex and versatile 
(Kessenbrock et al. 2010; Mbeunkui & Johann 2009).  
In addition, tumour cells secrete a variety of growth factors into the 
microenvironment including osteopontin, galectin-3 and TGFβ (Mbeunkui & 
Johann 2009). Osteopontin and galectin-3 are associated with metastatic 
disease in a variety of cancer types including CRC (Wu et al. 2013; Mole et al. 
2011), while TGFβ is known to inhibit early-stage CRC tumour growth but 
promote advanced CRC metastasis (Roberts & Wakefield 2003). TGFβ secretion 
by cancer cells also promotes recruitment of anti-inflammatory immune cells to 
tumour site, as well as activates adjacent fibroblasts, which differentiate into 
cancer-associated fibroblasts (CAFs) and promote tumourigenesis (Yeung et al. 
2013; Hawinkels et al. 2014; Calon et al. 2014). 
Fibroblasts are the major cell-type of the stroma and when differentiated into 
CAFs, they are crucial for tumour progression and metastasis of most cancer 
types including CRC (Mbeunkui & Johann 2009; Kalluri & Zeisberg 2006; 
Tommelein et al. 2015). In fact, CAFs have a variety of functions within the 
TME: they promote wound healing and control inflammation by regulating 
immune cell infiltration through cytokine and chemokine release such as TGFβ, 
IL6, IL1 and CCL2; they play an important role in ECM remodelling, as they 
secrete MMPs and contribute to ECM deposition by producing collagen 
(Mbeunkui & Johann 2009; Cirri & Chiarugi 2011); they are also involved in the 
epithelial-to-mesenchymal transition (EMT) of tumour cells, which promotes 
their ability to invade surrounding tissues, as well as angiogenesis, the 
formation of new blood vessels essential for tumour growth (Mbeunkui & 
Johann 2009; Cirri & Chiarugi 2011). 
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Rapid tumour growth results in hypoxic conditions in the TME, which triggers 
vascular endothelial growth factor (VEGF) release by pericytes, CAFs and 
tumour cells (Bhome et al. 2015). VEGF induces angiogenesis by promoting 
endothelial cell migration to the hypoxic regions and generation of new blood 
vessels. VEGF is also overexpressed in CRC tissue and expression correlates 
with patient survival (Cao et al. 2009), thus its presence in the TME appears to 
be important for CRC tumour progression. 
Once tumours have formed, they secrete chemokines and cytokines such as IL8, 
CCL2, IL6 and TNFα, which recruit innate and adaptive immune cells to the 
tumour site (Bhome et al. 2015; Vesely et al. 2011). These cells can have pro- 
and anti-tumour effects depending on their nature. Immunosurveillance 
mechanisms instigated by M1 macrophages, T-helper 1  (Th1) cells, cytotoxic T 
cells and Natural Killer cells (NK) can inhibit tumour progression, but tumours 
are able to manipulate the TME in order to evade this anti-tumour immune 
response by recruiting anti-inflammatory immune cells such as M2 
macrophages, regulatory T cells (Treg) and Th2 cells (Bhome et al. 2015; Vesely 
et al. 2011).  
Macrophages are a major component of the TME, and in some cases, they can 
represent more than 50% of the tumour mass (Lewis & Pollard 2006). 
Increased macrophage density is generally associated with poor prognosis 
(Tsutsui et al. 2005; Hamada et al.; Hanada et al. 2000; Mäkitie et al. 2001); 
however, in CRC, the amount of macrophage infiltrate correlates with a 
favourable prognosis (Zhou et al. 2010; Forssell et al. 2007). This may be due to 
the fact that macrophages are a very heterogenic population and depending on 
their nature, they can have different functions in tumourigenesis. The two major 
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subtypes are M1 and M2 macrophages. M1 cells are activated by microbial 
products and initiate a pro-inflammatory response by secretion of pro-
inflammatory cytokines such as TNFα, generation of reactive oxygen species 
(ROS) and cytotoxic activity against the cancer cells. M2 or ‘alternatively 
activated’ cells are generally immunosuppressive through release of anti-
inflammatory cytokines such as IL10, and are thought to promote tumour 
progression (Noy & Pollard 2014; Bhome et al. 2015; Balkwill & Mantovani 
2012; Mantovani & Sica 2010; Solinas et al. 2009). Profiling experiments on 
tumour-associated macrophages (TAMs) have demonstrated that the TAM 
population is very diverse and composed of various different subtypes but are 
more inclined toward an M2-like tumour-promoting phenotype (Ojalvo et al. 
2009; Ojalvo et al. 2010). Each subtype appears to be uniquely suited to 
perform specific tasks such as invasion, angiogenesis, immune surveillance and 
metastasis (Figure 1.4; Qian & Pollard 2010). Interestingly, TAMs have been 
found to populate pre-metastatic lesions producing a favourable environment 
for the establishment of metastases, also know as the ‘pre-metastatic niche’ 
(Joyce & Pollard 2009). 
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Figure 1.4 The macrophage population in the TME. Various different 
subtypes of macrophages exist in TME, each expressing a particular set of 
signals that have a well-defined role. These include activated macrophages (also 
known as M1), immunosuppressive or ‘alternatively activated’ macrophages 
(known as M2), angiogenic macrophages, metastatis-associated macrophages, 
perivascular macrophages and invasive macrophages. Adapted from Qian & 
Pollard 2010. 
As with macrophages, neutrophils can be divided into anti-tumour (N1) and 
pro-tumour (N2) subpopulations. N1 cells generate a cytotoxic response against 
the tumour cells, either directly or by recruiting cytotoxic T cells to the tumour 
site, while N2 cells promoted by TGFβ are characterised by high expression of 
CCL2, VEGF and MMP9, which contribute to tumour progression (Sionov et al. 
2014). 
Macrophages and neutrophils at the tumour site recruit and activate various 
types of T cells. Cytotoxic T cells mediate tumour cell growth arrest and killing 
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by releasing interferon gamma (IFNγ) and inducing tumour cell lysis 
(Matsushita et al. 2015). In early stages of CRC, the presence of cytotoxic T cells 
in and around the tumour has been shown to be a predictor of patient survival 
(Reissfelder et al. 2015), suggesting that therapies promoting cytotoxic T cell 
activity could be effective for treating CRC. On the other hand, Tregs are 
responsible for suppressing pro-inflammatory immune responses by secreting 
anti-inflammatory cytokines such as IL10 and TGFβ to inhibit the activity of 
cytotoxic T cells (Facciabene et al. 2012). Th cells are another T cell type present 
at the tumour site: Th1 cells are necessary of the activation of cytotoxic T cells, 
while activated Th2 cells mediate a response similar to wound healing, which 
promotes tumour progression (Knutson & Disis 2005; Bhome et al. 2015). More 
importantly, the immune landscape appears to evolve with tumour progression. 
In CRC, the innate immune cells increase with tumour stage while the adaptive 
T cell population decreases (Bindea et al. 2013).  
Therefore, it is apparent that the tumour fine-tunes its microenvironment to tip 
the balance towards pro-tumour signals by selectively manipulating the cell 
types and signals in its TME. An overview of the various cells types and signals 
in the TME is shown in Figure 1.5. Inflammatory signals including cytokine 
levels appear to be major contributors to this process. 
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Figure 1.5 Overview of the TME. Tumour cells secrete a variety of signals 
resulting in ECM remodelling, angiogenesis, CAF differentiation, immune 
infiltration and suppression of anti-tumour immune response.  
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1.4 IL6, a key player in CRC? 
Inflammation is part of the body’s defence mechanism against infection and 
injury for ‘self’ preservation. Detection of ‘non-self’ leads to activation of 
inflammatory pathways resulting in recruitment of immune cells that destroy 
any ‘non-self’ and promote wound healing through tissue regeneration. While 
acute inflammation is therapeutic, chronic activation of inflammatory pathways 
is detrimental. Indeed, the inflammatory response is tightly controlled through 
cytokine-driven communication inducing pro-inflammatory signals to promote 
healing and anti-inflammatory signals when inflammation is no longer needed 
(Hanada & Yoshimura 2002). Deregulation of this response leads to chronic 
inflammation resulting in disease including autoimmune disorders, 
cardiovascular disease, arthritis, type 2 diabetes, IBD and cancer.  
Over 150 years ago, Rudolf Virchow first hypothesised that inflammation plays a 
role in the development of cancer based on his observations that inflammatory 
cells infiltrate tumours (Balkwill & Mantovani 2001; Virchow 1863). In the last 
30 years, extensive research on the topic has validated this idea and rekindled 
the interest of researchers in the cancer field. Chronic inflammation is now 
thought to promote various stages of carcinogenesis including cellular 
transformation, proliferation and survival, angiogenesis and metastasis 
(Aggarwal et al. 2006; Hu et al. 2015; Raposo et al. 2015; Kidane et al. 2014; 
Terzić et al. 2010). These effects are thought to be primarily mediated by 
inflammatory cytokines. 
In the case of CRC, inflammation is thought to play an important role in both 
sporadic CRC and colitis-associated CRC (CAC). These two forms of CRC are 
thought to share many similarities and follow the same essential stages of CRC 
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development (Figure 1.2; Terzić et al. 2010). However, in CAC, chronic 
inflammation precedes cancer and thus contributes to CRC formation, while in 
sporadic CRC, the general view is that inflammation occurs following tumour 
formation. However, in the case of sporadic CRC, intestinal injury caused by 
external stimuli can also cause colonic inflammation (e.g. diet, refer to section 
1.1). In both cases, inflammation in the colon induces ROS formation and 
oxidative damage to DNA (Westbrook et al. 2009) as well as promotes crypt 
regeneration (Pull et al. 2005), resulting in mutations leading to cancer. ROS 
can also inactivate DNA repair enzymes (Colotta et al. 2009), further promoting 
the frequency of mutations due to DNA replication errors. Furthermore, 
inflammation induced oxidative DNA damage has been shown to be gene-
specific, affecting p53 and TGFβ receptor type II genes, common mutations in 
CRC, with relatively no damage to the β-Actin gene (Choi et al. 2002). 
Interestingly, p53 gene mutations have been shown to induce a pro-
inflammatory microenvironment via NFκB activation in CRC tumours 
(Schwitalla et al. 2013). Hyper-activation of pro-inflammatory COX2 and NFκB 
pathways are commonly observed in CRC tissue (Charalambous et al. 2009; 
Terzić et al. 2010; Kraus & Arber 2009), which lead to aberrant cell growth 
through cytokine deregulation. In fact NFκB is activated in more than 50% of 
CRC tumours (Kojima et al. 2004; Karin & Greten 2005) and promotes 
expression of most pro-tumourigenic cytokines (Terzić et al. 2010; Marusawa & 
Jenkins 2014).  
Pro-inflammatory cytokines are thought to be involved in cancer development 
and progression. These include tumour necrosis factor-α (TNFα), IL1β, IL8 and 
IL6. TNFα, IL8 and IL1β are thought to exhibit their tumourigenic effects 
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through activation of the NFκB pathway (Manna & Ramesh 2005; Karin 2009; 
Hoesel & Schmid 2013). The latter emerged as a promising target for cancer 
therapy, however further research revealed its inhibition could be cancer-
promoting through suppression of p53 activity (Hellin et al. 1998) making it an 
unsuitable candidate. Therefore, in the search for a new therapeutic candidate 
IL6 signalling emerged as an attractive target as it has been shown to play a 
central role in mediating chronic inflammation and cancer (Scheller et al. 2006; 
Waldner et al. 2012; Chang et al. 2014; Taniguchi & Karin 2014; Terzić et al. 
2010). IL6 is downstream of TNFα, IL8 and IL1β signalling, suggesting that 
these other pro-inflammatory cytokines may display their cancer-promoting 
effects in part through inducing IL6 expression. 
IL6 is a pleiotropic cytokine with a wide range of biological effects including 
inflammation, immune regulation, haematopoiesis and oncogenesis. IL6 signals 
through a classical pathway where it binds to the IL6 receptor (IL6R) with low 
affinity on the cell surface (O’Reilly et al. 2013). IL6/IL6R complexes bind to the 
gp130 transmembrane receptor. The IL6/IL6R/gp130 complex then 
homodimerizes to form a hexameric complex (Murakami et al. 1993), which 
activates the Janus tyrosine kinase (JAK) family that in turn activates the signal 
transducers and activators of transcription 3 (STAT3) through phosphorylation. 
Activated STAT3 can then dimerize and translocate to the nucleus, where it can 
bind to the promoter regions of its target genes and induce transcription (Figure 
1.4; O’Reilly et al. 2013; Jarnicki et al. 2010). IL6 can also signal through a non-
classical pathway, in a process known as trans-signalling via the soluble IL6R 
(sIL6R), thus allowing IL6 to signal to cells lacking cell surface IL6R expression 
(Figure 1.4; O’Reilly et al. 2013). Under normal conditions, IL6/JAK/STAT3 
Chapter 1 
	   -43- 
pathway is rapidly terminated by the suppressor of cytokine signalling 3 
(SOCS3) feedback inhibitor (Figure 1.4; Rigby et al. 2007). However, in chronic 
inflammation, inactivation of SOCS3 by proteolytic degradation or promoter 
hypermethylation results in aberrant activation of this pathway (Kim et al. 
2015; Li et al. 2012). In addition to STAT3 signalling, IL6 can also activate other 
tumour-promoting pathways including ERK, MAPK and PI3K/AKT (Figure 1.6; 
Guo, Xu, Lu, Duan, & Zhang, 2012).  
IL6 also seems to be particularly important in IBD and CRC pathogenesis 
(Scheller et al. 2006; Terzić et al. 2010; Ullman & Itzkowitz 2011; Waldner et al. 
2012; Taniguchi & Karin 2014). IL6 trans-signalling in IBD is thought to 
promote chronic activation of effector T cells and resistance to apoptosis as well 
as inhibit differentiation of regulatory T cells, resulting in chronic activation of 
IL6 producing T cells in colonic tissue (Atreya et al. 2000). Furthermore, IL6 is 
associated with CRC tumour stage, size, metastasis and patient survival. IL6 is 
overexpressed at the tumour site in CRC patients (Maihöfner et al. 2003; 
Nagasaki et al. 2014; Chung et al. 2006; Lu et al. 2015; Uchiyama et al. 2012) 
and plasma levels of the cytokine correlate with tumour size and patient 
prognosis (Chung & Chang 2003; Uchiyama et al. 2012). Epidemiological 
studies have found that a gain of function polymorphism (-174 G>C) in the IL6 
gene promoter is associated with increased CRC risk (Landi et al. 2003; Kim et 
al. 2009; Woo & Humphries 2013). In vitro, IL6 was found to directly stimulate 
invasiveness (Hsu & Chung 2006) and proliferation of CRC cell lines with 
addition of anti-IL6 antibody resulting in inhibition of this effect (Schneider et 
al. 2000). Christian Becker and co-workers found that tumour growth in vivo 
using a mouse model for CRC was mediated by IL6 trans-signalling and 
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blockade of sIL6R or gp130 was sufficient to inhibit tumour growth (Becker et 
al. 2005). Tumour-associated immune cells have also been shown to secrete 
increased amounts of IL6 and sIL6R into the TME, thus promoting cancer 
progression through stimulation of IL6 trans-signalling in adjacent tumour cells 
(Matsumoto et al. 2010).  
IL6 can also promote angiogenesis through direct vessel sprouting (Gopinathan 
et al. 2015) as well as through STAT3-mediated induction of VEGF expression 
(Waldner et al. 2010). STAT3 activation by IL6 is thought to mediate 
tumourigenesis in the colon by inducing expression of a number of genes that 
protect from apoptosis and promote cell cycle progression (Bcl-2, Survivin, 
Hsp70, Cyclin D1, cMyc; Bromberg & Wang, 2009) and inhibition of 
JAK2/STAT3 signalling induces CRC cell apoptosis (Du et al. 2012). In 
addition, SOCS3 disruption in vivo in a mouse model for sporadic CRC 
increased STAT3 signalling inducing crypt proliferation and resulting in 
increased colonic tumour load and size (Rigby et al. 2007). More recently, it was 
reported that IL6-mediated STAT3 activation in CRC cells prevented nuclear 
translocation of hMSH3, an important effector of DNA mismatch repair, thus 
promoting DNA damage and carcinogenesis (Tseng-Rogenski et al. 2014). In 
addition to STAT3 signalling, IL6 may also been shown to alter gene expression 
through epigenetic mechanisms including genome-wide methylation via 
induction of DNA methyltransferase 1 (DNMT1; Hodge et al. 2007; Hodge et al. 
2005; Foran et al. 2010) and deregulation of microRNA (miRNA) expression 
such as miR21 (Löffler et al. 2007). MiRNAs are small RNA molecules involved 
in regulating most cellular pathways, and changes in their expression have been 
implicated in cancer; miRNAs could thus be important regulators of IL6-
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mediated CRC and this is discussed in the following segment of this 
introduction (section 1.3). 
IL6 therefore appears to play a key role in CRC development and progression, 
primarily via activation of STAT3 signalling. While STAT3 has emerged as a 
promising target for cancer therapy, targeting STAT3 signalling has proved 
quite challenging and numerous drugs that have been developed thus far do not 
have the desired potency (Furqan et al. 2013). Further understanding the 
mechanisms controlling IL6-mediated CRC carcinogenesis could lead to the 
discovery of new potential therapeutic strategies.  
 
Figure 1.6 IL6 classic and trans-signalling pathways. In the classic 
pathway, IL6 binds to the IL6R membrane bound receptor with low affinity and 
signals through gp130 to activate JAK/STAT3 signalling. In trans-signalling, 
IL6 binds to the soluble IL6R (sIL6R) with high affinity, which interacts with 
gp130 and activates JAK/STAT3 signalling; this pathway is activated in chronic 
inflammation. 
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1.5 MiRNAs, master regulators of carcinogenesis? 
While the Vogelstein model for colorectal carcinogenesis includes stepwise 
genetic mutations responsible for CRC initiation and progression, it was 
established at a time when non-coding DNA sequences were regarded as ‘junk’ 
with no particular function ascribed and the concept of epigenetics was not yet 
well understood. It is now known that factors other than DNA sequence are 
involved in controlling gene expression and phenotypic change. The study of 
these factors is referred to as epigenetics. Over the years, the Vogelstein model 
of CRC carcinogenesis has been modified to include epigenetic changes that 
contribute to carcinogenesis (Slaby et al. 2009). 
Three main epigenetic mechanisms are known to regulate gene expression 
within cells: DNA methylation, histone modification and RNA silencing (Gibney 
& Nolan 2010). These processes play a crucial role in disease and particularly 
cancer. Regulation of gene expression by DNA methylation occurs via covalent 
addition of a methyl (CH3) group to position C-5 on cytosine DNA residues 
located in specific gene promoter regions named CpG islands (GC-rich regions 
of 1000bp in length) resulting in gene silencing. Changes in DNA methylation in 
cancer were first discovered in 1983 (Feinberg & Vogelstein 1983). While 
oncogene promoter regions such as ras are hypomethylated (Feinberg & 
Vogelstein 1983), tumour suppressor genes such as p53 are known to be 
silenced through hypermethylation. Histone modifications such as 
deacetylation are responsible for regulating chromatin condensation, which in 
turn controls gene expression (Gibney & Nolan 2010). Enzymes that catalyse 
these reactions are known as histone deacetylases (HDAC) and are 
overexpressed in human cancers. In CRC, where they have been linked to early 
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tumour initiating events such as loss of APC (Zhu et al. 2004) as well as later 
events such as metastasis (Choi et al. 2001). As for RNA silencing, non-coding 
RNA sequences transcribed from what was previously regarded as ‘junk’ DNA 
play a key role in regulating gene expression. At present four classes of 
regulatory non-coding RNAs are known: long non-coding RNAs, piwi-
interacting RNAs, short interfering RNAs and miRNAs. While a full review of 
these various epigenetic mechanisms and their role in cancer are beyond the 
scope of this thesis, there are several excellent general reviews on these topics 
(Ropero & Esteller 2007; Johnstone 2002; Moazed 2009; Kaikkonen et al. 
2011; Feinberg et al. 2002). For the purposes of this review, I will concentrate 
on describing miRNAs, their role in CRC and their interaction with IL6. 
The study of miRNAs has gained a lot of momentum in recent years as emerging 
evidence shows these are involved in regulating most key cellular processes 
including differentiation, proliferation and apoptosis (He & Hannon 2004). The 
existence of miRNAs was only identified two decades ago with the discovery of 
lin4 in C. elegans, which is involved in larvae development and found to 
regulate lin14 mRNA translation through binding the 3’ untranslated region 
(UTR). This suggested a novel mechanism for regulating gene expression (Lee et 
al. 1993), however the implications of this discovery in humans and other 
animals was not understood at that time. It was only seven years later that a 
second miRNA, let7 was discovered (Reinhart et al. 2000). Unlike lin4, let7 had 
homologues in numerous species including human (Pasquinelli et al. 2000). It 
is now established that most miRNAs are highly conserved and expressed in 
most complex eukaryotes. New miRNAs are continuously being discovered and 
the most recent release of the miRNA database contains 35828 mature miRNAs 
Chapter 1 
	   -48- 
in 223 species with 2588 in humans alone (the June 2014 release 21 of the 
miRBase miRNA database; Griffiths-Jones 2004). 
MiRNAs are transcribed from non-coding regions of the genome; these can 
either be intergenic regions or non-coding regions within genes also known as 
introns (He & Hannon 2004). They are on average 20-25 nucleotides in length. 
Their biogenesis pathway (Figure 1.7) begins with transcription of a primary 
miRNA (pri-miRNA) by RNA polymerase II or III, which is then folded onto 
itself and cleaved by Drosha RNA endonuclease to form stable RNA hairpin 
structures known as precursor miRNAs (pre-miRNAs, 60-80 bp in length). The 
latter are then transported from the nucleus to the cytoplasm by Exportin 5 and 
Ran-GTP where they are cleaved by Dicer to form miRNA duplexes (20-25 bp in 
length). One strand of the duplex (the mature miRNA) is selectively loaded onto 
the RNA-induced silencing complex (RISC), which identifies target mRNAs 
based on partial base complementarity resulting in mRNA cleavage or 
translational repression (He & Hannon 2004). Following this process, the 
miRNA remains intact and can proceed to bind to another target mRNA; thus 
one miRNA strand can affect multiple mRNA strands (He & Hannon 2004) 
suggesting that only small changes in miRNA expression are sufficient to 
significantly alter target expression. While miRNAs are generally thought to 
bind to the 3’UTR of target mRNAs to suppress expression, more recently a 
5’UTR binding mechanism has been described (Kloosterman et al. 2004). Due 
to miRNAs only requiring partial base complementarity with their target 
sequences, it is thought that a single miRNA can target up to 200 different 
mRNAs (Krek et al. 2005) and 60% of mRNAs have complementary miRNA 
binding sites (Friedman et al. 2009).  
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Figure 1.7 MiRNA biogenesis pathway. The miRNA gene is transcribed to 
form a pri-miRNA, which is cleaved by Drosha RNA endonuclease into the pre-
miRNA. The latter is exported from the nucleus by Exportin5 into the 
cytoplasm, where it is cleaved by Dicer RNA endonuclease and unwound to 
yield the mature miRNA strand. The mature miRNA then associates with the 
RISC complex and binds to the mRNA seed region with partial base 
complementarity and induces either translational repression or mRNA 
degradation. Adapted from He & Hannon 2004. 
MiRNAs have tissue-specific expression as they are involved in differentiation 
and specialisation of these tissues, thus their deregulation has significant 
consequences. Changes in miRNA expression in cancer cells was initially 
identified in B-cell chronic lymphocytic leukaemia (Calin et al. 2002) and it is 
now estimated that more than 50% of miRNA sequences occur in regions 
associated with chromosomal abnormalities in cancer (Calin & Croce 2006). 
Over the last decade, a breadth of research into miRNA expression and cancer 
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has led to the notion that aberrant expression of miRNAs plays an important 
role in carcinogenesis. Each malignancy has a unique miRNA profile including 
CRC (Table 1), thus miRNAs can differentiate human cancers and potentially act 
as biomarkers for disease (Calin & Croce 2006). MiRNAs with altered 
expression in cancer are either regarded as oncogenic or tumour-suppressive 
depending on the genes they regulate (Calin & Croce 2006). 
The first miRNAs found to be downregulated in CRC, miR143 and miR145, were 
identified by high throughput profiling just over a decade ago. They are 
clustered on chromosome 5 around a fragile genomic region often deleted in 
cancer (Michael et al. 2003). Expression of these tumour-suppressive miRNAs 
is able to inhibit cell growth and invasion by inhibiting cMyc and Mucin1 gene 
expression (Cui et al. 2014). Additionally, miR143 has been shown to target 
KRAS, an important oncogene in CRC carcinogenesis (Chen et al. 2009). 
Subsequent studies have identified many other differentially regulated miRNAs 
in CRC (Table 1; Pucci & Mazzarelli 2011, Yang et al. 2009, Nishida et al. 2011.), 
and selected examples involved in regulating key pathways described in the 
Vogelstein model for CRC carcinogenesis will be described here (Figure 1.8). 
MiR21 is upregulated in CRC and IBD; it targets pro-apoptotic and tumour 
suppressor genes including PTEN and has been associated with CRC 
mestastasis and poor prognosis (Asangani et al. 2008). MiR125b upregulation 
has also been associated with poor prognosis in CRC and has been shown to 
directly target p53 mRNA (Nishida et al. 2011; Le et al. 2009). The miR200 
family targets ZEB1, a key mediator EMT involved in tumour metastases 
(Brabletz et al. 2011), is transcriptionally regulated by p53 (Feng et al. 2011) and 
is downregulated in CRC (Yang et al. 2009). P53 is also thought to regulate 
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miR34a (Feng et al. 2011), another tumour-suppressor miRNA downregulated 
in CRC known to promote cell cycle arrest. Recently, a miR34 mimic became the 
first miRNA-based cancer therapy to reach phase I clinical trials (Agostini & 
Knight 2014). Loss of APC, a crucial step in early CRC carcinogenesis, may be 
mediated by upregulation of miR135b (Valeri et al. 2013). MiRNAs identified as 
being deregulated in CRC are thus crucial modulators of the cellular phenotype. 
Alterations in their expression appear to drive the process of carcinogenesis in 
the colon rather than be a mere consequence of it. However, the mechanisms 
regulating miRNA expression in cancer are not yet fully understood.  
Interestingly, miRNAs deregulated in CRC are able modulate IL6 signalling. 
MiR34a can target IL6R and IL6-mediated activation of STAT3 represses 
miR34a expression (Rokavec et al. 2014). MiR124a and miR375 (downregulated 
in CRC) can target STAT3 and JAK2 mRNAs respectively (Koukos et al. 2013; 
Xu et al. 2014). IL6 mRNA is also a validated target of let7, which is also 
downregulated in CRC (Iliopoulos et al. 2009). IL6 is a known inducer of a 
number of tumour-promoting transcription factors with the potential to induce 
expression of different miRNAs, however only few miRNAs have been identified 
to be regulated by IL6, these include miR21 (as mentioned previously), miR370, 
miR148 and miR152 ( Löffler et al. 2007; McCoy 2011). Therefore, miRNAs may 
underlie the strong link between IL6 and CRC and more importantly, IL6 may 
regulate key miRNAs involved in CRC progression.  
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Table 1. MiRNAs commonly deregulated in colorectal cancer. Adapted 
from Pucci & Mazzarelli 2011, Yang et al. 2009, Nishida et al. 2011. 
Downregulated Upregulated Hypermethylated 
let7a miR106b-93-25 miR124 
miR192 miR155 miR34b 
miR34a miR21 miR137 
miR143 miR181b-1 
 
miR145 miR17-92 cluster 
 
miR215 miR96 
 
miR200 family miR135b 
 
miR27b miR125b  
miR124a   
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1.6 Thesis hypothesis and objectives 
Hypothesis 
CRC development and progression appears to be strongly linked to lifestyle 
mainly through diet. Although it is speculated that dietary carcinogens are the 
main cause, mechanisms of their activation in the colon remain unclear. It is 
also well established that inflammation plays a key role in CRC and that IL6 
appears to be essential to this process. Furthermore, in recent years epigenetic 
mechanisms and miRNAs in particular have emerged as important regulators of 
CRC progression, however the processes that regulate their expression in cancer 
are not yet well established. Determining these various mechanisms would 
bridge the gaps in the current understanding of CRC development and 
progression, and could possibly lead to the identification of better preventive 
strategies as well as therapeutic targets. 
I hypothesise that elevated levels of IL6 in the CRC TME stimulate epigenetic 
and genetic alterations by inducing miRNA deregulation and local activation 
of dietary mutagens, thereby promoting CRC progression.  
Objectives of project  
I aim to investigate my hypothesis through the following objectives: 
1. Investigate the role of IL6 on dietary pro-carcinogen-mediated DNA damage 
in vitro and determine whether miRNAs are involved in observed effects;  
2. Determine the effect of IL6 treatment on epithelial CRC cell lines in vitro 
and investigate the underlying molecular mechanisms involved in 
phenotypic changes including selective mRNA and miRNA expression; 
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3. Interrogate changes in miRNA expression in response to IL6 in cultured 
CRC cells and investigate their role in IL6-mediated effects; 
4. Investigate the role of IL6 in the TME using in vitro co-culture of immune 
cells with CRC cells. 
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Interleukin-6 promotes dietary 
carcinogen-induced DNA damage by 
regulating cytochrome P450 enzymes. 
 
 
 
 
 
 
 
N.B. Results from this chapter have been included in the following peer-
reviewed publication: 
Patel, S.A.A. and Gooderham, N.J., 2015. Interleukin-6 promotes dietary 
carcinogen-induced DNA damage in colorectal cancer cells. Toxicology 
Research, 4, pp.858-66 (Appendix D). 
Patel, S.A.A. et al., 2014. Interleukin-6 mediated upregulation of CYP1B1 and 
CYP2E1 in colorectal cancer involves DNA methylation, miR27b and STAT3. 
British journal of cancer, 111(12), pp.2287-96 (Appendix D). 
Chapter 2 
 - 57 - 
2.1 Introduction 
CRC is largely regarded as an environmental disease and results from an 
accumulation of environment-induced genetic and epigenetic changes. 
Epidemiological studies have suggested a strong link between diet and 
colorectal carcinogenesis in part due to the presence of dietary pro-carcinogens 
such as BaP and PhIP (Chao et al. 2005).  These pro-carcinogens require 
metabolic activation to their respective DNA-damaging agents by CYP450 
enzymes. CYP2E1, CYP1B1 and CYP1A1 are found extra-hepatically and are 
overexpressed in CRC tissue (Patel et al. 2014; McFadyen et al. 2004; Murray et 
al. 1997), suggesting a potential for in situ metabolism and increased 
susceptibility to dietary carcinogen-induced mutations. Therefore, CYP450s 
may play a crucial role in diet-induced CRC. 
Pro-inflammatory cytokine IL6 is thought to play a central role in 
carcinogenesis and overexpression of IL6 occurs at the tumour site of multiple 
cancer types including CRC (Maihöfner et al. 2003; Chung et al. 2006; Lu et al. 
2015; Uchiyama et al. 2012). In addition, diets with a high animal fat content 
can promote local inflammation in the colon (Erdelyi et al. 2009), suggesting 
that diet may promote CRC through induction of IL6, however the underlying 
mechanisms remain unknown. IL6 is known to regulate CYP450 enzymes. 
Previous studies in hepatocytes have generally reported that IL6 inhibits 
CYP450 expression (Abdel-Razzak et al. 1993; Jover et al. 2002; Hakkola et al. 
2003). However, conflicting reports exist in different tissue types (Smerdová et 
al. 2014; Tindberg et al. 1996), suggesting that the effect of IL6 on CYP450 
expression may vary depending on tissue type and the relation between 
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overexpression of IL6 and CYP450 expression in CRC has not been widely 
investigated.  
In vitro techniques commonly use cells cultured as two-dimensional (2D) 
monolayers. However, when cultured in this manner, cells are flattened onto the 
culture surface thus changing their structure, and parameters such as cell-to-
cell interaction and tissue architecture are lost (Figure 2.1). In vitro three-
dimensional (3D) cell culture systems in which cells are grown as spheroids 
constitute a better model of in vivo tissue without the use of animal models. 
Previous studies comparing 2D and 3D cell culture systems have shown 3D cell 
morphology and growth rate more accurately represents in vivo tumours 
(Pampaloni et al. 2007). Thus, using 3D cell culture could increase the in vivo 
relevance of in vitro experimental results and here I have used this novel culture 
method to validate findings from 2D cell culture. 
 
Figure 2.1 Classic cell culture method changes cell structure. Cells are 
flattened onto the plastic culture surface and cell-to-cell interaction is very 
limited. 
In this chapter, I have investigated mechanisms involved in diet-associated CRC 
by studying the effect of IL6 on BaP- and PhIP-induced DNA damage as well as 
underlying mechanisms for observed effects using in vitro models. Exploring 
these mechanisms is important to further understand the role of IL6 in diet-
associated colorectal carcinogenesis and could potentially lead to the 
identification of novel preventive or therapeutic strategies. 
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2.2 Materials and methods 
2.2.1 Cell culture 
The human colorectal adenocarcinoma cell lines HCT116 and SW480 (detailed 
in Table 2) were obtained from ATCC (LGC Prochem, Middlesex, UK). HCT116 
p53-/- cells were kindly gifted by Professor Bert Vogelstein (John Hopkins 
University, Baltimore, MD, USA) and provided by Professor David Phillips 
(King’s College London, UK). Cells were routinely cultured in RPMI1640 
medium (GIBCO, Life technologies, Paisley, UK) supplemented with 10% foetal 
bovine serum (FBS), 100units/ml penicillin, 100µg/ml streptomycin and 2mM 
L-glutamine (GIBCO, Life technologies). All cells were incubated at 37°C in a 
humidified incubator (5% CO2). Cells between passages 3-7 were used for 
experiments. For 3D cell culture, cells were seeded at a density of 5 x 105 
cells/well in a 24-well Algimatrix system (Invitrogen, Life technologies) 
according to the manufacturer’s protocol. Cells were monitored and culture 
medium was changed routinely. Spheroids cultured for 7-10 days were used in 
all experiments (Figure 2.2). To isolate spheroids from the matrix, matrix-
dissolving buffer (Invitrogen, Life technologies) was used according to the 
manufacturer’s protocol.  
 
Figure 2.2 Three-dimensional cell culture. (A) 3D culture method using 
Algimatrix. (B) Pictures of HCT116 and SW480 spheroids (x10 magnification).  
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Table 2. Characteristics of HCT116 and SW480 cell lines. 
Feature HCT116 SW480 
Organism Homo sapiens Homo sapiens 
Tissue Colon Colon 
Morphology Epithelial Epithelial 
Disease Colorectal adenocarcinoma Colorectal adenocarcinoma 
Stage Dukes' type D Dukes' type B 
Gender Male Male 
Doubling time 16 hours 20 hours 
KRAS mutation 
Heterozygote mutant (GGC 
to GAC in codon 13) 
Homozygote mutant (GGT 
to GTT mutation in codon 
12) 
p53 status Wild-type 
Mutant (G273A, C309T) 
constitutively activated 
APC status Wild-type (2843 residues) 
C-terminus truncated at 
residue 1338 
β-catenin status 
Heterozygote mutant, 
stabilising deletion at S45 
residue 
Wild-type 
Microsateillite 
stability 
Instable Stable 
Repair pathway Mismatch repair deficient Mismatch repair proficient 
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2.2.2 Cell treatments 
Prior to treatment, HCT116 and SW480 were maintained in culture medium 
supplemented with 5% dextran-coated charcoal-stripped FBS for at least 72 
hours. Charcoal-stripping serum allows for the removal of hormones, growth 
factors and cytokines.  
Cells were seeded at a density of 1x105 cells per well of a 6-well plate (for 2D cell 
culture). IL6 was not expressed in HCT116 and SW480 cells (gene expression 
assays yielded unquantifiable signals, Figure S.4 in Appendix A). Human 
recombinant IL6 produced in HEK293 cells was obtained in the form of a 
lyophilised powder (HumanKine, Sigma-Aldrich, Dorset, UK) and rehydrated in 
PBS containing 0.1% human serum albumin (Sigma-Aldrich). IL6 was added to 
the cells for 24 and 48 hours at doses of 0-5000pg/ml (chosen within the range 
secreted by stromal cells in the colorectal TME; Nagasaki et al. 2014).  
For treatment with dietary carcinogens, cells were pre-treated with IL6 as 
described above, washed with PBS and treated with a dose-range of BaP (0-
10µM, Sigma-Aldrich) and PhIP (0-100µM, Toronto Research Chemicals Inc., 
Toronto, Canada). Both chemicals were dissolved in DMSO and final vehicle 
control concentration of 0.2% was used. 
For demethylation and STAT3 inhibition, cells were co-treated for 24 and 48 
hours with 1000pg/ml IL6 and either 4µM 5-aza-2’-deoxycytidine (Sigma-
Aldrich) or 25µM STAT3 inhibitor (STAT3 inhibitor VIII 5,15-
diphenylporphyrin, Millipore, Feltham, UK), respectively. STAT3 inhibitor and 
5-aza-2’-deoxycytidine were dissolved in DMSO (vehicle control concentration 
of 0.1%). 
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2.2.3 Micronucleus assay 
Micronucleus (MN) assay was performed according to OECD guidelines. Cells 
were seeded at a density of 5x104 cells per well of a 24-well plate for 2D cell 
culture. Spheroids grown for 10 days were used for 3D culture. Cells were 
treated with IL6, BaP or PhIP as detailed in section 2.2.2, washed with PBS and 
cultured for a further 72 hours prior to harvest.  Etoposide (Sigma-Aldrich) was 
used as a positive control in all assays at a concentration of 125nM as it is a 
known inducer of MN formation. Cells were then harvested and resuspended in 
culture medium containing 2% pluronic (GIBCO, Life technologies).	   Cell 
survival was determined by counting the number of viable cells using a 
haemocytometer with Trypan-Blue exclusion as per manufacturer’s protocol 
(GIBCO, Life technologies). Cells were fixed with 100% methanol onto 
microscope slides at a density of 2x104 cells per slide and stained for 60 seconds 
with acridine orange (0.1mg/ml dissolved in PBS, Sigma-Aldrich). Frequency of 
MN was scored blind in 1000 cells per sample and three biological replicates 
were performed per treatment (Figure 2.3). 
 
Figure 2.3 Micronucleus assay protocol. 
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2.2.4 RNA extraction 
Total RNA was isolated from cells using TRIzol reagent (Invitrogen, Life 
technologies) according to the manufacturer’s protocol. RNA extracts were 
quantified by UV spectroscopy (UV-VIS Nano-spectrophotometer, Implen, 
Essex, UK) with purity assessed from 260/280nm and 260/230nm ratios. 
Extracts were stored at -80°C until used.  
2.2.5 Reverse transcription and quantitative-Polymerase Chain 
Reaction 
For mRNA reverse transcription, RNA extracts (100-500ng) from each sample 
were added to 300ng of random primers, heated for 5min at 65°C and then 
immediately placed on ice. Each sample was incubated with 0.5mM dNTPs, 1x 
first strand buffer, 8µM dithiothreitol and 100units of Superscript II reverse 
transcriptase (Invitrogen, Life technologies) for 10min at 25°C, 90min at 42°C 
and 15min at 70°C on a thermocycler (Peltier Thermal Cycler PTC-200, MJ 
Research, Waltham, Massachusetts, USA). A miRNA reverse transcription kit 
was used for miRNA expression according to the manufacturer’s protocol 
(Taqman, Applied Biosystems, Life technologies). Quantitative-Polymerase 
Chain Reaction (qPCR) was performed using pre-designed gene expression 
assays (detailed in Appendix A) and FAST PCR master mix (Taqman, Applied 
Biosystems, Life technologies), and measured in a StepOnePlus fast real-time 
PCR system (Applied Biosystems, Life technologies) according to the 
manufacturer's protocol. GAPDH and U6 expression were used to normalise 
cellular mRNA and miRNA expression respectively (Appendix A). Gene 
expression was quantified using the delta-Ct method.  
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2.2.6 Fluorescence detection of ethoxyresorufin-O-deethylase 
activity 
CYP1A and CYP1B1 enzymes catalyse the O-deethylation of 7-ethoxyresorufin 
(7-ER) to fluorescent product resorufin, thus the ethoxyresorufin-O-deethylase 
(EROD) activity of CYP1A/1B1 enzymes can be measured by quantifying the 
amount of resorufin produced in the presence of 7-ER. Cells were seeded at a 
density of 1x105 cells per well of a 24-well plate in 1ml of stripped medium and 
treated as previously described (section 2.2.2). Following treatment, cells were 
washed once with PBS and incubated with 8µM 7-ER for 4 hours at 37°C. 
Fluorescence measurements were taken at λ excitation=560nm and λ
emission=590nm every 10 minutes using a fluorescence plate reader (Fluostar, 
BMG Labtech, Ortenberg, Germany). A resorufin standard curve was prepared 
over the range 0-5000pmol per 1ml of culture medium. Subsequently, total 
protein was extracted from cells collected in each assay and quantified as 
described in section 2.2.9. Activity rate was calculated as follows: 
1. Blank measurement subtracted from all fluorescent measurements; 
2. Fluorescence vs time (min) plotted and gradient g calculated from the 
linear portion of the graph; 
3. Using resorufin standard curve, g converted into pmol resorufin/min; 
4. Data set normalised to amount of protein contained within each sample; 
5. Activity rate expressed as pmol resorufin/mg protein/min. 
2.2.7 Transfection of miR27b inhibitor 
MiR27b inhibitor was obtained from miRIDIAN (Thermo Fisher Scientific, 
Cramlington, UK) and transfected into the cells using Lipofectamine 2000 
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(Invitrogen, Life technologies) according to the manufacturer’s protocol. Briefly, 
cells were seeded at a density of 1x105 cells per well of a 24-well plate and cell 
culture medium was replaced by 400µl/well of Opti-MEM (GIBCO, Life 
technologies) prior to the addition 150µl/well of Opti-MEM containing 8µl of 
Lipofectamine 2000 reagent and 2.5µl of 20µM stock of miRNA inhibitor or 
miRIDIAN miRNA negative control. Cells were incubated with the transfection 
complexes for 6 hours prior to harvest. 
2.2.8 Chromatin immunoprecipitation-qPCR  
Four million SW480 cells were treated with 1000pg/ml IL6 and 25µM STAT3 
inhibitor for 60min prior to harvest. Chromatin Immunoprecipitation (ChIP) 
assay was performed using a magnetic ChIP kit (Thermo Fisher Scientific) as 
per manufacturer’s protocol with an anti-STAT3 antibody (sc-482X, Santa Cruz 
Biotechnology, Heidelberg, Germany). PCR primers were designed to amplify 
STAT3 binding sites of interest using Primer-BLAST (NCBI, Ye et al., 2012). 
Rabbit IgG was used as a negative control for non-specific binding. Binding was 
calculated as a percentage of the total input chromatin. Sequences of the 
primers used were as follows:  
CYP2E1 site 1  forward 5’-TGAATTTTCCTTCTGGCCCCAT-3’,  
reverse 5’-TGATGAGGAGGTTTGTCTGAGC-3’;  
CYP2E1 site 2  forward 5’-CTCCATCCTCACCAGGTCAC-3’,  
reverse 5’-CCAACCAATGCCCTCTTGCT-3’. 
2.2.9 Immunoblotting 
Cells were treated as described in section 2.2.2. Lysates were prepared from the 
treated cells using RIPA buffer (Sigma-Aldrich) as per manufacturer’s 
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instructions and quantified by BCA assay (Thermo Fisher Scientific). 
Immunoblotting was performed as previously described (Lauber & Gooderham 
2011) and 30µg of protein sample was loaded into each well of a 10% SDS-
polyacrylamide gel. Anti-STAT3 (ab50761), anti-pSTAT3 (ab32143) and 
secondary antibodies (Abcam, Cambridge, UK) were used at a dilution of 
1:10000. Blots were also incubated with anti-β-actin antibody (A2228, 1:10000 
dilution, Sigma-Aldrich), which was used as an internal loading control. Target 
protein bands were visualised using Luminata Forte chemiluminescent reagent 
(Millipore). Blots were exposed and quantified using the Kodak image station 
4000MM. (Kodak, Watford, UK).  
2.2.10 Statistical analysis 
Data were obtained from measurements made in at least three biological 
replicates and presented as a mean ± standard error (SEM). Significant 
differences (p<0.05) were determined using Student’s t-test, one-way analysis 
of variance (ANOVA) followed by a Dunnett post-test or a linear trend analysis 
and two-way ANOVA followed by a Bonferroni post-test. Pearson’s product-
moment correlation coefficient test was used for correlation analysis (GraphPad 
Prism 5, GraphPad Software Inc., La Jolla, CA, USA).  
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2.3 Results 
2.3.1 IL6 promotes chemical-induced DNA damage by food-derived 
pro-carcinogens BaP and PhIP. 
 
The in vitro MN assay is a commonly used toxicological test for detecting 
genotoxic potential of compounds due to its simplicity of scoring, accuracy and 
adaptability to different cell types. More importantly, studies in humans have 
shown strong associations between micronuclei frequency and cancer risk 
(Bonassi et al. 2011). Formation of micronuclei, i.e. small membrane-bound 
DNA fragments in the cytoplasm, occurs during cell division when a whole 
chromosome or a chromosomal fragment is not incorporated into the nucleus of 
one of the daughter cells. Standard MN assays utilise immature blood cells, but 
non-standard versions of the assay have been developed using different cell 
types including epithelial cells. Here, I have adapted the assay for use with 
human colorectal adenocarcinoma epithelial cell lines grown as 2D and 3D 
cultures. I determined the optimum post-treatment time point for scoring the 
micronuclei in this system as 72 hours, since this was the time-point at which 
the highest number of MN were observed following treatment with BaP (Figure 
2.4). 
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Figure 2.4 Micronucleus assay optimisation. HCT116 cells grown as 
monolayers were treated with 10µM BaP for 24 hours; cells were taken 24, 48 
and 72 hours post-treatment and scored for micronuclei (MN) frequency. Data 
are expressed as fold change compared to vehicle control at each time point. 
Significance was assessed using Student’s t-test comparing treated group to 
control (GraphPad Prism 5, *p<0.05, ***p< 0.001). Error bars represent the 
SEM for independent cultures (n=3). 
Using the optimised method, a dose-dependent increase in BaP- and PhIP-
induced MN frequency in HCT116 and SW480 cell lines cultured in 2D was 
observed.  Interestingly, pre-treatment with IL6 significantly enhanced the pro-
carcinogen-induced DNA damage while treatment with IL6 on its own had no 
effect (Figure 2.5 A, B and 2.6 A, B). In addition, HCT116 was more susceptible 
to DNA damage compared to SW480 cells possibly due to the lack of mismatch 
repair in HCT116 (Table 2). Cytotoxicity was also measured to ensure cell 
viability post-treatment. While some toxicity with high dose BaP and IL6 was 
observed, the differences were not statistically significant compared to control 
(Figure 2.5 C, D, 2.6 C, D).   
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Figure 2.5 Micronucleus assay with 2D HCT116. HCT116 cells grown as 
monolayers were pre-treated with IL6 for 48 hours followed by a 24 hour 
treatment with BaP or PhIP; cells were taken 72 hours post-treatment. 
Etoposide was used as a positive control. (A, B) Micronuclei (MN) frequency per 
1000 cells following treatment. (C, D) Cytotoxicity following treatment 
expressed as % of cell survival. Statistically significant differences are shown for 
comparisons between carcinogen treated vs IL6 pre-treated samples (*p<0.05, 
**p<0.01, ***p<0.001), IL6 alone vs IL6 pre-treated and carcinogen treated 
(†p<0.05, ††p<0.01, †††p<0.001) and vehicle vs carcinogen treated (‡p<0.05, 
‡‡p<0.01, ‡‡‡p<0.001). Significance was calculated using one-way ANOVA with 
a Dunnett post-test (GraphPad Prism 5). Error bars represent the SEM for 
independent cultures (n=3).  Adapted from Patel & Gooderham 2015. 
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Figure 2.6 Micronucleus assay with 2D SW480. SW480 cells grown as 
monolayers were pre-treated with IL6 for 24 hours followed by a 24 hour 
treatment with BaP or PhIP; cells were taken 72 hours post-treatment. 
Etoposide was used as a positive control. (A, B) Micronuclei (MN) frequency per 
1000 cells following treatment. (C, D) Cytotoxicity following treatment 
expressed as % of cell survival. Statistically significant differences are shown for 
comparisons between carcinogen treated vs IL6 pre-treated samples (*p<0.05, 
**p<0.01, ***p<0.001), IL6 alone vs IL6 pre-treated and carcinogen treated 
(†p<0.05, ††p<0.01, †††p<0.001) and vehicle vs carcinogen treated (‡p<0.05, 
‡‡p<0.01, ‡‡‡p<0.001). Significance was calculated using one-way ANOVA with 
a Dunnett post-test (GraphPad Prism 5). Error bars represent the SEM for 
independent cultures (n=3). Adapted from Patel & Gooderham 2015. 
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 The assay was repeated using HCT116 cells grown as 3D spheroids. In general, 
results were in agreement with that found in 2D culture (Figure 2.7). However, 
the increase in DNA damage observed with IL6 pre-treatment was not as 
pronounced in 3D culture compared to 2D. MN frequency was increased by 1.5 
fold in 3D culture with IL6 pre-treatment, whereas in 2D culture, it was 
increased by 2-3 fold. Furthermore, MN frequencies with BaP and PhIP alone 
were increased in 3D cells compared to 2D cells. Etoposide, a topoisomerase II 
inhibitor and potent inducer of MN formation, was used as a positive control in 
all assays and does not require activation to induce DNA damage. Pre-treatment 
with IL6 did not enhance etoposide-induced DNA damage suggesting that IL6 
may have an effect on the activation pathway of the pro-carcinogens rather than 
on induction of MN formation.  
Therefore, these data demonstrate that presence of IL6 in colon epithelial cells 
along with food-derived pro-carcinogen can enhance DNA damage suggesting a 
potential role for IL6 in promoting cancer development and progression in the 
colon. 
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Figure 2.7 Micronucleus assay with HCT116 grown as 3D spheroids. 
Cells grown as 3D spheroids on Algimatrix were pre-treated with IL6 for 24 
hours followed by a 24 hour treatment with BaP or PhIP; cells were taken 72 
hours post-treatment. Etoposide was used as a positive control. (A) Micronuclei 
frequency per 1000 cells following treatment. (B) Cytotoxicity following 
treatment expressed as % of cell survival. Statistically significant differences are 
shown for comparisons between carcinogen treated vs IL6 pre-treated samples 
(*p<0.05, **p<0.01, ***p<0.001). Significance was calculated using one-way 
ANOVA with a Dunnett post-test (GraphPad Prism 5). Error bars represent the 
SEM for independent cultures (n=3). Reproduced from Patel & Gooderham 
2015. 
IL6 has been reported to downregulate p53 gene expression (Hodge et al. 
2005). The tumour suppressor protein p53 is crucial to maintain genomic 
stability and is commonly deactivated in cancer. Both of the cell lines used in 
this study have p53 activity. To test whether inactivation of p53 may be 
responsible for the IL6 effect observed, I performed a MN assay on HCT116 
p53-/- cells obtained from Professor Bert Vogelstein’s laboratory (John Hopkins 
University, Baltimore, MD, USA) and as well, I looked at the effect of IL6 
treatment on p53 gene expression by qPCR. No significant downregulation of 
p53 gene expression was observed at the dose of IL6 used in this study (Figure 
2.8 A, B and C). In addition, MN frequency was not increased in the p53-null 
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HCT116 cells when compared to wild-type HCT116, rather total number of MN 
was decreased (Figure 2.6 A and B, Figure 2.8 E). Therefore, this demonstrates 
that the observed effect of IL6 on MN induction by BaP and PhIP is not caused 
by downregulation of p53, further suggesting that IL6 may affect the activation 
pathway of the pro-carcinogens.  
Previous studies in this laboratory have demonstrated that overexpression of 
IL6, CYP1B1 and CYP2E1 occurs in malignant tissue resected from CRC patients 
(Patel et al. 2014), indicating that IL6 may be associated with a change in 
metabolic competency. BaP and PhIP are both activated to their genotoxic form 
intracellularly by CYP1A1 and CYP1B1 enzymes. In addition, CYP2E1 is also 
known to activate dietary carcinogens such as acrylamide, found in starchy 
foods cooked at high temperatures. Therefore, I proceeded to investigate the 
effect of IL6 on CYP1A1, CYP1B1 and CYP2E1 expression in CRC cells.  
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Figure 2.8 IL6-mediated induction of BaP- or PhIP-mediated 
micronuclei formation is not caused by downregulation of p53 
expression. HCT116 and SW480 cells grown as 2D monolayers (A, B) and 3D 
spheroids (C) were treated with IL6 and p53 expression was measured by RT-
qPCR. Data were normalised to expression of GAPDH and are show relative to 
control. (D-E) HCT116 p53-/- cells were grown as monolayers and treated for 24 
hours with BaP or PhIP. Cells were taken 72 hours post-treatment. Mean 
micronuclei frequency per 1000 cells (D) and mean cytotoxicity as % of cell 
survival compared to control (E) were determined following treatment. 
Significance was calculated using one-way ANOVA with Dunnett post-test 
comparing treated group to vehicle control (GraphPad Prism 5, ***p<0.001). 
Error bars represent the SEM for independent cultures (n=3). Adapted from 
Patel & Gooderham 2015. 
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2.3.2 Can IL6 regulate CYP450 expression? 
In the current study, I examined the effect of a dose range of IL6 treatment at 
various time points on CYP450 expression in CRC cells. A dose-dependent 
upregulation of CYP1B1 and CYP2E1 in both HCT116 and SW480 cells following 
IL6 treatment was observed (Figure 2.9), and was further confirmed in cells 
cultured as 3D spheroids (Figure 2.10). However, treatment with IL6 did not 
significantly alter CYP1A1 expression (Figure 2.9 A and 2.10 A).  
Furthermore, I investigated the effect of pre-treatment with IL6 followed by BaP 
or PhIP treatment on CYP1A1 and CYP1B1 expression, the two CYP isoforms 
that activate these chemicals, but found no significant changes with IL6 pre-
treatment followed by BaP or PhIP compared to BaP or PhIP treatment alone 
(Figure 2.11). This may be due to the fact that IL6 is removed prior to BaP and 
PhIP treatment and therefore, CYP1B1 induction is not sustained following IL6 
removal. BaP (but not PhIP) is a known inducer of the AhR pathway that 
controls CYP1A1 and CYP1B1 expression and here, as expected, BaP significantly 
induced expression of both CYP1B1 and CYP1A1. Similar results were also 
obtained with cells cultured in 3D (Figure 2.12).  
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Figure 2.9 IL6 effect on CYP1A1, 1B1 and 2E1 gene expression. HCT116 
and SW480 cells were treated with 0, 100 and 1000pg/ml IL6 for 24 and 48 
hours. CYP1A1 (A), CYP1B1 (B) and CYP2E1 (C) expression were measured by 
RT-qPCR. Data were normalised to expression of GAPDH and are shown 
relative to control. Significance was calculated using one-way ANOVA with a 
Dunnett post-test comparing treated groups to vehicle control and linear trend 
analysis (GraphPad Prism 5, *p<0.05, **p<0.01, ***p<0.001). Data are 
presented as a mean of at least three biological replicates. Error bars represent 
the SEM for independent cultures. Reproduced from Patel et al. 2014. 
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Figure 2.10 IL6 effect on CYP1A1, 1B1 and 2E1 gene expression in 3D 
cultures. HCT116 and SW480 cells grown as 3D spheroids were treated with 0, 
1000 or 5000pg/ml IL6 for 24 hours. CYP1A1 (A), CYP1B1 (B) and CYP2E1 (C) 
expression were measured by RT-qPCR. Data were normalised to expression of 
GAPDH and are shown relative to control. Significance was assessed using a 
Student’s t-test comparing the treated group to vehicle control (GraphPad Prism 
5, *p<0.05, **p<0.01). Data are presented as a mean of three biological 
replicates. Error bars represent the SEM. Reproduced from Patel & Gooderham 
2015. 
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Figure 2.11 CYP1A1 and CYP1B1 gene expression following IL6 pre-
treatment and BaP or PhIP treatment in 2D cultured HCT116 and 
SW480 cells. Cells grown as monolayers were pre-treated with 1000pg/ml 
IL6 for 24 hours (SW480) or 48 hours (HCT116) followed by a 24 hour 
treatment with BaP or PhIP. CYP1A1 and CYP1B1 expression were measured by 
RT-qPCR. Data were normalised to expression of GAPDH and are shown 
relative to control. Statistically significant differences were calculated using one-
way ANOVA with a Dunnett post-test (GraphPad Prism 5) and are shown for 
comparisons between vehicle vs carcinogen treated samples (*p<0.05, 
**p<0.01, ***p<0.001) and IL6 alone vs IL6 pre-treated and carcinogen treated 
(†p<0.05, ††p<0.01, †††p<0.001). Error bars represent the SEM for 
independent cultures (n=3). Adapted from Patel & Gooderham 2015. 
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Figure 2.12 CYP1A1 and CYP1B1 gene expression following IL6 pre-
treatment and BaP or PhIP treatment in 3D cultured HCT116 and 
SW480 cells. Cells grown as 3D spheroids on Algimatrix were pre-treated 
with 1000pg/ml IL6 for 24 hours followed by a 24 hour treatment with 1µM BaP 
or 10µM PhIP. CYP1A1 and CYP1B1 expression were measured by RT-qPCR. 
Data were normalised to expression of GAPDH and are shown relative to 
control. Significance was calculated using one-way ANOVA with a Dunnett post-
test comparing treated group to vehicle control (GraphPad Prism 5, *p<0.05, 
**p< 0.01, ***p< 0.001). Error bars represent the SEM for independent cultures 
(n=3). 
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In addition, CYP1A/1B1 activity was measured in 2D HCT116 cells using the 
EROD assay following IL6, BaP and PhIP treatment (Figure 2.13). No 
significant changes were observed with IL6 treatment (Figure 2.13 A) likely due 
to the fact that this assay measures both CYP1A and 1B1 enzyme activities and 
CYP1A1 expression is not significantly changed with IL6 treatment.  
Interestingly, 3D cells appear to have increased EROD activity compared to 2D 
cells (Figure 2.13 B), which could possibly explain the previously observed 
increase in MN frequency by BaP and PhIP in 3D cells.  
Taken together, these data suggesting that it is the initial induction of CYP1B1 
expression (in the first 24 to 48 hours) by IL6 treatment prior to the addition of 
the carcinogens that appears to result in increased amounts of activated 
carcinogens and DNA damage. 
 
Figure 2.13 CYP1A/1B1 activity in HCT116 cells. (A) Cells grown as 2D 
monolayers were treated with and without 1000pg/ml IL6 for 48 hours or pre-
treated with 1000pg/ml IL6 for 48 hours followed by a 24 hour treatment with 
1µM BaP or 10µM PhIP. EROD activity of CYP1A/1B1 enzymes was measured 
and significance was calculated using one-way ANOVA with a Dunnett post-test 
comparing treated group to vehicle control (GraphPad Prism 5, ***p< 0.001). 
(B) EROD activity was measured in 2D and 3D cultured HCT116 cells. 
Significance was calculated using a Student’s t-test (GraphPad Prism 5, *p< 
0.05). Data are expressed as activity rate in pmol resorufin/mg protein/min. 
Error bars represent the SEM for at least three independent cultures. 
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2.3.3 What are the mechanisms involved in IL6-mediated 
upregulation of CYP2E1 and CYP1B1? 
In order to determine the mechanism underlying IL6 induction of CYP1B1 and 
CYP2E1 expression, I examined the different pathways involved in their 
regulation.  
The AhR pathway is the most studied pathway by which CYP1B1 and CYP1A1 
mRNA expressions are induced whereby activation of the receptor usually 
following presence of aromatic hydrocarbons such as BaP, results in nuclear 
translocation, promoter binding and gene transcription. However, CYP1A1 
mRNA expression was not induced upon IL6 treatment, thus the AhR pathway 
is not likely to be involved in IL6-mediated induction of CYP1B1.  
MiRNAs that target CYP1B1 and CYP2E1 mRNA are another means of 
regulating expression. MiR27b and miR378 are currently the only validated 
miRNAs to target CYP1B1 and CYP2E1 mRNA expression respectively by direct 
binding to their 3’UTR (Tsuchiya et al. 2006; Mohri et al. 2010). I thus 
investigated the effect of IL6 on miR27b and miR378 and found downregulation 
of miR27b but no change in miR378 expression in both HCT116 and SW480 cell 
lines (Figure 2.14 A and C). Furthermore, miR27b expression produced a 
significant inverse correlation with CYP1B1 expression (Figure 2.14 D), while 
miR378 expression did not correlate with CYP2E1 expression. MiR27b 
downregulation with IL6 treatment was further confirmed in cells grown as 3D 
spheroids (Figure 2.15). Transfection of a miR27b inhibitor appeared to result in 
an upregulation of CYP1B1 expression, although this result was not statistically 
significant (Figure 2.16). No significant changes were observed in miR27b 
expression with IL6 pre-treatment followed by BaP or PhIP compared BaP or 
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PhIP treatment alone (Figure 2.17), which correlates with what was observed for 
CYP1B1 expression (Figure 2.11), suggesting that downregulation of miR27b and 
modulation of CYP1B1 mRNA occur in the first 24 to 48 hours of IL6 treatment 
and are not maintained following IL6 removal. Therefore, these data suggest a 
possible post-transcriptional mechanism for IL6-mediated regulation of CYP1B1 
via miR27b and that regulation of CYP2E1 does not occur via miR378.	   
 
Figure 2.14 MiRNA involvement in IL6-mediated regulation of 
CYP1B1 and CYP2E1 gene expression. HCT116 and SW480 cells grown as 
monolayers were treated with 1000pg/ml IL6 for 24 and 48 hours. MiR378 (A) 
and miR27b (C) expression were measured by RT-qPCR. Fold change 
expression of miR378 was correlated with fold change expression of CYP2E1 (B) 
and fold change expression of miR27b with fold change CYP1B1 expression (D). 
Data were normalised to expression of U6 RNA. Significance was assessed using 
Student’s t-test. Pearson’s product-moment correlation coefficient test was used 
for correlation analysis (GraphPad Prism 5, *p<0.05, **p<0.01). Data are 
presented as a mean of at least three biological replicates and are shown relative 
to control. Error bars represent the SEM for independent cultures. Reproduced 
from Patel et al. 2014. 
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Figure 2.15 MiR27b expression following IL6 treatment in 3D 
cultures. HCT116 and SW480 cells grown as 3D spheroids were treated with 0 
and 1000-5000pg/ml IL6 for 24 hours. MiR27b expression were measured by 
RT-qPCR in HCT116 (A) and SW480 (B) cells. Data were normalised to 
expression of U6 RNA and are shown relative to control. Significance was 
assessed using Student’s t-test (GraphPad Prism 5, **p<0.01).  Data are 
presented as a mean of at least three biological replicates. Error bars represent 
the SEM for independent cultures. 
 
Figure 2.16 MiR27b regulation of CYP1B1 mRNA in HCT116 and 
SW480 cells. Cells were transfected with a miR27b inhibitor for 6 hours and 
expression of miR27b and CYP1B1 were measure by RT-qPCR. Data were 
normalised to expression of U6 RNA for miR27b expression and GAPDH for 
CYP1B1 expression, and are shown relative to control. Significance was assessed 
using Student’s t-test (GraphPad Prism 5, *p<0.05).  Data are presented as a 
mean of at least three biological replicates. Error bars represent the SEM for 
independent cultures.  
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Figure 2.17 MiR27b expression following IL6 pre-treatment and BaP 
or PhIP treatment. Cells grown as monolayers were pre-treated with IL6 for 
48 hours (HCT116- A) or 24 hours (SW480- B) followed by 24 hour treatment 
with BaP or PhIP. MiR27b expression was measured by RT-qPCR. Data were 
normalised to expression of U6 RNA and are shown relative to control. 
Significance was assessed using one-way ANOVA with a Dunnett post-test 
comparing treated group to vehicle control (GraphPad Prism 5, *p<0.05, 
**p<0.01). Error bars represent the SEM for independent cultures (n=3). 
Adapted from Patel & Gooderham 2015. 
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treating cells with IL6 and a STAT3 inhibitor. IL6-mediated induction of 
CYP2E1 but not CYP1B1 was prevented in cells when STAT3 activity was 
inhibited, suggesting that STAT3 can regulate CYP2E1 expression (Figure 2.19 A 
and B). An analysis of the CYP2E1 promoter region revealed two potential STAT 
binding sites at positions -36bp and -617bp upstream of the start site (Figure 
2.20 A; TFSEARCH ver1.3; Heinemeyer et al. 1998). ChIP experiments 
confirmed that IL6 induced STAT3 binding to both CYP2E1 regions and binding 
was prevented when STAT3 was inhibited. Furthermore, binding was higher at 
the promoter proximal region (position -36bp, CYP2E1 site 2) compared to the 
distal region (Figure 2.20 B).  
 
 
Figure 2.18 Levels of phosphorylated STAT3 are increased upon IL6 
treatment. SW480 cells were treated with 1000pg/ml IL6 for 24 hours. STAT3 
and phosphorylated STAT3 (pSTAT3) protein expression were determined by 
immunoblotting and quantified using a Kodak image station 4000MM. Protein 
expression was normalised to β-actin expression (loading control). Significance 
was assessed using Student’s t-test (GraphPad Prism 5, **p<0.01).  Data are 
presented as a mean and error bars represent the SEM for independent cultures 
(n=3). 
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Figure 2.19 STAT3 involvement in IL6-mediated regulation of 
CYP1B1 and CYP2E1 gene expression. HCT116 and SW480 were treated 
with 1000pg/ml IL6 or IL6 with 25µM STAT3 inhibitor VII for 24 hours 
(SW480) and 48 hours (HCT116). CYP2E1 (A) and CYP1B1 (B) expression was 
measured by RT-qPCR. Data were normalised to expression of GAPDH and are 
shown relative to control. Data are presented as a mean of at least three 
biological replicates and error bars represent the SEM for independent cultures. 
Significance was calculated using one-way ANOVA with a Dunnett post-test 
comparing treated groups to vehicle control (GraphPad Prism 5, **p<0.01). 
Adapted from Patel et al. 2014. 
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Figure 2.20 STAT3 binds to the CYP2E1 gene promoter. (A) STAT3 
binding sites in the CYP2E1 promoter region predicted using TFSEARCH ver1.3 
(Heinemeyer et al. 1998). (B) SW480 cells were treated with 1000pg/ml IL6 or 
a combination of IL6 and 25µM STAT3 inhibitor VII for 60min and STAT3 
binding was measured by ChIP-qPCR using an anti-STAT3 antibody. Data are 
presented as a mean of at least three biological replicates and error bars 
represent the SEM for independent cultures. Significance was calculated using 
two-way ANOVA with a Bonferroni post-test comparing treated groups to 
vehicle control (GraphPad Prism 5, *p<0.05). ChIP experiments were repeated 
using IgG antibody to control for non-specific binding and performed in 
duplicate. Adapted from Patel et al. 2014. 
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2.3.4 How does IL6 mediate downregulation of miR27b expression? 
Having determined that miR27b downregulation is responsible for IL6-
mediated CYP1B1 upregulation, I next investigated the mechanism involved. 
MiR27b is located within a miRNA cluster in the C9orf3 gene (chromosome 9) 
and its expression has been reported to be regulated through methylation of an 
adjacent CpG island (Yan et al. 2011). As IL6 is also known to promote genome-
wide methylation through activation of DNMT1 by AKT-mediated 
phosphorylation (Hodge et al. 2007), the role of DNA methylation in IL6 
regulation of miR27b was investigated using 5-aza-2’-deoxycytidine treatment, 
a potent inhibitor of DNA methylation. When DNA methylation was inhibited, 
the downregulation of miR27b by IL6 was also prevented in both cell lines 
blocking the induction of CYP1B1 expression by IL6 (Figure 2.21). These data 
therefore suggest that DNA methylation is involved in miR27b downregulation 
and upregulation of CYP1B1 by IL6. 
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Figure 2.21 DNA methylation involvement in IL6-induced 
downregulation of miR27b. HCT116 and SW480 cells were treated with 
1000pg/ml IL6, 4µM 5-aza-2’-deoxycytidine or IL6 with 5-aza-2’-deoxycytidine 
for 24 and 48 hours. (A) MiR27b expression was measured by RT-qPCR. (B) 
CYP1B1 expression was measured by RT-qPCR. Data were normalised to 
expression of U6 RNA for miR27b expression and GAPDH for CYP1B1 
expression, and are shown relative to control. Significance was calculated using 
Student’s t-test and one-way ANOVA with a Dunnett post-test comparing 
treated groups to vehicle control (GraphPad Prism 5, *p<0.05, **p< 0.01). Data 
are presented as a mean of at least three biological replicates. Error bars 
represent the SEM for independent cultures. Adapted from Patel et al. 2014. 
HCT116 CYP1B1
0 p
g/m
l IL
6
10
00
 pg
/m
l IL
6
4µ
M 
5-a
za
-de
ox
yc
yti
din
e 
IL6
+ 5
-az
a d
eo
xy
cy
tid
ine
0 p
g/m
l IL
6
10
00
 pg
/m
l IL
6
4µ
M 
5-a
za
-de
ox
yc
yti
din
e 
IL6
+ 5
-az
a d
eo
xy
cy
tid
ine
0.0
0.5
1.0
1.5
2.0 *
*
24h 48h
Fo
ld
 c
ha
ng
e
SW480 CYP1B1
0 p
g/m
l IL
6
10
00
 pg
/m
l IL
6
4µ
M 
5-a
za
-de
ox
yc
yti
din
e 
IL6
+ 5
-az
a d
eo
xy
cy
tid
ine
0 p
g/m
l IL
6
10
00
 pg
/m
l IL
6
4µ
M 
5-a
za
-de
ox
yc
yti
din
e 
IL6
+ 5
-az
a d
eo
xy
cy
tid
ine
0
1
2
3
4
*
**
24h 48h
Fo
ld
 c
ha
ng
e
HCT116 miR27b
0 p
g/m
l IL
6
10
00
 pg
/m
l IL
6
4µ
M 
5-a
za
-de
ox
yc
yti
din
e 
IL6
+ 5
-az
a d
eo
xy
cy
tid
ine
0 p
g/m
l IL
6
10
00
 pg
/m
l IL
6
4µ
M 
5-a
za
-de
ox
yc
yti
din
e 
IL6
+ 5
-az
a d
eo
xy
cy
tid
ine
0.0
0.5
1.0
1.5
*
24h 48h
Fo
ld
 c
ha
ng
e
SW480 miR27b
0 p
g/m
l IL
6
10
00
 pg
/m
l IL
6
4µ
M 
5-a
za
-de
ox
yc
yti
din
e 
IL6
+ 5
-az
a d
eo
xy
cy
tid
ine
0 p
g/m
l IL
6
10
00
 pg
/m
l IL
6
4µ
M 
5-a
za
-de
ox
yc
yti
din
e 
IL6
+ 5
-az
a d
eo
xy
cy
tid
ine
0.0
0.5
1.0
1.5
2.0
* *
24h 48h
**
Fo
ld
 c
ha
ng
e
B
A
Chapter 2 
 - 90 - 
2.4 Discussion 
Inflammation has long been associated with cancer particularly CRC as chronic 
bowel inflammation is an important risk factor for disease. One of the drivers of 
this link is thought to be the pro-inflammatory cytokine IL6, which is known to 
be overexpressed in CRC tumours (Maihöfner et al. 2003; Nagasaki et al. 2014; 
Chung et al. 2006; Lu et al. 2015; Uchiyama et al. 2012). Here, I propose a 
novel role for IL6 as a promoter of dietary carcinogen- induced DNA damage in 
CRC cells.  
In the current study, IL6 was able to promote DNA damage induced by BaP and 
PhIP, two carcinogens present in meats cooked at high temperatures. To the 
best of my knowledge, this was the first account of this IL6-mediated effect, 
however two studies conducted by Dr Lenka Umannová and colleagues have 
previously reported that TNFα, another pro-inflammatory cytokine, increased 
BaP-induced DNA adduct formation in rat liver and alveolar type II epithelial 
cells through induction of CYP1B1 expression (Umannová et al. 2011; 
Umannová et al. 2008), suggesting that other pro-inflammatory cytokines may 
have a similar effect.   
I determined DNA damage using the MN assay, which detects double-strand 
DNA breaks to evaluate genotoxicity. This assay is a regulatory acceptable assay 
used along with the Ames test (an in vitro bacterial gene mutation assay using 
strains of Salmonella typhimurium) as part of a core system used by the UK 
government to assess genotoxic potential of chemicals in vitro (Committee on 
Mutagenicity of Chemicals in Food Consumer Products and the Environment 
2011). However, in the current study, the purpose was to assess genotoxic 
potential and not to comply with regulatory requirements, and thus results were 
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not validated using a second method for detecting DNA damage. Indeed, the 
Ames test would not be appropriate to validate the IL6-mediated effects 
observed in the MN assay as bacterial organisms lack the endogenous 
mammalian mechanisms involved in these effects (CYP450 expression, miR27b, 
STAT3 activation). Other mammalian genotoxicity assays have been shown to 
have low specificity leading to false positive/negative results (Kirkland et al. 
2007; Kirkland et al. 2005).  Recently, the γH2AX assay, a novel test for 
detecting double-strand breaks in mammalian cells, has emerged as a promising 
new alternative (Garcia-Canton et al. 2012), but it has not been tested on as 
many compounds as the other standard tests and is not included in the current 
regulatory guidelines. Nonetheless, had time permitted, it would have been a 
useful tool to further validate the current MN assay findings.  
I suggest that IL6 promotes dietary carcinogen-mediated DNA damage through 
induction of CYP1B1 expression, a member of the CYP450 family of enzymes 
known to activate BaP and PhIP. I also found that IL6 increased CYP2E1 
expression, another CYP450 protein known to activate dietary carcinogens such 
as acrylamide (Ghanayem et al. 2005). CYP450s play a crucial role in activation 
of xenobiotic chemicals such as pro-carcinogens and drugs, as well as in tumour 
development and progression (Murray et al. 1997; Gooderham et al. 2007; 
Braeuning et al. 2011; Kasai et al. 2013; Rodriguez & Potter 2013), therefore it is 
important to understand the mechanisms underlying their regulation. Previous 
studies on IL6 regulation of CYP450 enzymes present conflicting reports. 
Generally IL6 is thought to have an inhibitory effect in hepatic cells (Abdel-
Razzak et al. 1993; Jover et al. 2002; Hakkola et al. 2003), however a few 
studies in other cell types have shown increased expression of CYP450 in 
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response to IL6 (Smerdová et al. 2014; Tindberg et al. 1996; Kurzawski et al. 
2012), which are in agreement with the data presented here in CRC cells. 
Therefore, this suggests that IL6 effect on CYP450 may be tissue-dependent and 
prior to the current study, there were no previous reports of this effect in CRC 
cells. Furthermore, the majority of these studies used much higher doses of IL6 
(up to 50ng/ml), while here lower doses of IL6 (0-5000pg/ml) were used that 
are within the range secreted by stromal cells in the TME (up to 8000pg/ml; 
Nagasaki et al., 2014). 
Kurzawski et al. have shown that CYP1B1 expression but not CYP1A1 is 
increased in response to IL6 and they established that this regulation is 
independent of the AhR pathway but they did not propose an alternate 
mechanism (Kurzawski et al. 2012). In the current study, I demonstrate that 
miR27b, a miRNA known to target CYP1B1, is downregulated in response to IL6 
in a mechanism involving DNA methylation, resulting in CYP1B1 upregulation 
by IL6. A CpG island located near the miR27b gene has been shown to be 
methylated and regulate miR27b expression (Yan et al. 2011), and my findings 
of IL6-mediated regulation of miR27b could be further validated by 
investigating DNA methylation at that site following IL6 treatment using 
bisulphite-sequencing techniques or qPCR methylation kits. Furthermore, IL6 
has been shown to promote global DNA methylation changes through activation 
of DNMT1 by AKT (Hodge et al. 2007), knockout studies could be used in order 
to confirm whether DNMT1 and PI3K/AKT pathway activation are involved in 
the observed effects. While miR27b and IL6 have both been shown to be 
involved in inflammation-related pathways (Jin et al. 2013; Lee et al. 2012), 
direct regulation of miR27b by IL6 has not been previously reported. 
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Additionally, IL6 overexpression has been reported in vivo in CRC tissue 
(Maihöfner et al. 2003; Chung et al. 2006; Lu et al. 2015; Uchiyama et al. 2012) 
whereas miR27b has been shown to be downregulated (Table 1, section 1.3; 
Yang et al. 2009), suggesting that IL6 may be involved in downregulating 
miR27b expression in vivo as well. 
Furthermore, CYP2E1 expression regulation is not yet well understood and here 
I propose a transcriptional mechanism via direct STAT3 binding to the CYP2E1 
promoter region in response to IL6 treatment. This was demonstrated using a 
ChIP assay, which showed that following IL6 treatment, STAT3 binds to site 2 
of the CYP2E1 promoter with more affinity than site 1 (Figure 2.20). The role of 
these binding sites could be further investigated by deleting each of the sites and 
determining CYP2E1 expression with IL6 treatment or by performing reporter 
gene assays with the CYP2E1 promoter STAT3 binding sites. CYP2E1 plays a 
crucial role in drug bioavailability (Koop 1992) and thus changes in CYP2E1 
expression may lead to modification in drug response, therefore it is crucial to 
understand how this enzyme is regulated.  
A STAT3 inhibitor was used to investigate STAT3 involvement in the IL6 
mediated effects observed in these studies. When the inhibitor was added along 
with IL6, STAT3 binding was prevented suggesting that the inhibitor was 
effective at preventing STAT3 activation by IL6. An inhibitor only control was 
not included in these studies as phosphorylated STAT3 levels are very low in the 
absence of IL6 treatment (Figure 2.18). However, the lack of an inhibitor only 
control means any non-specific effects of the inhibitor are not accounted for in 
these experiments. 
When comparing different cell culture methods, we observed that IL6-mediated 
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effects on promoting BaP- and PhIP-induced DNA damage were not as 
pronounced in 3D cultures as compared to 2D cultures. It has generally been 
shown that a decrease in drug sensitivity is observed in cells cultured in 3D 
compared to 2D (Li et al. 2008; Doillon et al. 2004) likely due to the differences 
in level of exposure caused by the architecture of the spheroid, thus 3D culture 
is thought to better recapitulate in vivo responses. In addition, 3D cells without 
IL6 pre-treatment had a higher level of DNA damage in response to BaP and 
PhIP but not etoposide compared to 2D cells, likely due to the increased 
CYP1A/1B1 activity observed in 3D cells; this may also explain the reduced 
ability for IL6 to further promote BaP/PhIP activation and DNA damage in 3D 
cells.  
In critically evaluating the limitations of the current study, future studies using 
a STAT3 inhibitor only control and validation of current findings using other 
experimental techniques and in vivo studies are indicated. Despite this, the IL6-
mediated effects were observed in two different in vitro culture systems (2D and 
3D) as well as in two different CRC cell lines (HCT116 and SW480), thus 
providing some validation to the current findings. While these findings need to 
be further developed to demonstrate their significance in vivo, they do provide a 
potential mechanistic insight into the link between diet, inflammation and CRC. 
If these data do indeed prove to be relevant in vivo, they would also suggest that 
drugs activated by CYP1B1 or CYP2E1 could be a potential novel therapeutic 
strategy for CRC patients that have high levels of IL6 at the tumour site and that 
dietary prevention methods for patients with an inflammatory bowel condition 
could have the potential to reduce their CRC risk. 
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2.5 Summary 
Here, I investigated the effect of IL6 on DNA damage caused by dietary pro-
carcinogens in CRC cells. Pre-treatment with IL6 enhanced BaP- and PhIP-
induced MN formation while IL6 on its own was not genotoxic. IL6 affected the 
activation pathway of the pro-carcinogens by inducing CYP1B1 expression 
potentially through repression of miR27b in a mechanism involving DNA 
methylation (Figure 2.22). CYP2E1 expression was also induced by IL6 possibly 
through a STAT3-meditated mechanism (Figure 2.22). Increased levels of 
CYP1B1 and CYP2E1 in the cell along with presence of dietary carcinogens could 
result in increased quantities of genotoxic metabolites, thus resulting in DNA 
damage and CRC progression. While these data need to be further validated 
using further in vitro and in vivo experimentation, the discovery of this 
potential novel pathway provides further understanding of the possible 
mechanisms by which IL6 can promote carcinogenesis. Previous reports of IL6-
mediated effects (reviewed in section 1.4) suggest that other pathways are also 
likely to be involved. The next chapter (Chapter 3) focuses on these other 
pathways by investigating the role IL6 plays in altering behaviour of CRC cells.  
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Figure 2.22 Proposed mechanism of CYP1B1 and CYP2E1 regulation 
by IL6 in CRC cells. IL6 present in the TME binds to the soluble IL6 receptor 
(sIL6R), which interacts with transmembrane protein gp130 leading to 
activation of JAK/ STAT3 and PI3K/AKT pathways. Activated STAT3 forms a 
homodimer, translocates to the nucleus and binds to the CYP2E1 promoter 
region, thus inducing its transcription. Activated AKT phosphorylates DNMT1 
leading to its nuclear translocation and DNA methylation at a CpG island 
located near miR27b. Lower expression of miR27b results in increased CYP1B1 
mRNA expression. Reproduced from Patel et al. 2014. 
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Interleukin-6 promotes behavioural 
changes in colorectal cancer cells. 
 
 
 
 
 
 
 
N.B. Results from this chapter have been included in the following peer-
reviewed publication: 
 
Patel, S.A.A. and Gooderham, N.J., 2015. Interleukin-6 mediates crosstalk 
between immune and cancer cells via miR21 and miR29b. Molecular Cancer 
Research (In Press). 
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3.1 Introduction 
Metastatic CRC is responsible for the high disease mortality rate and due to the 
aggressiveness of the disease, metastases often occur before local growth 
produces symptoms (Wang et al. 2012); thus early detection remains 
challenging. Further understanding the mechanisms that promote CRC 
metastasis is key to improving disease outcome. 
The formation of metastases involves the primary tumour invading adjacent 
tissues, entering the systemic circulation and successfully establishing 
micrometastases at distant sites (often in the liver). This multi-step process 
requires overexpression of a number of metastasis-promoting molecules such as 
MMP2 (Kesanakurti et al. 2013; Mott & Werb 2004; Azzam et al. 1993), 
Cathepsin D (CTSD; Ahmad et al. 2012; Rochefort et al. 1990) and VEGF 
(Brown et al. 1997) as a result of the tumour cells undergoing further molecular 
changes. 
Presence of pro-inflammatory cytokine IL6 in the TME is thought to promote 
cancer progression (Nagasaki et al. 2014; Waldner et al. 2012). IL6 induces 
proliferation and invasion of a variety of cancer cell types (Schneider et al. 
2000; Hsu & Chung 2006; Becker et al. 2005). IL6 is known to activate the 
tumour-promoting STAT3 transcription factor via JAK resulting in expression 
of a number of tumour-promoting genes and miRNAs (Johnson et al. 2012; Wei 
et al. 2003; Waldner et al. 2010).  
MiRNAs are dysregulated in CRC and are thought to play a crucial role in 
promoting tumour metastasis. MiR135b is upregulated in malignant CRC cells 
and has been shown to target APC gene expression, an important tumour-
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suppressor gene silenced during CRC initiation (Nakamura et al. 1992; Fearon 
& Vogelstein 1990). MiR21 is commonly overexpressed in numerous diseases 
including IBD and CRC (Asangani et al. 2008), and targets pro-apoptotic and 
tumour-suppressor genes (Asangani et al. 2008; Liu et al. 2012; Li et al. 2014); 
its expression is reported to be induced by STAT3 transcription factor signalling 
(Yang et al. 2010). Let7a is a tumour-suppressor miRNA that is downregulated 
in multiple cancer types including CRC (Akao et al. 2006), and has been shown 
to target IL6 mRNA (Iliopoulos et al. 2009). MiRNAs are therefore intimately 
involved in the regulation of the cancer cell phenotype as well as IL6 signalling, 
thus miRNAs may underlie the strong link between IL6 and CRC progression. 
In the current chapter, I have investigated the effect of IL6 on CRC cell 
behaviour and the potential underlying molecular mechanisms using in vitro 
2D and 3D cell culture methods. My data suggest that IL6 promotes metastatic 
behaviour in the CRC cells, particularly in the HCT116 cell line. Changes in gene 
and miRNA expression appear to be involved in this process. 
Chapter 3 
 - 100 -  
3.2 Materials and Methods 
3.2.1. Cell culture 
Human HCT116 and SW480 cells were cultured in 2D and 3D culture as 
previously described (section 2.2.1). 
3.2.2. Cell proliferation assay 
Viable cells were quantified using AlamarBlue (Invitrogen, Life technologies) 
according to the manufacturer's protocol. Briefly, cells were seeded in a 24-well 
plate at a density of 1x104 cells per well. AlamarBlue (10% of final volume) was 
added at 24 hour intervals. Under these conditions, AlamarBlue is enzymatically 
converted to the fluorescent product resorufin, which can be measured in a 
spectrofluorimeter. The enzymatic conversion to resorufin is proportional to cell 
number. Fluorescence (excitation 560nm/ emission 590 nm) was read in a 
Fluostar plate reader (BMG Labtech) after 1 hour incubation at 37°C. 
Background fluorescence was determined as 10% AlamarBlue in culture 
medium. Results are expressed as fold change compared to the vehicle control. 
3.2.3. Wound-healing assay 
HCT116 and SW480 CRC cells are able to proliferate in dextran-coated 
charcoal-stripped FBS supplemented culture medium. One hundred thousand 
cells/well were plated in 24-well plates and grown for 72 hours in culture 
medium supplemented with 5% dextran-coated charcoal-stripped FBS until 
confluent. Cells were wounded using a sterile tip, washed 3 times with PBS, and 
1ml of culture medium supplemented with 1% dextran-coated charcoal-stripped 
FBS containing IL6 treatment was added to each well. Pictures were taken at 0, 
24 and 72 hours (10x magnification). A grid placed underneath the plate was 
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used to normalise width of the channels and 3 pictures were taken per channel 
for wound width measurements. Wound width for each well was measured and 
normalised to the width of 1 square on the grid. The percentage migration was 
calculated as follows:  
t= time elapsed since wound created 
x(h)= percentage of wound size at t=h hours 
      = (average width of channel t=h hours/ grid width) / (average width of 
channel t=0 hours/ grid width) *100 
(at t= 0 hour, x(0)= 100%) 
% migration(h)= [1-x(h)]*100 
Results are expressed as fold change compared to the vehicle control. 
3.2.4. Transwell migration and invasion assays 
For the migration assay, 3x104 cells per well were plated in 100µl of culture 
medium supplemented with 1% dextran-coated charcoal-stripped FBS in the 
upper chamber of a 96-transwell insert system with 8µm pores (Figure 3.1, BD 
Falcon, Oxford, UK). In the lower chamber, 100µl of culture medium 
containing 10% FBS was added as a chemoattractant. For the invasion assay, 
20ul matrigel was added to upper chamber and left to set at room temperature 
prior to addition of the cells. In both cases, treatment was added to the upper 
chamber and cells were left to migrate to the lower chamber for 72 hours. The 
cells were then removed from the upper chamber using a moist cotton swab 
and cells in the lower chamber were incubated with 10% AlamarBlue 
(Invitrogen, Life technologies) for 2 hours at 37°C to quantify them. Results are 
expressed as fold change compared to vehicle control.  
% migration(h)= [1-((average width of channel t=h hours/ grid width) / 
(average width of channel t=0 hours/ grid width))]*100 
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Figure 3.1 Transwell migration and invasion assay method. 
3.2.5. IL6 treatment and STAT3 inhibition 
Treatments were performed as previously described in section 2.2.2. 
3.2.6. RNA extraction 
Total RNA was isolated from cells using TRIzol reagent (Invitrogen, Life 
technologies) as previously described (section 2.2.4). 
3.2.7. Reverse transcription and qPCR 
Reverse transcription and qPCR were performed as previously described 
(section 2.2.5). Details of primers used are included in Appendix A. 
3.2.8. Transfection of miRNA mimics 
MiRNA mimics were obtained from miRIDIAN mimics (Thermo Fisher 
Scientific, Cramlington, UK) and transfected into the cells using Lipofectamine 
2000 (Invitrogen, Life technologies) according to the manufacturer’s protocol. 
Briefly, cells were seeded at a density of 1x105 cells per well of a 24-well plate 
and culture medium was replaced with 400µl/well of Opti-MEM (GIBCO, Life 
technologies) prior to the addition 150µl/well of Opti-MEM containing 8µl of 
Lipofectamine 2000 reagent and 2.5µl of 20µM stock of miRNA mimic or 
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miRIDIAN miRNA negative control. Cells were incubated with the transfection 
complexes for 24 hours prior to harvest.  
3.2.9. Tissue specimens 
Tissue samples were kindly provided by Dr Hutan Ashrafian from the St Mary’s 
Biobank (Imperial College London, UK) and ethical approval was obtained from 
the Imperial College Research Ethics Committee. The study was conducted 
according to the Helsinki guidelines. Surgical specimens of primary tumours 
and adjacent normal colon were taken at operation with informed consent from 
7 patients with histologically verified colorectal cancer. For all patients, tissue 
sections of both malignant and adjacent normal (taken outside of the tumour 
margin) were provided. Tissue samples were homogenised, protein was 
extracted using RIPA buffer (Sigma-Aldrich) according to the manufacturer’s 
protocol and RNA was extracted using TRIzol reagent (Invitrogen, Life 
technologies) as described previously (section 2.2.4). IL6 was quantified from 
protein samples using the MSD ultra-sensitive multiplex human pro-
inflammatory cytokine kit (kindly gifted by Dr Hector Keun, Imperial College 
London, UK) according to the manufacturer’s protocol using the MSD Sector 
Imager 2400 (MSD, Rockville, Maryland, USA), while gene and miRNA 
expression was determined from the RNA samples using reverse transcription 
and qPCR as previously described (section 2.2.5). 
Statistical analysis 
In vitro cell culture. Statistical significance was assessed as previously 
described (section 2.2.10). Tissue samples. Significant differences between 
tumour and normal tissue were calculated using a Mann-Whitney test 
(GraphPad Prism 5). 
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3.3 Results 
3.3.1 Can IL6 alter CRC cell behaviour? 
The ability for cancer cells to proliferate, migrate and invade surrounding 
tissues is crucial for cancer progression and metastasis. IL6 is reported to 
influence metastatic behaviour, therefore the effect of a dose range of human 
recombinant IL6 (0-20,000pg/ml) was determined on behaviour of CRC cell 
lines HCT116 and SW480 in vitro.  
Chronic treatment with IL6 promoted cell proliferation; however, HCT116 cells 
were more susceptible to IL6 treatment compared to SW480 cells. In the latter, 
the effect was only observed following 5 days of chronic treatment while a 
significant increase in proliferation after 48 hours was observed in HCT116 cells 
(Figure 3.2). Furthermore, these effects were only apparent at the highest dose 
of IL6 (20,000pg/ml). Addition of a STAT3 inhibitor prevented this IL6-
mediated effect in both cell lines, suggesting that STAT3 signalling is likely to be 
involved in the observed proliferative response (Figure 3.2). 
 
 
 
 
 
 
 
Chapter 3 
 - 105 -  
 
 
Figure 3.2 Cell proliferation in response to IL6 treatment. HCT116 and 
SW480 cells were treated daily for 5 days with a dose range of IL6 (0-
20,000pg/ml). Cell proliferation was determined using AlamarBlue. Data are 
expressed as fold change compared to vehicle control (0pg/ml IL6). Significance 
was calculated using two-way ANOVA followed by a Bonferroni post-test 
(GraphPad Prism 5, ***p<0.001, **p<0.01, * p<0.05). Error bars represent the 
SEM for independent cultures (n=3). 
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In addition, cell migration and invasion in response to IL6 treatment was 
assessed in both cell lines grown in 2D and 3D cell culture. Cell migration was 
investigated using a wound-healing assay. Treatment with IL6 significantly 
increased cell motility in both HCT116 and SW480. However, the latter 
responded only to doses  >200pg/ml after 72 hours (Figure 3.3 C and D) while 
HCT116 cell migration was significantly increased with ≥40pg/ml after a 24 
hour treatment and with ≥10pg/ml after 72 hours (Figure 3.3 A and B). The 
effect IL6 treatment in HCT116 cells was further confirmed using transwell 
migration and invasion assays where the cells had increased motility with 
≥5pg/ml IL6 (Figure 3.4 A), whereas IL6 failed to produce a significant 
response in SW480 cells (Figure 3.4 B). Inhibiting STAT3 signalling prevented 
the IL6-mediated increase in migration and invasion in HCT116 cells (Figure 3.4 
A). Moreover, a bell-shaped dose response curve for HCT116 migration and 
invasion was observed with IL6 treatment. This response was not caused by a 
drop in cell viability at the higher treatment doses since cell proliferation at 
those doses was unaffected by IL6 treatment (Figure 3.2). IL6 treatment has 
been shown to produce a bell-shaped dose response (van Dam et al. 1993; Wang 
et al. 2004), as signal transduction does not rely solely on ligand concentration 
but requires multivalent ligand binding to induce receptor crosslinking (in the 
case of IL6, signalling is mediated by dimerization of gp130) for activation of 
downstream signalling. 
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Figure 3.3 Effect of IL6 on wound healing in HCT116 and SW480 
cells. (A and C) Wound assays were performed over 72 hours using HCT116 
and SW480 cells treated with IL6 (0-1000pg/ml). (B and D) Pictures of 
wounded HCT116 (B) and SW480 (D) cells taken at 0 or 72 hours with or 
without IL6 treatment (10x magnification). Data are expressed as fold change 
compared to vehicle control (0pg/ml IL6). Significance was calculated using 
one-way ANOVA with a Dunnett post-test comparing treated groups to vehicle 
control (GraphPad Prism 5, *p<0.05, **p<0.01, ***p<0.001). Error bars 
represent the SEM for independent cultures (n=3). 
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Figure 3.4 Effect of IL6 on HCT116 and SW480 cell migration and 
invasion. Transwell migration and invasion assays were performed over 72 
hours in HCT116 (A) and SW480 (B). Migrated cells to the bottom chamber 
were quantified using AlamarBlue. Data are expressed as fold change compared 
to vehicle control (0pg/ml IL6). Significance was calculated using two-way 
ANOVA with a Bonferroni post-test comparing treated groups to vehicle control 
(GraphPad Prism 5, *p<0.05, **p<0.01, ***p<0.001). Error bars represent the 
SEM for independent cultures (n=3). 
With cells grown as 3D spheroids, the effect observed was not as apparent as in 
2D cell culture, however invasion of HCT116 cells was significantly induced with 
a dose-dependent trend by IL6 treatment while again, no effect was observed in 
SW480 cells (Figure 3.5). This difference in susceptibility to IL6 treatment 
between the cell lines is in agreement with the respective responses for cell 
proliferation.  
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Figure 3.5 Effect of IL6 on migration and invasion of HCT116 and 
SW480 cells grown as 3D spheroids. Cells were grown on bioscaffolds 
(Algimatrix) for 10 days. Scaffolds of HCT116 and SW480 cell spheroids were 
added to the upper chamber and the transwell migration and invasion assay was 
performed over 72 hours. 10% FBS was added to the bottom chamber as a 
chemoattractant. For the invasion assay, the upper chamber was coated with 
matrigel prior to adding the cells. Cells appearing in the bottom compartment 
were quantified using AlamarBlue. Data are expressed as fold change compared 
to vehicle control (0pg/ml IL6). Significance was calculated using one-way 
ANOVA with a Dunnett post-test comparing treated groups to vehicle control 
and linear trend analysis (GraphPad Prism 5, *p<0.05). Error bars represent 
the SEM for independent cultures (n=3). 
Inflammatory cytokines can also act as chemoattractants. To determine whether 
the effects observed were due to molecular changes within the cells and not a 
chemoattractive effect of IL6, transwell migration experiments were repeated 
using IL6 as the chemoattractant in the bottom chamber. No increase in 
HCT116 migration was noted (Figure 3.6), suggesting that IL6 changes the 
cellular behaviour of HCT116 cells, potentially through molecular alterations 
rather than just acting as a chemoattractant.  
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Figure 3.6 Effect of IL6 as a chemoattractant in HCT116 cells. 
Transwell migration assays was performed over 72 hours with HCT116 cells 
seeded in the upper chamber. IL6 was added to the bottom chamber as a 
chemoattractant. Cells appearing in the bottom compartment were quantified 
using AlamarBlue. Data are expressed as fold change compared to vehicle 
control (0pg/ml IL6). Significance was calculated using one-way ANOVA with a 
Dunnett post-test comparing treated groups to vehicle control (GraphPad Prism 
5). Error bars represent the SEM for independent cultures (n=3). 
In order to gain further insight into these potential IL6-mediated molecular 
changes, I investigated whether the cells were undergoing phenotypic changes 
to become more mesenchymal-like. 
3.3.2 Does IL6 treatment promote EMT? 
Cancer cells commonly undergo phenotypic changes in response to various 
stimuli. One such change is EMT, where cells lose their epithelial phenotype 
characterised by tight cell-cell junctions and become mesenchymal-like with the 
ability to invade surrounding tissue (Lamouille et al. 2014). EMT is a key 
process in metastasis and as I previously observed increased cell migration and 
invasion in response to IL6, I investigated whether EMT was responsible for 
this effect. E-cadherin is a cell adhesion molecule expressed at high levels in 
epithelial cells but lost in mesenchymal cells; its downregulation is a classic 
marker for EMT. I thus measured E-cadherin gene expression in the cells 
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following IL6 treatment. Interestingly, HCT116 has increased expression of E-
cadherin while again no significant changes were observed in SW480 and in 
either cell line when grown as 3D cultures (Figure 3.7), suggesting EMT might 
not be occurring in response to IL6 in these cells. I therefore investigated 
whether expression of other genes known to be involved in CRC metastasis were 
changed in response to IL6. 
 
Figure 3.7 IL6 effect on E-cadherin gene expression. (A) HCT116 and 
SW480 cells grown in 2D cell culture were treated with 0, 10, 100 and 
1000pg/ml IL6 for 48 and 24 hours respectively. (B) HCT116 and SW480 3D 
spheroids were grown for 10 days prior to treatment with 1000pg/ml and 
5000pg/ml IL6 for 24 hours respectively. E-cadherin expression was measured 
by RT-qPCR. Data were normalised to expression of GAPDH and are shown 
relative to vehicle control. Significance was calculated using Student’s t-test or 
one-way ANOVA with a Dunnett post-test comparing treated groups to vehicle 
control and linear trend analysis (GraphPad Prism 5, *p<0.05). Error bars 
represent the SEM for independent cultures (n=3). 
3.3.3 Are oncogenes known to be involved in CRC metastasis 
regulated by IL6? 
A number of genes involved in cancer metastasis and growth were investigated 
in response to elevated levels of IL6 in CRC cell lines HCT116 and SW480. The 
tumour-suppressor p53 expression was not significantly changed in response 
IL6 treatment (Figure 3.8 and 3.9). Expression of VEGFA, MMP2, CTSD and 
JAK2, which are actively involved in different aspects of tumour promotion (as 
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detailed in the introduction, section 3.1), were upregulated by IL6 in HCT116 
cells with a significant dose-dependent trend (Figure 3.8). This effect was not 
observed in SW480 cells, possibly explaining the lack of cellular response to IL6 
treatment observed previously (Chapter 3.3.1). In addition, JAK2, MMP2 and 
CTSD expression appeared to be increased with IL6 treatment in HCT116 3D 
spheroids (Figure 3.9), however these changes were not statistically significant. 
 
Figure 3.8 IL6 effect on JAK2, VEGFA, CTSD, MMP2 and p53 gene 
expression. HCT116 and SW480 cells were treated with 0, 10, 100 and 
1000pg/ml IL6 for 48 and 24 hours respectively. JAK2, VEGFA, CTSD, MMP2 
and p53 expression were measured by RT-qPCR. Data were normalised to 
expression of GAPDH and are shown relative to vehicle control. Significance 
was calculated using one-way ANOVA with a Dunnett post-test comparing 
treated groups to vehicle control and linear trend analysis (GraphPad Prism 5, 
*p<0.05). Data are presented as a mean of three biological replicates. Error bars 
represent the SEM for independent cultures. 
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Figure 3.9 JAK2, CTSD, MMP2 and p53 gene expression changes in 
response to IL6 in HCT116 3D spheroids. HCT116 3D spheroids were 
grown for 10 days prior to treatment with 0 and 1000pg/ml IL6 for 24 hours. 
JAK2, CTSD MMP2 and p53 expression were measured by RT-qPCR. Data were 
normalised to expression of GAPDH and are shown relative to vehicle control. 
Significance was assessed using a Student’s t-test (GraphPad Prism 5). Data are 
presented as a mean of three biological replicates. Error bars represent the SEM 
for independent cultures. 
As I previously observed that STAT3 inhibition prevented the IL6-mediated 
induction of cell proliferation, I investigated the effect of STAT3 inhibition on 
JAK2, CTSD and MMP2 gene expression in HCT116 cells, as VEGFA is already 
known to be regulated by STAT3 (Wei et al. 2003). Co-treatment with IL6 and 
the STAT3 inhibitor appeared to bring expression levels back to control values, 
however none of these changes were significant; thus STAT3 may be involved in 
regulating expression of these genes but further validation is required (Figure 
3.1o).  
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Figure 3.1o STAT3 involvement in JAK2, CTSD and MMP2 gene 
expression. HCT116 cells were treated with 0, 1000pg/ml IL6 and IL6 + 25µM 
STAT3 inhibitor for 48 hours. JAK2, CTSD and MMP2 expression were 
measured by RT-qPCR. Data were normalised to expression of GAPDH and are 
shown relative to vehicle control. Significance was calculated using one-way 
ANOVA with a Dunnett post-test comparing treated groups to vehicle control 
(GraphPad Prism 5). Data are presented as a mean of three biological replicates. 
Error bars represent the SEM for independent cultures. 
3.3.4 Can IL6 treatment induce changes in miRNA expression? 
I tested expression of a number of CRC tumour-suppressing (miR375, miR124a 
and let7a) and tumour-promoting miRNAs (miR31, miR21, miR135b and 
miR96). MiR29b expression was also investigated due to its controversial role in 
tumourigenesis; indeed it has been found to have oncogenic (Wang et al. 2011; 
Xu et al. 2013) and tumour-suppressive roles (Jia et al. 2014; Melo & Kalluri 
2013; Subramanian et al. 2014; Wang et al. 2014; Inoue et al. 2014). In HCT116 
grown in 2D culture, miR135b, miR21 and miR29b appear to be upregulated in 
response to IL6 with significant dose-dependent trends, while only miR21 and 
miR29b were upregulated in SW480 cells (Figure 3.11). In 3D cell culture, no 
significant changes were observed in miRNA expression with IL6 treatment 
(Figure 3.12).  
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Figure 3.11 IL6 effect on miRNA expression. HCT116 and SW480 cells 
grown as monolayers, were treated with 0, 10, 100 and 1000pg/ml IL6 for 48 
and 24 hours respectively. MiRNA expression was measured by RT-qPCR. Data 
were normalised to expression of U6 RNA and are shown relative to vehicle 
control. Significance was calculated using one-way ANOVA with a Dunnett post-
test comparing treated groups to vehicle control and linear trend analysis 
(GraphPad Prism 5, *p<0.05, ***p<0.001). Data are presented as a mean of 
three biological replicates. Error bars represent the SEM for independent 
cultures 
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Figure 3.12 MiRNA expression changes in response to IL6 in HCT116 
and SW480 3D spheroids. HCT116 and SW480 3D spheroids were grown 
for 10 days prior to treatment with 1000pg/ml and 5000pg/ml IL6 for 24 hours 
respectively. MiRNA expression was measured by RT-qPCR. Data were 
normalised to expression of U6 RNA and are shown relative to vehicle control. 
Significance was assessed using Student’s t-test (GraphPad Prism 5). Data are 
presented as a mean of three biological replicates. Error bars represent the SEM 
for independent cultures. 
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3.3.5 What effects do miR21 and miR29b have on CRC cells? 
Following the observation that IL6 induces miR21 and miR29b expression in 
vitro, I determined the effect of these miRNAs on cell growth, migration and 
invasion using overexpression studies (Figure 3.13 A). I found that both 
miRNAs appeared to induce cell proliferation however these changes were not 
significant compared to the mimic control (Figure 3.13 B). Additionally, miR29b 
appeared to induce cell invasion in the HCT116 cell line (Figure 3.13 C), 
suggesting a potential pro-metastatic role for miR29b. As observed previously 
(section 3.3.1), induction of invasion was not observed in SW480. In order to 
determine whether elevated levels of IL6 can induce miRNA expression changes 
in vivo, I tested human tumour and adjacent normal samples for IL6 and 
miRNA expression. 
3.3.6 Do IL6 and miRNA expression change in malignant colorectal 
tissue? 
Tumour tissue and adjacent normal samples resected from CRC patients were 
analysed for IL6, miR21 and miR29b expression. However, IL6 expression was 
not significantly increased in the tumour tissue compared to adjacent normal in 
this sample set (Figure 3.14 A and B). Additionally, no change in miR29b or 
miR21 expression was observed in these samples (Figure 3.14 C and D). 
Therefore, these data do not exclude the possibility that IL6 may regulate 
miR29b and miR21 in vivo, however this remains unverified in the current 
study. Furthermore, the sample set only included 7 patients, which is too 
limited a number to accurately assess potential effects. 
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Figure 3.13 Effect of miR29b and miR21 expression on CRC cells. (A) 
miR21 and miR29b mimics were transfected into the cells. MiRNA expression 
data were normalised to expression of U6. (B) Transwell migration and invasion 
assays were performed over 72 hours. Migrated cells were quantified using 
AlamarBlue. (C) Cell proliferation was determined using AlamarBlue. Data are 
shown relative to mimic control. Significant differences were calculated using 
one-way ANOVA followed by a Dunnet post-test (GraphPad Prism 5, 
***p<0.001, *p<0.05). Error bars represent the SEM for independent cultures 
(n=3). 
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Figure 3.14 IL6, miR29b and miR21 expression in CRC tissue 
samples. IL6 concentration was measured in protein extracted from tissue 
samples (A). IL6 mRNA (B), miR29b (C) and miR21 (D) expression were 
measured by RT-qPCR. Gene expression data were normalised to expression of 
GAPDH and U6 for mRNA and miRNA expression respectively, and are shown 
relative to normal tissue control. Significant differences between tumour and 
normal tissue were calculated using a Mann-Whitney test (GraphPad Prism 5, 
n=7). 
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3.4 Discussion 
IL6 is a key regulator of the inflammatory response; it is also thought to be 
important in CRC initiation and progression, and increased levels of IL6 are 
present in CRC tumours and stroma (Maihöfner et al. 2003; Nagasaki et al. 
2014; Chung et al. 2006; Lu et al. 2015; Uchiyama et al. 2012). In the current 
study, I investigated the effect of IL6 on CRC cell behaviour in vitro using 
HCT116 and SW480 cells grown as 2D and 3D cultures. I established that 
elevated levels of IL6 promote CRC cell proliferation, migration and invasion, 
which are key behavioural features of metastatic cells. These changes were 
accompanied by increased expression of oncogenes such as JAK2, MMP2, CTSD 
and VEGFA. STAT3 signalling inhibition appeared to reverse this effect, 
although the IL6-induced changes were not significant and thus the effect of 
STAT3 could not be confirmed with statistical significance. Again, the lack of 
STAT3 inhibitor only control means any non-specific effect of the inhibitor is 
not accounted for in these experiments (more detail on the implication of this in 
Chapter 2, section 2.4). Importantly, the doses of IL6 used in these studies were 
in-keeping with IL6 levels found in the TME (Nagasaki et al. 2014) and under 
these conditions, induced changes may be subtle and difficult to confirm 
statistically with small experimental numbers. Further experimentation using 
higher IL6 doses is needed to validate any potential changes observed here.  
Furthermore, the changes observed in response to IL6 were primarily observed 
in HCT116 cells compared to SW480, possibly due to the fact that no changes in 
MMP2 and CTSD expression were observed in the latter. When comparing 
relative expression of these genes in both cell lines, I observed that these are 
expressed at much higher levels in SW480 cells compared to HCT116 (Figure 
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3.15), thus possibly explaining their reduced susceptibility to induction by IL6.  
 
Figure 3.15 CTSD and MMP2 gene expression in HCT116 and SW480. 
MMP2 (A) and CTSD (B) expression were measured by RT-qPCR in HCT116 
and SW480 cells. Data are shown relative to expression of GAPDH. Significance 
was assessed using Student’s t-test (GraphPad Prism 5, ***p<0.001). Data are 
presented as a mean of three biological replicates. Error bars represent the SEM 
for independent cultures. 
Furthermore, only a select few genetic markers of cell migration and invasion 
were investigated here. Such a targeted approach can miss key changes 
mediated by IL6 and therefore a more complete study should include an 
investigation of the IL6 effect on global gene regulation.  Of these select few 
gene targets, knockdown and overexpression studies could be useful additional 
studies to establish their involvement in the behavioural changes observed 
following IL6 treatment.  
Also, HCT116 are known to have cancer stem cell (CSC)-like properties 
(Botchkina et al. 2009); CSC cells are thought to be important drivers of cancer 
progression playing a key role in metastasis and drug-resistance. As with 
normal stem cells, these cells are regulated by their microenvironment and the 
IL6-STAT3 pathway has been reported to be an important regulator of CSCs 
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(Liu et al. 2014; Zhu et al. 2014; Korkaya et al. 2011), providing another 
plausible explanation for the higher susceptibility of HCT116 cells to IL6 
treatment compared to SW480 cells. 
I also observed changes in miRNA expression in response to IL6, in particular 
increased expression of miR21 and miR29b. MiR21 is a known oncogenic 
miRNA as it targets pro-apoptotic PTEN and PDCD4 expression (Asangani et 
al. 2008; Liu et al. 2012; Li et al. 2014). MiR21 overexpression has previously 
been reported in CRC tissue and it is also thought to be associated with 
metastasis. It is known to be regulated by STAT3 (Yang et al. 2010), which is 
activated by IL6, thus my data concur with previous observations. Mir29b has a 
disputed role in cancer; it has been reported to be both tumour promoting and 
suppressing (Wang et al. 2014; Luo et al. 2011; Slaby et al. 2009; Jiang et al. 
2014). I found that miR29b induced cell invasion, suggesting a potential pro-
tumourigenic role in the current CRC model. MiR21 and miR29b have also been 
reported as circulatory miRNAs able to integrate into surrounding cells acting 
as paracrine signalling molecules (Ogata-Kawata et al. 2014; Dorval et al. 2013; 
Guay & Regazzi 2013; Yang et al. 2012; Wu et al. 2010; Valadi et al. 2007), 
suggesting these miRNAs may play a role in the TME in addition to their 
potential oncogenic roles within the CRC cells. 
In addition, it appeared that IL6 effects observed in cells cultured as 3D 
spheroids were generally less obvious than in cells grown as 2D cultures. 
Decreased drug sensitivity has been reported when comparing cells cultured in 
3D to 2D (Li et al. 2008; Doillon et al. 2004), and these differences are likely 
due to the changes in tissue architecture: access to the inner cells of the 
spheroid is limited resulting in uneven treatment exposure levels. While this 
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effect was only mildly observed in the previous chapter (Chapter 2), it appears 
to be more apparent with the current study, particularly when no increase in 
miR29b and miR21 were observed in 3D cultured cells in response to IL6 
compared to an induction in 2D cells of up to 20-fold (Figure 3.11). Uneven 
exposure of cells to treatment would be an unlikely explanation for such 
differences; other possible reasons could include differences in miRNA 
processing mechanisms or higher background expression of these miRNAs in 
3D cultures compared to 2D cultures. However, when comparing expression 
levels in untreated cells (Appendix C, Figure S.11), miR21 and miR29b levels 
appear to be similar between cells grown in 2D and 3D cultures. Another 
possibility is that 3D cultures are more effective at secreting these miRNAs, and 
thus higher levels of the miRNAs in response to IL6 are readily transported out 
of the cells making them undetectable when analysing miRNA expression 
within the cells. This could be verified by analysing miRNA levels in the cell 
culture medium of 3D spheroids treated with IL6 and comparing these to that of 
2D cultures. The lack of response in 3D cultured cells compared to the observed 
2D culture findings is not readily explainable; therefore it is important to 
understand why these differences occur and which system more closely relates 
to in vivo models and relevance to the CRC disease state. 
As an attempt to determine in vivo relevance of the current in vitro findings, I 
investigated possible changes in IL6, miR21 and miR29b expression in CRC 
tumour tissue compared to adjacent normal. In the current sample set no 
significant changes were observed. However, studies with larger CRC tissue 
sample sets have reported that IL6, miR21 and miR29b expression are 
increased in malignant cells (Maihöfner et al. 2003; Xu et al. 2012; Tan et al. 
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2013; Uchiyama et al. 2012; Nagasaki et al. 2014; Lu et al. 2015); therefore 
regulation of these miRNAs by IL6 may still occur in vivo but the data presented 
here were insufficient to draw any conclusions. In addition, using adjacent 
normal tissue from the same patients as a control cohort may not be suitable as 
it has been suggested that these tissues may be undergoing phenotypic changes 
due to their proximity to the tumour cells and microenvironment (Clare et al. 
2012). It is also important to note that only a very small number of patients 
(n=7) were used in the current study, which is not a large enough population to 
provide an accurate representation of the CRC cohort. Given these limitations, 
the significance of these results is difficult to assess and a larger study is 
necessary in order to draw any conclusions.  
Interestingly, it was recently discovered that miR21 and miR29a are able to bind 
Toll-Like receptor 8 (TLR8) contained within endosomes in immune cells to 
induce an inflammatory response (Fabbri et al. 2012). Given that I have 
observed IL6-medieated increased expression of miR21 and miR29b, a miRNA 
closely related to miR29a, I investigated the potential role of IL6 and these 
miRNAs in promoting crosstalk between tumour cells and immune cells in the 
microenvironment, which I have discussed in the next chapter (Chapter 4). 
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3.5 Summary 
Taken together, the data from this study demonstrated that IL6 alters CRC cell 
behaviour accompanied by changes in gene and miRNA expression (Figure 
3.16). MiR21 and miR29b were both upregulated by IL6 treatment in 2D culture 
and thus have emerged as interesting miRNAs due to their reported circulatory 
nature. Therefore, the next chapter will concentrate on their role in the TME 
using an in vitro co-culture system. 
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Figure 3.16 Suggested model for IL6-mediated CRC cell behavioural 
changes through altered gene and microRNA expression. IL6 activates 
STAT3 to induce expression of MMP2, CTSD, miR21 and miR29b resulting in 
increased cell proliferation, invasion and migration. 
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Interleukin-6 promotes intercellular 
communication in the tumour 
microenvironment via miR21 and miR29b. 
 
 
 
 
 
 
N.B. Results from this chapter have been included in the following peer-
reviewed publication: 
 
Patel, S.A.A. and Gooderham, N.J., 2015. Interleukin-6 mediates crosstalk 
between immune and cancer cells via miR21 and miR29b. Molecular Cancer 
Research (In Press). 
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4.1 Introduction 
Roughly half the cells contained in a malignant tumour are non-cancerous cells. 
Indeed, tumour cells are surrounded and infiltrated by a variety of stromal cells 
including fibroblasts and vascular endothelial cells, as well as immune cells, 
which interact with malignant cells to create the TME (Balkwill et al. 2012; 
Bhome et al. 2015). 
This complex environment is thought to promote cancer progression and has 
been identified as a potential target for therapy (Albini & Sporn 2007; Balkwill 
& Mantovani 2012; Noy & Pollard 2014). Understanding cell-cell 
communication within the TME is key to this therapeutic approach. The tumour 
cells are thought to communicate via extracellular signals with surrounding 
cells to promote their progression, and cytokines have emerged as important 
mediators of this crosstalk (detailed in Chapter 1, section 1.3). 
IL6 is secreted by tumour cells as well as surrounding CAFs and immune cells 
resulting in presence of high levels in the TME (stromal cells can secrete up to 
8000pg/ml; Nagasaki et al., 2014). Importantly, IL6 is also thought to play an 
important role in cancer progression (Nagasaki et al. 2014; Waldner et al. 2012; 
Taniguchi & Karin 2014; Grivennikov et al. 2009). In the previous chapter, I 
have demonstrated that IL6 can alter behaviour of CRC cells and induce 
expression of miRNAs miR21 and miR29b. 
In recent years, a new role for miRNAs as paracrine signalling molecules has 
emerged (Valadi et al. 2007). This hormone-like function is particularly 
apparent in the immune response where miRNAs facilitate the crosstalk 
between different types of immune cells (Mittelbrunn et al. 2011) and can also 
activate human immune cells by binding to TLR8 (Fabbri et al. 2012). Indeed, 
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miR21 and miR29a can act as TLR8 ligands in a similar way to viral single-
stranded RNA, resulting in stimulation of the host immune cell to produce and 
secrete pro-inflammatory cytokines including IL6.  
In this chapter, I have investigated the potential role of IL6, miR21 and miR29b 
in mediating intercellular communication between CRC cells and adjacent 
immune cells using an in vitro co-culture model.  
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4.2 Materials and Methods 
4.2.1 Cell culture 
The human monocyte-like THP1 cell line was kindly gifted by Dr James Pease 
(Imperial College London, UK) and routinely cultured in RPMI1640 medium 
(GIBCO, Life technologies, Paisley, UK) supplemented with 10% FBS, 
100units/ml penicillin, 100µg/ml streptomycin and 2mM L-glutamine (GIBCO, 
Life technologies). HCT116 and SW480 were cultured as 2D and 3D cultures as 
previously described (section 2.2.1). For co-culture experiments, THP1 
suspension cells were added to the CRC adherent cell lines. All cells were 
incubated at 37°C in a humidified incubator (5% CO2).  
4.2.2 IL6 and lipopolysaccharide treatment 
HCT116 and SW80 cells were treated as previously described (section 2.2.2). 
For THP1 cells, 1µg/ml lipopolysaccharide (LPS) purified from Escherichia 
coli 0127:B8 by phenol extraction (Sigma-Aldrich, Dorset, UK) and dissolved in 
cell culture medium was added to the cells for 3 hours to in order to stimulate 
pro-inflammatory cytokine secretion.  
4.2.3 Transwell migration and invasion assays 
Assays were performed as previously described (section 3.2.4). 
4.2.4 RNA extraction 
Total RNA was isolated from cells using TRIzol reagent (Invitrogen, Life 
technologies) as previously described (section 2.2.4). For miRNA isolation from 
cell culture medium, miRVANA PARIS kits were used (Applied biosystems, Life 
technologies) with 400µl of conditioned medium according to the 
manufacturer’s protocol. Synthetic C. elegans miR39 was spiked in to every 
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sample at a concentration of 0.15 fmol (Ambion. Life technologies) and used to 
normalise miRNA expression in culture medium. 
4.2.5 Reverse transcription and qPCR 
Reverse transcription and qPCR were performed as previously described 
(section 2.2.5). Details of primers used are included in Appendix A. 
4.2.6 Transfection of miRNA mimics 
Transfection experiments were performed as previously described (section 
3.2.8) using THP1 cells  
4.2.7 Enzyme-linked immunosorbent assay (ELISA) 
IL6 was quantified in cell culture medium using the Human IL6 Quantikine 
ELISA Kit according to manufacturer’s protocol (R&D systems, Abingdon, UK). 
The kit was kindly gifted by Dr Marc Dumas (Imperial College London, UK). 
Absorbance was measured in a Synergy H1 plate reader (Biotek, Potton, UK). 
4.2.8 Statistical Analysis 
Statistical significance was assessed as previously described (section 2.2.10). 
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4.3 Results 
4.3.1 Can conditioned medium from immune cells have an effect on 
CRC cell behaviour? 
In the TME, immune cells interact with cancer cells via a complex mixture of 
cytokines including IL6. To recapitulate this environment, conditioned medium 
from activated THP1 human monocytic cells containing an array of pro-
inflammatory cytokines including IL6, IL1β and TNFα, was added to CRC cells. 
THP1 cells were first stimulated for 3 hours with 1µg/ml LPS and IL6 expression 
and secretion levels were measured (Figure 4.1).  
 
 
Figure 4.1 IL6 expression and secretion in LPS-stimulated THP1 
cells. THP1 cells were treated with 1µg/ml LPS for 3h. (A) IL6 mRNA 
expression in THP1 cells was measured by RT-qPCR. Data were normalised to 
expression of GAPDH and are shown relative to vehicle control.  (B) IL6 
secretion was measure by ELISA assay in conditioned media from triplicate 
cultures of THP1 cells. Data are expressed as IL6 concentration in pg/ml. 
Significance was assessed using Student’s t-test (GraphPad Prism 5, 
***p<0.001). Error bars represent the SEM (n=3).  
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Conditioned medium from the stimulated THP1 cells was then used to treat 2D 
HCT116 and SW480 cells for 24 hours. A transwell assay was performed to 
determine the effect of the conditioned medium on cell migration and invasion 
(Figure 4.2). As with IL6 treatment (Chapter 3, section 3.3.1), a significant 4 
fold increase in cell invasion was observed in HCT116 cells treated with 
conditioned medium from LPS stimulated THP1 cells. This induction of 
invasion is similar to that seen with 80pg/ml of IL6 alone (Chapter 3, section 
3.3.1), suggesting that this effect is primarily mediated by IL6 and not the other 
pro-inflammatory cytokines present in the conditioned medium. However, cell 
migration was not induced and no significant changes were noted in SW480 
cells and HCT116 grown as 3D spheroids, which is similar to our findings with 
IL6 treatment alone (Chapter 3, section 3.3.1). While MMP2 expression 
appeared to be increased in HCT116 cells following a 24 hour treatment with 
conditioned medium, these changes were not significant (Figure 4.3). 
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Figure 4.2 Effect of LPS-stimulated THP1 culture medium on SW480 
and HCT116 cell migration and invasion. THP1 cells were treated with 
1µg/ml LPS for 3 hours, conditioned medium was collected and used to treat 
SW480 and HCT116 cells for a further 24 hours. A transwell migration and 
invasion assay was performed over 72 hours with HCT116 (A), SW480 (B) cells 
grown in 2D culture and 3D HCT116 spheroids (C). Cells were added to the 
upper chamber and 10% FBS was added to the bottom layer as a 
chemoattractant. For the invasion assay, the upper chamber was coated with 
matrigel prior to cell seeding. Cells in the bottom compartment were quantified 
using AlamarBlue. Data are expressed as fold change of vehicle control (non-
stimulated THP1 conditioned medium). Significance was assessed using 
Student’s t-test (GraphPad Prism 5, ***p<0.001). Error bars represent the SEM 
for independent cultures (n=3). 
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Figure 4.3 Effect of activated THP1 culture medium on MMP2 and 
CTSD expression in CRC cells. THP1 cells were treated with 1µg/ml LPS for 
3 hours. Conditioned medium was used to treat SW480 and HCT116 cells for 24 
hours. CTSD and MMP2 expression were measured by RT-qPCR. Data were 
normalised to expression of GAPDH and are shown as a fold change of vehicle 
control (non-stimulated THP1 conditioned medium). Significance was assessed 
using Student’s t-test (GraphPad Prism 5). Error bars represent the SEM for 
independent cultures (n=3). 
4.3.2 Do CRC cells have an effect on surrounding immune cells? 
In the current model, only THP1 cells are able to secrete IL6, as HCT116 and 
SW480 do not produce detectable amounts of IL6 mRNA (Appendix A, Figure 
S.4). So as to determine whether the cancer cells can stimulate THP1 cells to 
sustain IL6 production, I cultured HCT116 or SW480 cells with THP1 cells for 
24 hours and measured IL6 expression and secretion by the THP1 cells (Figure 
4.4). Interestingly, co-culture alone was not able to significantly induce IL6 
production by THP1 cells. However, when the CRC cells were pre-treated with 
IL6 for 24 hours prior to co-culture, IL6 production was significantly induced 
in the THP1 cells suggesting that factors released by IL6-treated CRC cells but 
not untreated CRC cells are responsible for THP1-mediated IL6 secretion. 
Interestingly, co-culture with IL6-treated SW480 cells was more effective at 
inducing IL6 synthesis in immune cells compared with HCT116 cells. I then 
investigated whether miRNAs could be the factors released by IL6-treated CRC 
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cells involved in inducing IL6 production by THP1 cells. 
 
Figure 4.4 Effect of CRC cells on IL6 synthesis by THP1 monocyte-
like cells. HCT116 and SW480 cells were pre-treated with or without 
1000pg/ml IL6 for 24 hours prior to co-culturing with THP1 cells for a further 
24 hours. (A) IL6 expression in THP1 cells was measured by RT-qPCR (n=6). 
Data were normalised to expression of GAPDH and are shown relative to 
negative control (THP1 alone). (B) IL6 secretion by THP1 cells was measured in 
the conditioned medium using an ELISA (n=3). Data are expressed as fold 
change compared to negative control (THP1 alone). Significance was calculated 
using one-way ANOVA with a Dunnett post-test (GraphPad Prism 5, *p<0.05, 
**p<0.01, ***p<0.001). Error bars represent the SEM for independent cultures. 
4.3.3 Are IL6-induced miRNAs involved in CRC-immune cell 
communication? 
In the previous Chapter (Chapter 3, section 3.3.4), I determined that IL6 
treatment of HCT116 and SW480 cells promoted expression of miR21 and 
miR29b. These two miRNAs have the potential to bind TLR8 to activate the 
immune cells and induce the NFκB pathway promoting IL6 expression. To 
investigate whether miR21 and miR29b are the factors secreted by IL6-treated 
CRC cells that promote THP1-mediated IL6 production, I first investigated 
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whether these miRNAs were secreted by the CRC cells (Figure 4.5). While 
miR21 and miR29b are secreted by CRC cells alone, their secretion is 
significantly increased when the cells are treated with IL6 and this secretion is 
greater in SW480 cells, which correlates with their increased ability to stimulate 
IL6 expression in THP1 cells. 
 
Figure 4.5 MiR21 and miR29b are secreted by IL6-treated CRC cells. 
HCT116 and SW480 cells were treated with or without 1000pg/ml IL6 and 
conditioned media from triplicate cultures was collected after 24 hours. (A) 
MiR21 and miR29b expression in the conditioned medium were measured by 
RT-qPCR. Data were normalised to expression of C.elegans miR39 spike-in (B). 
Data are expressed as fold change compared to negative control (unconditioned 
medium only). Significance was assessed using Student’s t-test (GraphPad 
Prism 5, *p<0.05, **p<0.01). Error bars represent the SEM for independent 
cultures (n=3). 
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To confirm whether secreted miR21 and miR29b are able to induce IL6 
expression in receiving immune cells, miRNA mimics were transfected into 
THP1 cells and IL6 mRNA expression was measured (Figure 4.6). Both miR21 
and miR29b mimics induced more than a 2 fold induction of IL6 expression in 
THP1 cells compared to the control mimic, suggesting that miR21 and miR29b 
secreted by IL6-treated CRC cells are able to further promote IL6 production in 
surrounding immune cells, thus generating a feedback loop.	  	  
	  
 
Figure 4.6 Effect of miR29b and miR21 on IL6 expression in THP1 
cells. MiR21 and miR29b mimics were transfected into THP1 cells. IL6 mRNA 
expression was normalised to expression of GAPDH. Data are shown relative to 
mimic control. Significant differences were calculated using a Student’s t-test 
(GraphPad Prism 5). Error bars represent the SEM for independent cultures 
(n=3). 
Activated immune cells induce the NFκB pathway, which is known to promote 
miR21 expression (Shin et al. 2011). As miR21 is a circulating miRNA and 
known to be oncogenic, I sought to determine whether activated immune cells 
could also secrete miR21. To investigate this, conditioned medium from 
Chapter 4 
 - 139 -  
stimulated THP1 cells was collected and measured for presence of miR21. 
Indeed, the latter was significantly increased in the conditioned medium of 
immune cells and was further induced when cells were activated by LPS (Figure 
4.7). Therefore, miR21 secretion into the TME by immune cells could be 
involved in promoting cancer progression.  
 
 
Figure 4.7 MiR21 is secreted by activated immune cells. THP1 cells 
were activated with 1µg/ml LPS for 3 hours and conditioned media from 
triplicate cultures was collected. (A) MiR21 expression in the conditioned 
medium was measured by RT-qPCR. Data were normalised to expression of 
C.elegans miR39 spike-in (B). Data are expressed as fold change compared to 
negative control (unconditioned medium only). Significance was calculated 
using Student’s t-test (GraphPad Prism 5, **p<0.01). Error bars represent the 
SEM for independent cultures (n=3). 
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4.4 Discussion 
The TME is a dynamic and complex environment that is closely regulated by the 
tumour cells through extracellular signals. The tumour is thought to regulate its 
TME in order to promote its survival and progression. The tumour and its TME 
are therefore constantly interacting and miRNAs have emerged as new potential 
mediators of this crosstalk. Here, I demonstrate that IL6-treated CRC cells 
induced THP1-mediated IL6 production when co-cultured. My data suggest that 
miR21 and miR29b are secreted by CRC cells in response to IL6 and can 
promote surrounding immune cells to secrete IL6. Activated immune cells were 
also able to secrete oncogenic miR21 into the TME, which could signal back to 
the CRC cells and further promote tumour progression (Figure 4.8).  
CM containing IL6 from LPS-treated THP1 cells promoted CRC cell invasion. 
Interestingly, IL6 alone was found to promote cell invasion to a similar level, 
suggesting that the effect of the CM is likely to be mediated by IL6, and this idea 
could be further confirmed by adding an IL6 antibody to the CM to block any 
IL6-mediated effect. Furthermore, when treated with LPS, undifferentiated 
monocyte-like THP1 cells are polarised towards a pro-inflammatory M1-like 
phenotype characterised by secretion of pro-inflammatory cytokines such as 
IL6. Previous studies have shown that pro-inflammatory tumour-infiltrating M1 
macrophages have a tumour-suppressive effect due to their ability to elicit an 
anti-tumour immune response, and are thus associated with a better prognosis 
in CRC cases (Edin et al. 2012; Engström et al. 2014). On the other hand, IL6 is 
known to promote tumour growth and invasion (Schneider et al. 2000; Hsu & 
Chung 2006; Becker et al. 2005), and high levels of IL6 correlate with poor 
disease outcome (Chung & Chang 2003). The results from the current study 
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suggest that pro-inflammatory M1-like immune cells in the TME are able to 
promote cancer cell invasiveness, most likely through IL6 secretion. However, it 
is recognised that the current in vitro co-culture model only contains two cell 
types and thus fails to accurately replicate the complex TME of tumours in vivo. 
Therefore, in this simplistic model, the ability for activated M1-like THP1 cells 
to communicate with other immune cells (such as cytotoxic T cells and Th1 
cells) and mount an anti-tumour response is eliminated, possibly explaining 
why they are observed to be tumour-promoting rather than tumour-suppressing 
here.  
Unlike the previous studies presented in Chapters 2 and 3, 3D culture models 
were not used here. This is due to the fact that cells grown as 3D spheroids did 
not have significantly increased expression of miR21 and miR29b following IL6 
treatment (discussed in Chapter 3, section 3.4). While the 3D cultured cells are 
reported to provide a more accurate representation of tumours in vivo, they 
would still fail at bridging the gap between 2D culture and in vivo here. As with 
2D cell culture, only a limited number of different cell types can be used, 
whereas the TME in vivo is composed of signals from a multitude of cell types 
(detailed in Chapter 1, section 1.3) including endothelial cells, fibroblasts and 
various immune cells (Th1, Th2, cytotoxic T cells, NK cells, M1 and M2 
macrophages). Therefore, studies looking at intercellular communication within 
the TME are best undertaken with in vivo models. 
The current study used THP1 cells to mimic monocytes, however THP1 cells are 
derived from a patient with acute monocytic leukaemia and thus their behaviour 
does not always accurately mimic that of normal peripheral blood monocytes. 
Had time permitted, use of normal peripheral blood monocytes isolated from 
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healthy donors would have been informative. Studies have shown that while 
using the THP1 cell line provides valuable information on molecular 
mechanisms of monocytes and macrophages in various conditions, further 
validating findings using primary cells and in vivo models is important (Qin 
2012; Schildberger et al. 2013). 
Previous reports have shown that functional miRNAs can be secreted by cells 
and exert their effect in receiving cells. Valadi et al. were the first to 
demonstrate that exosomes from mouse and human cells contained not only 
protein but also mRNA and miRNA molecules, some of which were expressed 
at higher levels in the vesicles compared to their cell of origin, suggesting 
certain miRNAs are loaded specifically into vesicles while others are kept inside 
the cell (Valadi et al. 2007). These miRNA-containing exosomes are able to 
integrate into surrounding cells and release functional miRNAs (Montecalvo et 
al. 2012). More interestingly, Fabbri et al. reported that miR21 and miR29a 
were able to bind TLR8 to activate the NFκB pathway in recipient immune cells 
resulting in cytokine production (Fabbri et al. 2012). This binding event was 
dependent on the presence of a GU motif in the nucleotide region 18-21 of the 
miRNAs (Fabbri et al. 2012). MiR29b is closely related to miR29a and contains 
a GU motif in region 19-23 (GUGUU), thus it has the potential to interact with 
TLR8 in the tumour-surrounding immune cells. These previous reports thus 
support my finding that miR21 and miR29b mimics could induce IL6 
expression in recipient immune cells.  However, the current study did not 
establish the exact mechanism by which miR21 and miR29b are able to do this. 
Although the study by Fabbri et al. suggests a mechanism by which the miRNAs 
activate NFκB signalling by binding to TLR8 (Fabbri et al. 2012), NFκB or 
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TLR8 knockdown studies in THP1 cells could be used in order to confirm 
whether the miRNAs signal through this pathway to mediate their effects. In 
addition, Fabbri et al. demonstrated in their model that the miRNAs were 
contained within exosomes (Fabbri et al. 2012), but here, the method of 
transfer of the miRNAs was not characterised. MiRNAs can be secreted by cells 
in various forms: they can be packaged in microvesicles and apoptotic bodies 
but can also be vesicle-free associated to AGO or HDL proteins (Turchinovich 
et al. 2013), thus an interesting further study would be to determine which of 
these methods the CRC cells use to secrete miR21 and miR29b using techniques 
such as ultra-centrifugation.  
Furthermore, immune cells secreted miR21 upon activation. Indeed, LPS-
mediated immune cell activation results in induction of the NFκB pathway, 
which is known to promote expression of a variety of pro-inflammatory 
cytokines including IL6 but also miRNAs such as miR21 (Shin et al. 2011). 
MiR21 is a known oncogenic miRNA, upregulated in a variety of cancer types 
(Asangani et al. 2008) and thus its secretion by surrounding immune cells 
could be another mechanism (in addition to cytokine secretion) by which these 
cells are able to promote tumour progression. Moreover, secreted oncogenic 
miRNAs (by immune or tumour cells) could integrate into nearby normal cells 
and promote their cellular transformation. A better understanding of the 
mechanisms involved in cellular communication within the TME is essential, 
and could potentially lead to the development of new therapeutic strategies. 
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4.5 Summary 
The current study demonstrates that LPS-activated THP1 cells secrete IL6 and 
miR21, which can induce adjacent tumour cell invasion thus promoting tumour 
progression. The findings also suggest that IL6-treated tumour cells can interact 
with immune cells through secretion of miR21 and miR29b, resulting in further 
secretion of IL6 by the immune cells (Figure 4.8). Although in vitro co-culture 
models are unable to accurately replicate the complexities of the TME in vivo, 
the findings from the current model do offer mechanistic support for a potential 
role for IL6 and miRNAs as mediators of cancer-immune cell crosstalk.  
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Figure 4.8 Proposed model for IL6-mediated CRC and tumour-
associated immune cell crosstalk involving miR21 and miR29b. IL6 is 
secreted by tumour-associated immune cells. Upon binding to IL6R on the 
colorectal cancer cell surface, pSTAT3 is translocated to the nucleus to induce 
expression of a number of oncogenes and miRNAs including miR21 and 
miR29b, which are then secreted into the TME via exosomes and are taken up 
by the tumour-associated immune cells. MiR21 and miR29b then bind to TLR8 
within the immune cells sustaining their activation and inducing further 
secretion of IL6 and miR21 into the microenvironment to promote cancer cell 
progression. 
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5.1 IL6 promotes environment-associated CRC: mechanisms and 
preventive/therapeutic strategies. 
In the current project, IL6 was shown to promote BaP and PhIP activation in 
CRC cells through induction of CYP1B1 expression. The latter was induced by 
IL6-mediated downregulation of miR27b expression through a mechanism 
involving DNA methylation. IL6 is thus able to induce epigenetic changes that 
promote dietary carcinogen-induced DNA damage. IL6 also induced expression 
of CYP2E1, another CYP450 enzyme known to metabolise drugs, however this 
mechanism did not appear to involve miRNAs but instead was mediated by a 
direct transcriptional regulation by STAT3 (Chapter 2).  
These CYP450 enzymes can also activate carcinogens from other environmental 
factors such as pollution or smoking (Crofts et al. 1997; Gautier et al. 1996; 
Shimada et al. 1997; Bolt et al. 2003; Lu & Cederbaum 2008). Smokers have 
been shown to have high plasma levels of IL6 (Ridker et al. 2000), thus these 
novel IL6-mediated CYP450 regulatory mechanisms could also be important in 
environment-associated CRC in general. As mentioned in the introduction 
(Chapter 1), CRC is widely regarded as a lifestyle disease and thus preventing 
IL6-mediated expression of CYP450s could potentially be an effective disease 
prevention strategy.  
In addition to foods containing carcinogens, consumption of high levels of 
alcohol has been associated with increased CRC risk (Pollack et al. 1984; Seitz et 
al. 1984; Kune et al. 1987) and increased levels of IL6 occur with alcohol 
consumption (Hong et al. 2002; Martinez et al. 1992), thus alcohol-promotion 
of CRC could involve IL6. Interestingly, ethanol can increase CYP2E1 expression 
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although the specific molecular mechanisms are not yet clear (Lieber 1997). 
This novel CYP2E1 regulatory pathway involving IL6 and STAT3 could provide 
a potential mechanism. 
CYP450 enzymes are also involved in metabolising a wide array of drugs, thus 
identifying mechanisms of their regulation in tumours could have significant 
implications in cancer therapies. High levels of IL6 at the tumour site has been 
associated with multiple drug resistance in a variety of cancer types (Ara et al. 
2013; Yan et al. 2014). IL6-mediated induction of local CYP450 expression 
could be involved in this effect as these enzymes could inactivate 
chemotherapeutic drugs, thus administrating selected drugs that are not 
inactivated by these enzymes or combining drugs with an anti-IL6 adjuvant 
therapy could potentially attenuate drug resistance. Another strategy would be 
using the increased CYP450 expression at the tumour site to improve drug 
specificity; indeed inflammation-associated cancers could also benefit from 
drugs that are selectively activated by either CYP1B1 or CYP2E1, and thus are 
preferentially targeting the cancer cells. In this case, drugs activated by CYP1B1 
would be a better option as this enzyme has been shown to have tumour-specific 
expression (Murray et al. 1997; Rochat et al. 2001) whereas CYP2E1 is also 
expressed at relatively high levels in hepatic tissue (Tan et al. 2001).  
While I have only investigated these IL6-mediated effects in CRC cells, this 
pathway could also be involved in other environment- and lifestyle-induced 
cancers such as lung, breast or prostate, and therefore similar prevention or 
therapeutic strategies could apply in these cases. 
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Furthermore, regular intake of NSAIDs has been associated with lower cancer 
risk including CRC, breast and lung, however the specific underlying 
mechanisms remain unclear (Smalley et al. 1999; Olsen et al. 2008; 
McCormack et al. 2011; Rothwell et al. 2011; Rothwell, Price, et al. 2012; 
Rothwell, Wilson, et al. 2012; Algra & Rothwell 2012). Prevention of IL6-
mediated induction of CYP1B1 and CYP2E1 expression may be partially 
responsible, for this effect. In addition, preventing other IL6-mediated cancer 
promoting pathways such as IL6 promotion of cancer cell metastatic behaviour, 
activation of STAT3 and upregulation of oncogenic miRNAs such as miR21, 
could also be responsible for NSAIDs chemoprotective properties (Figure 5.1). 
 
Figure 5.1 NSAIDs lower CRC risk by inhibiting IL6 production. 
NSAIDs inhibit cyclooxygenase-2 that catalyses prostaglandin E2 synthesis, 
which in turn regulates IL6 synthesis in immune cells. Adapted from Williams & 
Shacter 1997. 
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5.2 The role of IL6 in CRC progression: more than just STAT3 
activation? 
It has been suggested that IL6 could promote cancer progression primarily via 
STAT3 activation. Indeed, activation of the JAK/STAT3 pathway occurs in most 
cancer cells and results in transcription of a number of oncogenes that promote 
cell survival, proliferation, angiogenesis and metastasis (Teng et al. 2014; Du et 
al. 2012; Becker et al. 2005; Rokavec et al. 2012; Wei et al. 2003; Rokavec et al. 
2014); therefore STAT3 has emerged as a promising therapeutic target for 
cancer.  
In the current project, IL6 was shown to promote cell metastatic behaviour 
through increased expression of oncogenes and miRNAs (Chapter 3). 
Interestingly, inhibition of STAT3 signalling was able to prevent these effects, 
suggesting that STAT3 plays a central role in IL6-mediated CRC promotion. As 
mentioned previously, STAT3 was also found to directly regulate CYP2E1 
expression, which could potentially be involved in dietary carcinogen activation 
and chemotherapeutic drug resistance. The essential role of STAT3 in CRC 
progression has also been demonstrated in vivo in mouse models for colitis-
associated CRC, where lack of STAT3 resulted in significant reduction of tumour 
size and tumour burden (Bollrath et al. 2009; Grivennikov et al. 2009). 
However, lack of STAT3 did not completely prevent tumour formation. While 
STAT3 appears to be a crucial part of IL6-mediated CRC promotion, it is not the 
only mechanism by which IL6 exerts its effects. Indeed, data from the current 
project demonstrates that IL6 can promote dietary carcinogen-induced DNA 
damage through induction of CYP1B1 expression in a mechanism independent 
of STAT3 activation, as inhibition of STAT3 signalling did not prevent this effect 
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(Chapter 2). Genome-wide methylation is a known effect of IL6 (Yan et al. 2011; 
Wehbe et al. 2006) and is thought to be mediated by increased expression of 
DNMT1 through AKT activation (Hodge et al. 2007) resulting in altered 
expression of a number of tumour-suppressors and oncogenes. IL6 signalling is 
also known to activate a number of other tumour-promoting pathways such as 
PI3K/AKT and MAPK/ERK, and these pathways have been shown to be 
essential to IL6-mediated cancer progression (Zhang et al. 2013; Lo et al. 2011; 
Zhang et al. 2003; Wegiel et al. 2008). Therefore, while STAT3 appears to be a 
promising drug target for cancer therapy, the question arises: is inhibiting 
STAT3 sufficient or would anti-IL6 therapy be more effective? The findings 
from the current project and other studies (Zhang et al. 2013; Lo et al. 2011; 
Zhang et al. 2003; Wegiel et al. 2008) suggest the latter. 
Numerous anti-IL6 therapies have emerged (Figure 5.2). Amongst these, a 
monoclonal anti-IL6 antibody, siltuximab, is currently in phase I/II clinical 
trials although the initial studies have provided mixed results (Karkera et al. 
2011; Guo et al. 2010; Rossi et al. 2010) possibly due to the fact that antibody-
associated IL6 is not cleared from the circulation (Waldner et al. 2012; Jones et 
al. 2011). Another strategy is to target IL6R; an anti-IL6R antibody 
(tocilizumab) is and has shown promising effects in clinical trials for treating 
chronic inflammatory conditions such as arthritis (Sato et al. 1993; Tanaka et 
al. 2012). However, these therapies also inhibit the physiological effects of IL6 
and could have significant adverse effects. A more targeted strategy is to 
selectively inhibit IL6 trans-signalling, which is the pathway primarily involved 
in cancer progression (Scheller et al. 2006). To this effect, an inhibitor that can 
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bind to the IL6/sIL6R complex has been designed (spg130Fc) and is currently 
in preclinical trials (Waetzig & Rose-John 2012).  
 
Figure 5.2 Anti-IL6 therapies in clinical trials. 
In addition, in the current project, I have demonstrated the diverse roles of 
miRNAs in IL6-mediated CRC progression. A novel therapeutic strategy would 
be to use miRNAs to inhibit IL6 effects. MiRNA mimics could be used to target 
JAK or gp130 expression. The production of sIL6R by metalloproteinases of the 
ADAM family (ADAM10 and ADAM17; Briso et al. 2008) could potentially also 
be targeted by miRNA therapy to specifically inhibit IL6 trans-signalling. A 
miRNA mimic for miR34 has recently gone into phase I clinical trial for liver 
cancer (Agostini & Knight 2014), suggesting miRNA mimic therapy as a 
promising strategy for future cancer therapies.  
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5.3 Role of miRNAs in IL6-mediated CRC progression 
This project investigated the mechanisms by which IL6 can promote CRC 
progression with a focus on miRNA involvement. Given the current findings, it 
appears that miRNAs play an essential role in the various pathways of IL6-
mediated CRC promotion.  
Indeed, miR27b downregulation is responsible for CYP1B1 expression changes 
resulting in increased activation of dietary carcinogens and DNA damage. While 
miR27b expression changes were investigated due to its ability to regulate 
CYP1B1 expression (Tsuchiya et al. 2006), this miRNA appears to have other 
tumour-suppressive functions in various cancer types including CRC by 
targeting oncogenes such as VEGFC, TCPT and PPARγ (Lee et al. 2012; Lo et al. 
2012; Ye et al. 2013). Therefore, its downregulation by IL6 may have other 
tumour-promoting consequences in addition to increased dietary carcinogen-
induced DNA damage. 
Furthermore, this study demonstrated that IL6 induced expression and 
secretion of miR21 and miR29b in CRC cells. While the role of miR29b in cancer 
remains controversial (see discussion section in Chapter 3), it appears to be 
promoting tumour-like activity in the current study. Interestingly, miR29b has 
been shown to target the DNMT3 family of enzymes (Garzon et al. 2009); 
therefore regulation of miR29b by IL6 could be contributing to IL6-mediated 
global DNA methylation changes observed in previous studies (Hodge et al. 
2005; Wehbe et al. 2006; Li et al. 2012). It also appears to play a pro-
inflammatory role in the CRC TME by promoting IL6 secretion by adjacent 
immune cells. MiR21 on the other hand is a well-known oncogenic miRNA 
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known to downregulate a number of tumour-suppressor genes such as PTEN 
and PDCD4 (Asangani et al. 2008; Peacock et al. 2014; Meng et al. 2007). 
MiR21 expression is increased in nearly all cancer types but also in numerous 
infections as it is regulated by inflammatory pathways STAT3 and NFκB (Shin 
et al. 2011; Yang et al. 2010; Ma et al. 2013). It was therefore not surprising that 
miR21 expression and secretion were increased in response to IL6 and may 
contribute to the IL6 cancer promoting effects. Interestingly, miR21 is also 
upregulated in response to a variety of risk factors for CRC such as chronic 
inflammation, age, obesity, Western-style diet and smoking (Melnik 2015), 
suggesting that miR21 may be involved in the mechanisms by which these 
factors promote CRC initiation and progression. In addition, as with miR29b, 
miR21 plays a pro-inflammatory role in the CRC TME where it is not only 
secreted by IL6-stimulated cancer cells to induce immune cell IL6 synthesis but 
also secreted by activated immune cells. Due to its oncogenic functions, miR21 
has emerged as a promising drug target (Chan et al. 2014; Sicard et al. 2013) 
and could be particularly useful for inflammation-associated cancers including 
CRC. While therapeutic delivery of a miR21 inhibitor remains challenging 
(Sicard et al. 2013), the current findings along with previous research suggest 
that inhibiting IL6 signalling would result in miR21 downregulation along with 
inhibition of other cancer-promoting pathways.  
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5.4 Limitations of study and future work 
The current project was performed predominantly using in vitro cell culture 
models. While these models are appropriate for mechanistic studies, they do not 
provide an accurate representation of tumours in vivo and often results 
observed in vitro do not translate in vivo. As an attempt to bridge the gap 
between in vivo and in vitro, 3D cell culture was used to verify observations in 
2D cell culture (Pampaloni et al. 2007) and while this provides some validation, 
it does not prove in vivo relevance. A comparison of cellular behaviour between 
2D and 3D cell culture systems can be found in appendix C. While many of 
responses observed in 2D culture were reproducible using 3D cultures, some 
IL6-mediated effects were absent in 3D culture such as miR21 and miR29b 
regulation. These discrepancies emphasise the need to explore these questions 
further using in vivo models. In addition, the use of in vivo models remains the 
most thorough approach to studying TME with all its complexities. 
Using in vitro methods implies the use of cell lines. In the current study, 
immortalised epithelial cancer cell lines derived from CRC patients were used. 
Due to the immortalisation and culture processes, cell lines are inclined to drift 
from their original genotypic and phenotypic state particularly in the case of 
cancer cells as they are genetically unstable to begin with (Pan et al. 2009), thus 
cultured cells have many limitations. As most cell lines are established from 
cancer cells, investigating cancer-initiating events is difficult. While a few cell 
lines from non-malignant cells exist, these undergo similar immortalisation 
processes (including phenotypic and genotypic drifting) and can also be 
challenging to grow in large numbers. More importantly, cell lines that are 
cultured for long periods in laboratory settings are not only susceptible to 
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phenotypic and genomic alterations, but also to contamination by mycoplasma, 
bacteria and other cells. While cell lines are usually authenticated by cell banks 
(such as ATCC) prior to purchase, it is necessary to re-authenticate cell lines 
regularly. This can be done by routine cell morphology monitoring, short 
tandem repeat profiling and karyotyping. The cell lines used in this study were 
not subjected to this level of re-authentication, although they were assessed by 
examining their growth rate and morphology, as well as confirming their 
mycoplasma-free status.  
Another limitation of the current study is the lack of ‘omic’ investigation. 
Indeed, due to research budgetary restrictions, only targeted qPCR for specific 
genes and miRNAs were performed in response to IL6. These targets were 
informed by available literature on IL6 and CRC, and were a starting point to 
investigate the research hypothesis. However, this approach does not provide a 
complete picture of the effect of IL6 on the whole genome and miRNAome, and 
important responses are likely to be missed.  
Given these limitations, follow-up studies could include verifying the IL6-
mediated pathways identified in this project in vivo, investigating the role of IL6 
on cancer initiation using both primary cells and in vivo models, and 
determining the IL6 effect on whole genome and miRNAome expression.  
Having determined miRNA changes in response to IL6, future work could 
expand on determining the role of these miRNAs in CRC and whether 
manipulating these could have an effect on the cancer cells to identify potential 
miRNA therapeutic targets. This approach was successfully employed in 
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investigating the expression of CYP450s in colorectal tissue (see appendix D; 
Patel et al. 2014) 
As the current project has provided evidence that IL6 may be involved in 
promoting environment-associated CRC, these pathways could be important in 
other environment-associated cancer types such as breast, prostate and lung. 
Therefore, an extension of this project would be to investigate these pathways in 
other cancer types and determine whether the observed effects are specific to 
CRC or apply to other solid tumour types. 
While the current project focused on IL6 due to its central role in inflammation 
and CRC, other members of the IL6 cytokine family may have similar effects to 
those determined in this project. Indeed, oncostatin M, a member of the IL6 
family of cytokines, is overexpressed in cancer tissue and is more potent at 
activating STAT3 than IL6 (Lapeire et al. 2014). Also, the TME is a very 
dynamic and multivariate milieu, and IL6 is only one of the molecules present 
in the TME. As described previously (Chapter 1, section 1.3 and Figure 1.5), 
there are numerous signals within the TME including other cytokines, 
chemokines and growth factors, and investigating these other signals is crucial 
to understand which of these plays a key role in promoting cancer progression 
and develop effective TME-targeting therapies.  
Finally, this project has determined that miRNAs miR21 and miR29b (in 
response to IL6) potentially play an important role in the TME by mediating 
intercellular crosstalk between cancer and immune cells. However, it needs to 
be recognised that the immune cells (THP1) used in this study were derived 
from a leukaemia patient and thus differ from monocytes present in the TME, 
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therefore using primary non-malignant cells would provide further validation of 
the results found here. Further studies could also include determining the role 
of other miRNAs in the TME in a variety of cancer types. Another interesting 
aspect would be to investigate whether these secreted miRNAs can promote 
transformation of surrounding non-malignant cells.  
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5.5 Conclusions 
As described in the Introduction (Chapter 1), CRC development and progression 
appear to be linked to lifestyle (particularly diet) and inflammation, however the 
underlying mechanisms remain unclear. The main hypothesis of this project 
was that the presence of pro-inflammatory cytokine IL6 in the TME could 
promote CRC progression by inducing epigenetic and genetic changes, and that 
these changes occur partially through local activation of dietary carcinogens and 
miRNA deregulation. This project generated a number of findings (presented 
and discussed in Chapters 2-4) identifying three different mechanisms by which 
IL6 can promote CRC progression, and miRNAs were found to play an 
important role in each of these effects. First, IL6 promoted dietary carcinogens 
BaP- and PhIP-induced DNA damage by promoting their activation pathway. 
Second, IL6 induced CRC cell behavioural changes by stimulating cell 
proliferation, migration and invasion. Last, IL6 mediated cell-cell 
communication between immune and CRC cells via miRNAs to maintain pro-
inflammatory signals that promote CRC cell invasion. My studies are based on 
in vitro experimentation using cell models, which cannot accurately recapitulate 
the complexity of tumours in vivo. Therefore, additional studies are necessary 
to not only establish in vivo relevance but also determine whether these 
findings could be further investigated for therapeutic development. In 
conclusion, the findings of this project offer experimental mechanistic support 
for the proposed hypothesis and although in vivo significance needs to be 
demonstrated, these results do provide further insight into the potential 
mechanisms by which IL6 can promote CRC progression.  
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Appendix A: QPCR reference genes and expression 
assays 
 
 
 
 
Figure S.1 GAPDH and U6 expression with IL6 treatment. GAPDH and 
U6 expression were measured by RT-qPCR in HCT116 and SW480 cells 
following 24 (SW480) and 48 hour (HCT116) IL6 treatment. Data are presented 
as mean Ct value. Error bars represent the SEM for independent cultures (n=3). 
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Figure S.2 GAPDH expression with BaP and PhIP treatment. GAPDH 
expression was measured by RT-qPCR in HCT116 and SW480 cells following 
BaP and PhIP treatment with or without IL6 pre-treatment. Data are presented 
as mean Ct value. Error bars represent the SEM for independent cultures (n=3). 
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Figure S.3 U6 expression with BaP and PhIP treatment. U6 expression 
was measured by RT-qPCR in HCT116 and SW480 cells following BaP and PhIP 
treatment with or without IL6 pre-treatment. Data are presented as mean Ct 
value. Error bars represent the SEM for independent cultures (n=3). 
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Figure S.4 IL6 mRNA expression is not detected in HCT116 and 
SW480 cells. IL6 and GAPDH expression were measured by RT-qPCR in 
HCT116 and SW480 cells. Reactions using Taqman assays with Ct>35 are 
excluded from further analyses as these values approach the sensitivity limit of 
the real-time PCR system and are thus considered unreliable. Data are 
presented as mean Ct value. Error bars represent the SEM for at least three 
independent cultures. 
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Table S1. Taqman real-time qPCR probes used in this study. 
 
 
Gene/miRNA Species Taqman assay ID 
CYP1A1 H. sapiens Hs01054797_g1 
CYP1B1 H. sapiens Hs00164383_m1 
CYP2E1 H. sapiens Hs00559368_m1 
p53 H. sapiens Hs01034249_m1 
E-cadherin H. sapiens Hs01023894_m1 
VEGFA H. sapiens Hs00900054_m1 
JAK2 H. sapiens Hs00234567_m1 
CTSD H. sapiens Hs00157205_m1 
MMP2 H. sapiens Hs00234422_m1 
IL6 H. sapiens Hs00174131_m1 
GAPDH H. sapiens Hs99999905_m1 
miR-27b-3p H. sapiens 000409 
miR-378-5p H. sapiens 000567 
miR-31-5p H. sapiens 002279 
let7a-5p H. sapiens 000377 
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Gene/miRNA Species Taqman assay ID 
miR-39 C. elegans 000200 
miR-135b-5p H. sapiens 002261 
miR-96-5p H. sapiens 000186 
miR-124a-3p H. sapiens 001182 
miR-375 H. sapiens 000564 
miR-21-5p H. sapiens 000397 
miR-29b-3p H. sapiens 000413 
U6 H. sapiens 001973 
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Appendix B: Expression of pro-inflammatory 
cytokines in CRC tissue 
 
	  
Figure S.5 Pro-inflammatory cytokine expression in CRC tissue. 
Cytokine concentration was measured in protein extracted from tissue samples 
and measured using the MSD platform technology. Data are presented as a 
mean cytokine concentration (pg/ml). Significant differences between tumour 
and normal tissue were calculated using a Mann-Whitney test (GraphPad Prism 
5, n=7). 
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Figure S.6 Pro-inflammatory cytokine protein expression expression 
in CRC tissue samples in individual patients. Cytokine concentration was 
measured in protein extracted from tissue samples using the MSD platform 
technology. Average concentration (pg/ml) is plotted for tumour and adjacent 
normal tissue samples for each patient individually (n=7). 
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Appendix C: Cellular behavioural changes in 2D vs 
3D cell culture 
Tumours are spheres of cancer cells with a hypoxic core and a dynamic 3D 
microenvironment, which is thought to play an essential role in tumour biology. 
Standard in vitro methods consist of growing cells on flat plastic surfaces and 
hence fail to accurately replicate this 3D environment. Increasingly, novel 
culture methods are being developed in which cancer cells are cultured as 3D 
spheroids, thus recreating the in vivo tumour architecture in an in vitro 
environment. In this project, I used 3D cell culture to validate findings from 2D 
culture models. In order to determine if this new culture environment changes 
cellular behaviour, I performed various experiments comparing cells grown in 
these two different culture systems.  
Cells cultured in 3D bioscaffolds were shown to have decreased cell growth 
(Figure S.6) and migration (Figure S.7), while cell invasion was increased 
compared to 2D cultures (Figure S.7). Dietary carcinogen-induced micronuclei 
formation was increased in 3D culture (Figure S.8). While corresponding 
increase in CYP1B1 gene expression was observed, CYP1A1 gene expression was 
decreased in 3D compared to 2D culture (Figure S.9). However, EROD activity 
was increased in 3D cells (Figure 2.13 B), which could result in increased 
activation of the dietary carcinogens in 3D culture, thus possibly explaining why 
increased DNA damage was observed. Differences in gene and miRNA 
expression were observed between both cell culture systems (Figure S.9 and 
S.10) including downregulation of E-cadherin and p53, and upregulation of 
miR125b and miR31 in 3D cultures. This expression pattern is commonly found 
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in colorectal tumours in vivo (Slaby et al. 2009) and known to be involved in 
cancer progression. 
Taken together, these data suggest that cells grown as 3D spheroids have altered 
cellular behaviour compared to cells grown as monolayers and these differences 
are likely to be driven by changes in the genetic and epigenetic make-up of the 
cells. 
 
 
 
Figure S.7 Cell growth of HCT116 and SW480 cultured as 2D 
monolayers and 3D spheroids. Cells were grown on as monolayers or as 3D 
spheroids. Cell growth was determined by counting the number of cells using a 
haemocytometer with Trypan Blue exclusion. Data are expressed as average 
percentage growth per day (n=1). 	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Figure S.8 Migration and invasion of HCT116 and SW480 cells grown 
as 2D monolayers and 3D spheroids. Cells were grown on as monolayers 
or as 3D spheroids. Cells/ spheroids were added to the upper chamber. The 
transwell migration (A) and invasion (B) assays were carried out over 72 hours. 
10% FBS was added to the bottom chamber as a chemoattractant. For the 
invasion assay, the upper chamber coated with matrigel prior to adding the 
cells. Cells appearing in the bottom compartment were quantified using 
AlamarBlue. Data are expressed as fold change compared to 2D. Significance 
was calculated using Student’s t-test (GraphPad Prism 5, *p<0.05). Error bars 
represent the SEM for independent cultures (n=3). 	  	   	  	  
Migration 
2D 3D 2D 3D
0.0
0.5
1.0
1.5
2.0
2.5 HCT116 SW480
*
Fo
ld
 c
ha
ng
e
Invasion
2D 3D 2D 3D
0.0
0.5
1.0
1.5
2.0
2.5 HCT116 SW480
Fo
ld
 c
ha
ng
e
A
B
Appendix C 
	  -214- 
	  	  
Figure S.9 Micronuclei frequency in HCT116 grown as 2D 
monolayers and 3D spheroids. Cells grown as monolayers and 3D 
spheroids were treated for 24 hour with BaP or PhIP; cells were taken 72 hours 
post-treatment. Etoposide was used as a positive control. Micronuclei frequency 
per 1000 cells was measured following treatment. Statistically significant 
differences are shown for comparisons between cells grown in 2D or 3D culture 
(***p<0.001, **p<0.01, *p<0.05). Significance was calculated using one-way 
ANOVA with a Dunnett post-test (GraphPad Prism 5). Error bars represent the 
SEM for independent cultures (n=3). 
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Figure S.10 Comparison of gene and miRNA expression in HCT116 
grown as 2D monolayers and 3D spheroids. Cells were grown as 
monolayers and 3D spheroids. Gene and miRNA expression were measured by 
RT-qPCR. Data were normalised to expression of GAPDH and U6 RNA for gene 
and miRNA expression respectively; data are presented as relative expression. 
Significance was calculated using two-way ANOVA with a Bonferroni post-test 
comparing 2D to 3D cell culture (GraphPad Prism 5, *p<0.05, **p<0.01). Data 
are presented as a mean of three biological replicates. Error bars represent the 
SEM for independent cultures. 
	  
HCT116 miRNA and mRNA expression
CO
X2
MM
P2
CY
P2
E1
CY
P1
B1
CY
P1
A1
E-
ca
dh
eri
n
p5
3
mi
R3
1
mi
R1
25
b
let
7a
mi
R3
78
0.00000
0.00005
0.00010
0.002
0.004
0.1
0.2
0.3
2D HCT116 3D HCT116
** *** *
R
el
at
iv
e 
ex
pr
es
si
on
Appendix C 
	  -216- 
	  
Figure S.11 Principle component analysis of gene and miRNA 
expression in HCT116 and SW480 grown as 2D monolayers and 3D 
spheroids. Cells were grown as monolayers and 3D spheroids. Gene and 
miRNA expression were measured by RT-qPCR. Data were normalised to 
expression of GAPDH and U6 RNA for gene and miRNA expression 
respectively; relative expression was used in the principle component analysis 
(SIMCA, Umetrics, Crewe, UK). Scatter-plot with the two first largest 
components (A) and associated loading-plot with the gene and miRNAs 
responsible for the 2D vs 3D separation circled in red (B). Colours indicate the 
different classes in the data: 3D SW480 in yellow, 2D SW480 in red, 3D HCT116 
in blue and 2D HCT116 in green (each data point represents a biological 
replicate).
 
 
Behavioural changes in human colorectal 
cancer cell lines grown as 3D spheroids  
Saroor Patel1, James Ellis1, Rhiannon David1, Nigel Gooderham1  
1Department of Surgery and Cancer, Imperial College London, SW7 2AZ !!
•  Tumours are spheres of cancer cells with a hypoxic 
core and a dynamic 3D microenvironment.  
•  3D microenvironment is thought to play an essential 
role in tumour biology. 
•  Standard in vitro methods fail to accurately replicate 
this environment.  
Aim: To understand how cancer cells behave in 
these different culture systems and determine if 
they are more accurate in vitro models for disease. 
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Contact: saroor.patel10@imperial.ac.uk 
http://www.imperial.ac.uk/people/saroor.patel10 
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•  Cells grown in 3D bioscaffolds have reduced cell growth and migration, while cell 
invasion was increased compared to 2D cultures.  
•  Differences in gene and miRNA expression: downregulation of E-cadherin and p53, 
and upregulation of miR125b and miR31; xpr ssion pattern is commonly found in 
colorectal tumours in vivo and known to be involved in cancer progression.  
•  Altered valine consumption was also observed, which an be broken down to 
produce succinyl-CoA and feed into the TCA cycle. 
 
Conclusion: Cells grown as 3D spheroids have altered cellular behaviour 
compared to cells grown as monolayers; these differences are driven by 
changes in the genetic and epigenetic make-up of the cells. 
 
•  Cell culture: HCT116 & SW480 grown  in RPMI1640   + 10% FBS as 
monolayers or 3D spheroids. 
 
 
 
•  Growth Assay: Cells were grown then harvested and counted using 
Trypan Blue exclusion. 
•  Migration/Invasion assay:  Cells were seeded to the top chamber and 
allow d to migrate/inva e f r 72 hours. Cells in the bottom chamber were 
quantified using AlamarBlue. 
•  RT-qPCR: Total RNA was extracted  from cells  using TRIzol, reversed 
transcribed and quantified by PCR using Taqman reagents. 
•  NMR: Cell media was collected and analysed using 1H-NMR. 
A
B
 	   -217- 
Appendix D: Published research article 
Patel, S.A.A. et al., 2014. Interleukin-6 mediated upregulation of CYP1B1 and 
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Interleukin-6 mediated upregulation of
CYP1B1 and CYP2E1 in colorectal cancer
involves DNA methylation, miR27b and
STAT3
S A A Patel1, U Bhambra1, M P Charalambous1, R M David1, R J Edwards2, T Lightfoot3, A R Boobis2
and N J Gooderham*,1
1Computational and Systems Medicine, Department of Surgery and Cancer, Imperial College London, London SW7 2AZ, UK;
2Experimental Medicine and Toxicology, Department of Medicine, Imperial College London, London W12 0NN, UK and
3Department of Health Sciences, University of York, York YO10 5DD, UK
Background: The pro-inflammatory cytokine interleukin-6 (IL6) promotes colorectal cancer (CRC) development. It is also known to
regulate cytochrome P450 (CYP450) enzymes, which are involved in CRC tumour initiation and promotion via activation of
chemical carcinogens. Here, IL6 regulation of CYP450 expression was investigated in CRC.
Methods: The effect of IL6 on CYP 1A1, 1B1 and 2E1 expression was determined in vitro using CRC cell lines HCT116 and SW480,
and CYP450 expression was determined by immunohistochemistry in CRC tissues previously shown to have increased levels of IL6.
Results: In mechanistic studies, IL6 treatment significantly induced CYP1B1 and CYP2E1, but not CYP1A1, gene expression in
HCT116 and SW480 cells. CYP2E1 expression regulation occurred via a transcriptional mechanism involving STAT3. For CYP1B1
regulation, IL6 downregulated the CYP1B1-targeting microRNA miR27b through a mechanism involving DNA methylation. In
clinical samples, the expression of CYP1B1 and CYP2E1, but not CYP1A1, was significantly increased in malignant tissue
overexpressing IL6 compared with matched adjacent normal tissue.
Conclusions: Colonic inflammation with the presence of IL6 associated with neoplastic tissue can alter metabolic competency of
epithelial cells by manipulating CYP2E1 and CYP1B1 expression through transcriptional and epigenetic mechanisms. This can lead
to increased activation of dietary carcinogens and DNA damage, thus promoting colorectal carcinogenesis.
Colorectal cancer (CRC) is one of the most common malignancies
in the Western world where it is the second highest cause of
cancer-related mortality (Tenesa and Dunlop, 2009). Despite
multiple advances in treating the disease, 5-year survival rates
have not significantly improved in the last 20 years highlighting the
need for new diagnosis strategies.
Local inflammation in the colon is a known risk for CRC
development and progression (Feagins et al, 2009). We have
previously reported increased expression of a number of
inflammatory markers including pro-inflammatory cytokine
interleukin-6 (IL6), a key regulator of inflammation, in colon
tumour tissue and stroma (Figure 1) (Maihofner et al, 2003;
Charalambous et al, 2003; Charalambous et al, 2009). Indeed,
stromal cells including tumour-associated immune cells and
fibroblasts release high levels of IL6 (up to 6000 pgml! 1) in the
colorectal tumour microenvironment (Nagasaki et al, 2014).
Furthermore, elevated serum levels of IL6 are associated with
poor disease outcome and non-steroidal anti-inflammatory drugs
are known to reduce CRC risk by lowering levels of inflammation
(Williams et al, 1997; Smalley et al, 1999).
*Correspondence: Professor NJ Gooderham; E-mail: n.gooderham@imperial.ac.uk
Revised 4 September 2014; accepted 16 September 2014
& 2014 Cancer Research UK. All rights reserved 0007 – 0920/14
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Keywords: inflammation; microRNA; cytochrome P450; colorectal cancer; immunohistochemistry
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Interleukin-6 is also known to regulate CYP enzyme expres-
sion. Studies in hepatocytes have generally shown that IL6
inhibits CYP450 expression including CYP 1A1, 1A2, 3A4 and
2E1 (Abdel-Razzak et al, 1993; Jover et al, 2002; Hakkola et al,
2003). However, conflicting results have been reported; IL6 has
also been shown to induce CYP2E1 in astrocytes (Tindberg et al,
1996), suggesting that the effects of IL6 on CYP450 expression
vary depending on tissue type and the relation between IL6 and
CYP450 expression has not yet been defined in the colon.
CYP1B1 is known to be overexpressed in a number of tumour
types including lung, colon and breast (Murray et al, 1997). A
recent study in human hepatocellular carcinoma cells has
reported that IL6 treatment induced CYP1B1 gene and protein
expression (Kurzawski et al, 2012), suggesting that IL6 is able to
regulate CYP1B1. However, there have been very few other
studies to confirm this effect of IL6 on CYP1B1. Furthermore,
despite these numerous reports of IL6 regulating CYP450s, the
specific molecular mechanisms underlying the effects are not yet
well understood.
MicroRNAs (miRNAs) are small, B22 nucleotide long non-
coding gene-regulating RNAs; they silence gene expression by
binding to target mRNAs. MicroRNAs only require partial base
complementarity to bind to their targets and can thus target a
number of different mRNAs. Recent studies have found that
miRNAs can modulate CYP450 expression. For instance, miR27b
and miR378 have been reported to directly regulate CYP1B1 and
CYP2E1 expression, respectively (Tsuchiya et al, 2006; Mohri et al,
2010). Furthermore, emerging evidence suggests that epigenetic
events including DNA methylation and miRNA expression are
involved in CRC initiation and progression (Suzuki et al, 2012).
Interestingly, IL6 has been shown to alter miRNA expression
profiles (Yang et al, 2010) and to induce genome-wide methylation
of promoter regions (Webbe et al, 2006) resulting in gene silencing,
thus epigenetic mechanisms may be involved in IL6-mediated
regulation of CYP450s.
To investigate the relationship between IL6 and CYP450
expression in the neoplastic colon, we first determined the
expression of the CYP450 enzymes CYP 1A1, 1B1 and 2E1 in
the human CRC cell lines HCT116 and SW480 with subsequent
mechanistic studies to confirm increased levels of IL6 could alter
CYP450 expression and propose underlying mechanisms. Here to
extend the in vitro results, we measured the expression of the same
CYP450s in malignant tissues resected from CRC patients that
have increased expression of IL6 in the epithelium and stroma
(Figure 1; Maihofner et al, 2003), and compared expression with
that in adjacent normal tissues.
MATERIALS AND METHODS
Cell culture. The human colorectal adenocarcinoma cell lines
HCT116 and SW480 were obtained from ATCC (LGC Prochem,
Middlesex, UK) and were routinely cultured in RPMI-1640 medium
(GIBCO, Life Technologies, Paisley, UK) supplemented with 10%
fetal bovine serum (FBS), 100 unitsml! 1 penicillin, 100mgml! 1
streptomycin and 2mM L-glutamine (GIBCO, Life Technologies).
All cells were incubated at 37 1C in a humidified incubator (5%
CO2). Cells between passages 3 and 7 were used in the experiments.
IL6 treatment and demethylation/STAT3 inhibition. Before
treatment, HCT116 and SW480 were maintained in culture medium
supplemented with 5% dextran-coated charcoal-stripped FBS for at
least 72 h. Cells were seeded at a density of 1" 105 cells per well of a
6-well plate. HCT116 and SW480 do not express IL6; cells were
treated for 24 and 48h with recombinant human IL6 (HumanKine,
Sigma-Aldrich, Dorset, UK) dissolved in phosphate-buffered saline
(PBS) containing 0.1% human serum albumin (Sigma-Aldrich) at
doses of 0, 100 and 1000 pgml! 1 (chosen within the range secreted
by stromal cells in colon tumour microenvironment). For
demethylation/STAT3 inhibition, cells were co-treated for 24 and/
or 48 h with 1000pgml! 1 IL6 and either 4mM 5-aza-20-
deoxycytidine (Sigma-Aldrich) or 25mM STAT3 inhibitor (STAT3
inhibitor VIII 5,15-diphenylporphyrin, Millipore, Feltham, UK),
respectively. STAT3 inhibitor and 5-aza-20-deoxycytidine were
dissolved in DMSO (final vehicle control concentration of 0.1%).
RNA extraction. Total RNA was isolated from cells using TRIzol
reagent (Invitrogen, Life Technologies) according to the manu-
facturer’s protocol. RNA extracts were quantified by UV spectro-
scopy (UV–vis Spectrophotometer, Implen, Essex, UK) with purity
assessed from 260/280 nm and 260/230 nm ratios. Extracts were
stored at ! 80 1C until used.
Reverse transcription and quantitative PCR. For mRNA reverse
transcription, RNA extracts (100–500 ng) from each sample were
added to 300 ng of random primers, heated for 5min at 65 1C and
then immediately placed on ice. Each sample was incubated with
0.5mM dNTPs, 1" first strand buffer, 8mM dithiothreitol and
100 units of Superscript II reverse transcriptase (Invitrogen,
Paisley, UK) for 10min at 25 1C, 90min at 42 1C and 15min at
70 1C on a thermocycler (Peltier Thermal Cycler PTC-200, MJ
Research, Waltham, MA, USA). An miRNA reverse transcription
kit was used for miRNA expression according to the manufac-
turer’s protocol (Taqman, Applied Biosystems, Life Technologies,
Paisley, UK). Quantitative PCR was performed using pre-designed
gene expression assays and FAST PCR master mix (Taqman,
Applied Biosystems, Life Technologies), and measured in a
StepOnePlus fast real-time PCR system (Applied Biosystems, Life
Technologies) according to the manufacturer’s protocol. Gene
expression was quantified using the delta-Ct method.
Chromatin immunoprecipitation-quantitative PCR. SW480
cells were treated with 1000 pgml! 1 IL6 and 25 mM STAT3
inhibitor for 60min before collecting the cells. Chromatin
immunoprecipitation (ChIP) assay was performed using a
magnetic ChIP kit (Thermo Fisher Scientific, Cramlington, UK)
as per manufacturer’s protocol with an anti-STAT3 antibody (sc-
482X, Santa Cruz Biotechnology, Heidelberg, Germany). Rabbit
IgG was used as a negative control for non-specific binding.
Binding was calculated as a percentage of the total input
chromatin. Sequences of the primers used were as follows:
CYP2E1 site 1 forward: 50-TGAATTTTCCTTCTGGCCCCAT-30,
reverse 50-TGATGAGGAGGTTTGTCTGAGC-30;
CYP2E1 site 2 forward: 50-CTCCATCCTCACCAGGTCAC-30,
reverse: 50-CCAACCAATGCCCTCTTGCT-30.
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Figure 1. IL6 expression is increased in epithelial cells and stroma of
colorectal tumour samples. Data are adapted from our previous
publication (Maihofner et al, 2003) and are shown as fold change of
immunohistochemistry score relative to control. Significant differences
from normal tissue were calculated using Wilcoxon’s signed-rank test
(*Po0.05, ***Po0.001).
BRITISH JOURNAL OF CANCER IL6 upregulates CYP1B1 and CYP2E1 in colorectal cancer
2 www.bjcancer.com |DOI:10.1038/bjc.2014.540
Appendix D 
	   -220- 
Patients. The study adhered to the tenets of the Declaration of
Helsinki. Surgical specimens of primary tumours and adjacent
normal colon were obtained with informed consent from 40
patients (28 men and 12 women; aged 49–80 years, mean age 64.7
years±8.1 s.e.m.), with histologically verified colorectal cancer,
treated at the Department of Surgery, York District Hospital, York,
UK. Ethical approval for the study was obtained from the Human
Research Ethics Committee at York District Hospital. Nineteen
patients had colon cancer and twenty-one rectal cancers. Tumours
were classified according to Duke’s classification (Table 1). The
entire study was carried out blind using coded tissue sections.
Eligibility criteria for patients recruited to the study included
Caucasian origin, 45–80 years of age and no history of previous
gastrointestinal disease or any form of cancer, including familial
adenomatous polyposis.
Tissue specimens. Tissue samples taken at operation for histo-
pathological confirmation of disease were fixed in 4% buffered
formaldehyde and embedded in paraffin wax; sections surplus to
pathology requirements were made available for the study. For all
40 patients, tissue sections of both malignant and normal (taken
outside the tumour margin) colon or rectum were provided.
Antibodies and reagents. Specific anti-peptide antibodies raised
against individual CYP450 enzymes and the corresponding pre-
immune sera have been previously described (Edwards et al, 1998;
Kapucuoglu et al, 2003). These antibodies have previously been
used to detect human CYP450 protein expression (Piipari et al,
2000, Rodriguez-Antona et al, 2002). Biotin labelled secondary
antibodies and streptavidin/HRP complex were obtained from
DAKO Ltd (Ely, UK). All other chemicals were supplied by either
Sigma-Aldrich or Merck (Nottingham, UK) unless otherwise
specified.
Immunohistochemistry. The levels of expression and localisation
of CYPs 1A1, 1B1 and 2E1 in malignant and adjacent normal
colorectal tissue were determined using a modified avidin/biotin
immunohistochemistry procedure (Goggi et al, 1986). In pre-
liminary experiments, each of the immunohistochemistry assays
was optimised using a range of antisera dilutions (1/200 to 1/8000).
For each assay, the negative control antisera (pre-immune sera)
were confirmed negative for staining at the dilution optimised for
the primary antibody and blocking peptides confirmed specificity.
The dilutions used were 1/5000 for the anti-CYP1A1 antibody, and
1/1000 for the anti-CYP1B1 and anti-CYP2E1 antibodies. The
sections were deparaffinised and rehydrated through xylene and a
series of graded alcohol solutions. Endogenous peroxidase activity
was blocked by immersing the sections into a solution of 3%
hydrogen peroxide in distilled water for 30min at room
temperature, and then rinsed in cold running tap water for
10min. Incubating the sections with 5% normal swine serum for
30min at room temperature reduced non-specific background
staining. Sections were then washed twice with PBS and either the
primary antibody or the normal goat or rabbit IgGs (negative
control) was applied to each section and left at 4 1C overnight. The
next day, the slides were washed twice with PBS, and then
incubated with the secondary antibody solution (Biotinylated
swine anti-goat, mouse, rabbit immunoglobulin; 1/150 dilution),
for 1 h at room temperature. After being washed twice with PBS,
they were incubated with the StrepABComplex solution for 1 h at
room temperature, washed twice with PBS and immersed into the
substrate (300ml PBS, 90 ml hydrogen peroxide and 2.5ml 3,3-
diaminobenzidine) for 3min, and then rinsed with PBS and cold
running tap water. Sections were then successively immersed into
haematoxylin, acid alcohol and Scott’s tap water to counterstain.
Finally, the sections were dehydrated by successive immersion into
70% ethanol, 100% ethanol twice and xylene twice and mounted.
Immunohistochemical evaluation. Processed specimens were
scored under the light microscope and the intensity and
localisation of staining with CYPs 1A1, 1B1 and 2E1 antibodies
graded blind using coded slides. To assess and grade intensity and
distribution of immunoreactivity in the epithelial cells, a previously
described method of scoring the sections was used (Maihofner
et al, 2003, Charalambous et al, 2003, 2009). The distribution was
scored according to the number of positive cells; none (not
stained), 0; focal (o1/3 of cells stained), 1; multi-focal (1/3 to 2/3
of cells stained), 2; and diffuse (42/3 stained), 3; staining intensity
was scored as: none (not stained), 0; lightly stained, 1; and strong
staining, 2. The distribution and intensity scores were added to
produce the grade of staining. Sections treated with the normal
goat or rabbit IgGs (negative controls) or omitting the primary
antibody were devoid of staining. Positive staining controls
included sections of kidney, duodenum and liver.
Statistical analysis. The Wilcoxon’s signed-rank test was used to
compare the scoring of the respective immunoreactivity for CYP
1A1, 1B1 and 2E1 between tumour and adjacent normal tissues
(Stata Statistical Software 9, StataCorp LP, College Station, TX,
USA). Gene expression data were obtained from measurements
made in at least three biological replicates and presented as a
mean±standard error. Significant differences (Po0.05) were
determined using Student’s t-test and one-way analysis of variance
(ANOVA) followed by a Dunnett post-test or a linear trend
analysis (GraphPad Prism 5, GraphPad Software Inc., La Jolla, CA,
USA). Pearson’s product-moment correlation coefficient test was
used for correlation analysis (GraphPad Prism 5).
RESULTS
Can IL6 regulate CYP450 expression in CRC cells? To
determine whether IL6 can regulate CYP450s in colon cancer
cells, we performed mechanistic studies in in vitro models (human
CRC cell lines HCT116 and SW480) to examine the effect of IL6
treatment on CYP 1A1, 1B1 and 2E1 gene expression at various
time points using quantitative PCR.
CYP1A1 gene expression was detected but not significantly
changed in either cell line following 24- and 48-h IL6 treatment
(Figure 2A). However, CYP1B1 and CYP2E1 mRNA expression
was regulated dose dependently by IL6 as determined by positive
trend analyses and was significantly increased at the highest dose of
1000 pgml! 1 IL6 in both cell lines (Figure 2B and C). To the best
of our knowledge, this is the first account of CYP1B1 and CYP2E1
being upregulated by IL6 in colon tumour-derived epithelial cells.
What are the mechanisms involved in IL6-mediated upregula-
tion of CYP2E1 and CYP1B1?
IL6 regulates CYP2E1 expression through STAT3 transcription
factor. To understand the mechanism underlying IL6 induction of
CYP2E1 expression, we examined the different pathways involved in
CYP2E1 regulation. CYP2E1 is regulated at various stages of its
synthesis and includes transcriptional and post-transcriptional mechan-
isms. We looked at miRNA-mediated regulation of CYP2E1mRNA by
determining miR378 expression, a miRNA reported to target CYP2E1
(Mohri et al, 2010). However, no change in miR378 expression by IL6
was observed (Figure 3A) and we found no correlation between
CYP2E1 and miR378 expression in our model (Figure 3B).
IL6 is a potent inducer of the JAK/STAT3 pathway. An analysis of
the CYP2E1 promoter region revealed multiple potential STAT binding
sites (Figure 4A; TFSEARCH ver1.3; Heinemeyer et al, 1998). We thus
studied involvement of STAT3 in regulating IL6-mediated CYP2E1
induction using a STAT3 inhibitor, STAT3 inhibitor VIII 5,15-
diphenylporphyrin. Treatment with the inhibitor prevented IL6-
mediated CYP2E1 induction after 24h in both HCT116 and SW480
IL6 upregulates CYP1B1 and CYP2E1 in colorectal cancer BRITISH JOURNAL OF CANCER
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cell lines (Figure 4B). Furthermore, a ChIP analysis in SW480 cells
revealed that STAT3 does bind to the CYP2E1 promoter region
following IL-6 treatment (Figure 4D), compatible with a STAT3-
mediated mechanism for induction of CYP2E1 expression by IL6.
IL6 regulates CYP1B1 expression through repression of miR27b.
We next examined the mechanisms underlying IL6-mediated
induction of CYP1B1 expression. The aryl hydrocarbon receptor
(AhR) pathway is a well-known transcriptional regulator of
CYP1B1 and CYP1A1 expression. However, CYP1A1 mRNA
expression was not induced upon IL6 treatment (Figure 2A), thus
the AhR pathway is unlikely to be involved in IL6-mediated
induction of CYP1B1. Furthermore, we determined that STAT3
was not involved in regulating IL6-mediated CYP1B1 induction, as
treatment with the STAT3 inhibitor did not affect IL6-mediated
induction of CYP1B1 (Figure 4C).
Table 1. Patient demographic information
Patient Agea Sex
Tumour
site
Dukes’
stage Drug history
Tobacco
use Alcoholb
1 59 M Rectum A None No 1–7
2 58 F Colon B Azathioprine, Insulin, Prednisolone, Lisinopril, Frusemide, Ferrous sulphate No 1–7
3 79 M Rectum B Atenolol, Bendrofluazide No 8þ
4 72 M Colon B None No 8þ
5 60 F Rectum B Lipostat No 8þ
6 66 F Colon C 5-Fluorouracil, Enalapril No 0
7 69 M Rectum C Co-codamol No 1–7
8 52 M Rectum C Adalat No 1–7
9 68 M Colon B Atenolol, Prednisolone, Warfarin, Ferrous sulphate, Diltiazem, Isosobrbite
mononitrate, Gliclazide, Co-danthramer
No 1–7
10 69 M Rectum C Atenolol No 8þ
11 70 F Rectum B Lithium, Levothyroxine No 8þ
12 72 M Rectum B Captopril, Naproxen, Allopurinol, Isosobrbite mononitrate, Frusemide,
Atenolol, Prochlorperazine
No 1–7
13 56 M Colon A None No 8þ
14 76 M Colon A None No 1–7
15 58 F Colon N/K None No 0
16 66 F Colon B None No 0
17 54 M Rectum C None No 1–7
18 49 M Colon B None No 8þ
19 52 M Rectum B None No 8þ
20 68 M Colon B Salbutamol, Ferrous sulphate No 0
21 63 F Rectum A Salbutamol, Beclomethasone, Bendrofluazide No 1–7
22 56 M Colon C Losec No 8þ
23 68 M Rectum B Sotalol, Aspirin No 8þ
24 80 F Rectum B None No 0
25 59 M Rectum C None No 8þ
26 66 M Rectum N/K None Current 8þ
27 59 F Colon N/K Fibrogel No 0
28 74 M Colon N/K None No 1–7
29 64 M Rectum B Aspirin, Omeprazole, Simvastatin No 0
30 72 F Rectum C None No 8þ
31 50 M Rectum B Betagan Current 1–7
32 72 M Rectum B Diclofenac, Propanolol, Adalat, GTN, Isosorbide mononitrate No 8þ
33 55 M Colon B None No 1–7
34 67 F Rectum C Ibuprofen, Aspirin, Bendrofluazide No 1–7
35 74 M Colon C 5-Fluorouracil No 8þ
36 73 M Colon A None No 8þ
37 60 M Colon C None No 1–7
38 59 F Rectum B Voltarol No 0
39 73 M Colon C 5-Fluorouracil, Co-danthrusate, Manevac No 1–7
40 70 M Colon C Ferrous sulphate No 0
Abbreviation: N/K¼not known.
aAge in years.
bAlcohol consumption in units per week (1 unit¼ half a pint of beer or one glass of wine or one shot of spirits).
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MiR27b has been reported to directly target CYP1B1 mRNA by
binding to its 3’UTR to regulate its expression (Tsuchiya et al,
2006). IL6 significantly downregulated miR27b expression in both
cell lines in the current study (Figure 3C). Furthermore, there was a
significant inverse correlation between miR27b expression and
CYP1B1 expression (Figure 3D), suggesting that downregulation of
miR27b could be responsible for the increase in CYP1B1 mRNA
observed. To our knowledge, this is the first account of IL6
modulating miR27b expression, thus providing a potential post-
transcriptional mechanism by which CYP1B1 is regulated by IL6.
How does IL6 cause miR27b downregulation? We next deter-
mined the mechanism underlying miR27b regulation by IL6. MiR27b
is an intragenic miRNA located within the C9orf3 gene on
chromosome 9. Previous reports have shown that an intragenic
CpG island (chr9: 96 887 100–96 887 300) located close to miR27b can
be methylated in colon cancer cells and regulates miR27b expression
(Yan et al, 2011). Interleukin-6 is known to induce genome-wide
DNA methylation through phosphorylation of DNMT1 by activated
AKT, which increases DNMT1 nuclear translocation and activity
(Hodge et al, 2007); therefore, we examined the role of DNA
methylation in IL6 regulation of miR27b expression by inhibiting
DNA methylation using 5-aza-20-deoxycytidine treatment. We
observed that by inhibiting DNA methylation, we were able to
prevent miR27b downregulation by IL6 in both cell lines (Figure 5A),
implying that DNA methylation has a role in regulating miR27b
expression. Again, these changes inversely correlated with CYP1B1
expression (Figure 5B and C). These mechanistic data suggest that
IL6-mediated upregulation of CYP1B1 involves downregulation of
miR27b via DNA methylation.
Is CYP450 expression altered in malignant colorectal tissues
that overexpress IL6? Having shown that IL-6 regulates expres-
sion of CYP1B1 and 2E1, but did not alter expression of CYP1A1
in CRC cells, to confirm whether this may be relevant in vivo, we
measured the expression of these CYP450s by immunohistochem-
istry (Figure 6) in tissue sections of malignant and normal bowel
from colorectal cancer patients, in which IL6 expression has
previously been determined (Figure 1; Maihofner et al, 2003).
In most cases, we observed immunostaining only in epithelial cells.
Expression of CYP was generally greatest in luminal enterocytes with
involvement of the upper third of the crypts in some individuals. We
did not observe any expression in the base of crypts. Within the cells,
we noted the expression was cytoplasmic with the intensity of
expression greatest in perinuclear regions, suggesting localisation
within the endoplasmic reticulum. No expression was observed in the
mucous inclusions of goblet cells. In tumour tissue, staining was
confined to epithelial cells and there was no significant intratumour
heterogeneity in enzyme expression.
The CYP1A1 expression was observed in epithelial cells of
normal colorectal tissue in 7 out of 40 patients, while 11 out of 40
patients expressed CYP1A1 in malignant epithelial cells (Figure 6C
and D). Using our previously described immunohistochemistry
scoring procedures (Maihofner et al, 2003; Charalambous et al,
2003, 2009), we found that this did not translate into a significant
difference (Figure 6K). Expression of CYP1B1 in normal colorectal
tissue was detected in 18 out of 40 patients (Figure 6E), while the
majority of patients expressed CYP1B1 in malignant tissue (35 out
of 40 patients; Figure 6F). CYP1B1 was also expressed relatively
intensely in histologically normal crypts that were immediately
adjacent to tumour cells (Figure 6I). CYP2E1 was expressed in
both normal and tumour tissues, although expression was more
intense in malignant tissue (Figure 6G and H). In addition to
epithelial cells, plasma cells (found in the lamina propria) also
expressed CYP2E1 intensely (Figure 6J, inset).
We compared these CYP450 expression levels with patient
demographics and found no significant correlation between
alcohol, age, sex or tumour stage (data not shown).
More importantly, in line with our in vitro data, CYP1B1 and
CYP2E1 expression was significantly increased in tumour samples
compared with adjacent normal tissue while the CYP1A1
expression levels were not significantly changed (Figure 6K). We
have previously reported increased expression of inflammatory
cytokine IL6 in these same tumour tissue samples (Figure 1;
Maihofner et al, 2003). Furthermore, CYP1B1 and CYP2E1 gene
expression was also the only CYP450s to be induced by IL6 in our
in vitro mechanistic models and as CYP450 mRNA levels in
human cell culture have been reported to correlate well with
protein expression (Rodriguez-Antona et al, 2002), we therefore
propose that IL6 may be involved in the increased expression of
these proteins in tumour tissue.
DISCUSSION
The effect of IL6 on CYP450 expression in colorectal cancer has not
been widely investigated. Furthermore, only a few studies have
attempted to characterise the expression of individual CYP isozymes
using immunohistochemistry (Kumarakulasingham et al, 2005;
Androutsopoulos et al, 2013). Certain members of the CYP450
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Figure 2. IL6 effect on CYP450 gene expression. HCT116 and SW480
cells were treated with 0, 100 and 1000pgml! 1 IL6 for 24 and 48h.
CYP1A1 (A), CYP1B1 (B) and CYP2E1 (C) expression was measured by
RT-qPCR. Data were normalised to expression of GAPDH housekeeping
gene and are shown relative to control. Significance was calculated
using one-way ANOVA with a Dunnett post-test comparing treated
groups with vehicle control and linear trend analysis (*Po0.05,
**Po0.01, ***Po0.001). Data are presented as a mean of at least three
biological replicates. Error bars represent the s.e.m.
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family, including CYP1A1 and 1B1, can activate dietary pro-
carcinogens such as heterocyclic amines and polycyclic aromatic
hydrocarbons, which have been associated with colorectal cancer (Ito
et al, 1991; Crofts et al, 1997; Barrett et al, 2003; Boyce et al, 2004;
Sinha et al, 2005; Nothlings et al, 2009), and the expression of
CYP450 enzymes in tissues that are targets for xenobiotic genotoxicity
implies a potential for in situ activation. CYP450s, in particular
CYP2E1, can also metabolise several drugs resulting in either
inhibition or activation, and thus have an important role in drug
bioavailability (Koop, 1992). CYP450 enzymes have significant roles
in xenobiotic activation, tumour initiation and promotion (Murray
et al, 1997; Gooderham et al, 2007; Braeuning et al, 2011; Kasai et al,
2013; Rodriguez and Potter, 2013), hence, characterisation of CYP450
enzyme profiles in colon tissue and understanding the mechanisms
involved in their regulation can be important for diagnosis, prognosis
and treatment of disease.
Interleukin-6 has been reported to regulate CYP enzyme
expression (Abdel-Razzak et al, 1993; Tindberg et al, 1996; Jover
et al, 2002; Hokkola et al, 2003; Kurzawski et al, 2012) and is also
thought to be involved in colon cancer initiation and progression
(Feagins et al, 2009). We have previously shown IL6 expression is
present at higher levels in the neoplastic colon (Maihofner et al,
2003) and the current study extends these observations and
provides evidence for the localisation of several CYP450 enzymes
in colon tissue from the same patient cohort and we demonstrate
that CYP1B1 and CYP2E1 expression is significantly upregulated
in these tumour tissue samples. Moreover, we have conducted
mechanistic studies that give an insight into some of the regulatory
mechanisms involving IL6 that underlie CYP1B1 and 2E1 enzyme
expression in the colon.
Regarding CYP2E1, we found that IL6 induced CYP2E1
expression in human colon tumour-derived cell lines and in
support, we showed CYP2E1 levels were increased in tumour tissue
expressing higher levels of IL6 than matched normal tissue. It is
commonly thought that IL6 as well as other pro-inflammatory
cytokines repress CYP450 expression (Abdel-Razzak et al, 1993;
Jover et al, 2002) and CYP2E1 gene expression was previously
shown to be downregulated by IL6 in hepatic tissue (Hakkola et al,
2003), which is in contrast to our data. However, a study published
by Tindberg et al (1996) reported that inflammation induced
CYP2E1 gene expression in astrocytes. Taken together, these data
suggest that the effect of inflammation on CYP2E1 expression is
dependent on tissue type. We identified that IL6-mediated
induction of CYP2E1 in vitro was through a mechanism involving
direct binding of STAT3 to the CYP2E1 promoter. This is the first
account of a direct involvement of IL6 and STAT3 in CYP2E1
expression in colonic cells. It has previously been shown that both
STAT3 activation and CYP2E1 overexpression are linked to
alcohol consumption (Roberts et al, 1995; Norkina et al, 2007).
Epidemiological and animal studies have identified an association
between excessive alcohol intake and increased risk of colorectal
cancer (Pollack et al, 1984; Seitz et al, 1984; Kune et al, 1987; Kato
et al, 1990). More recently, a study published by Morita et al (2009)
demonstrated a correlation between CYP2E1 activity, alcohol
intake, meat consumption and the development of colorectal
cancer. Our findings provide a potential inflammatory STAT3-
mediated mechanism by which CYP2E1 expression could be
regulated by alcohol in the colon.
CYP1B1 has been suggested to be a tumour specific enzyme as it
is rarely found in healthy tissue (Murray et al, 1997). As expected,
there was a significant increase in CYP1B1 expression in tumour
tissue when compared with matched normal tissue in the current
study. These results are in agreement with previous studies, which
have shown increased CYP1B1 expression in colon cancer (Murray
et al, 1997; Gibson et al, 2003; Kumarakulasingham et al, 2005;
Chang et al, 2005; Androutsopoulos et al, 2013). Moreover, in
mechanistic studies we found that IL6 induced CYP1B1 gene
expression in colon tumour-derived epithelial cells. The relation-
ship between inflammation and CYP1B1 is not as well studied as
other CYP450 enzymes, despite both of these factors being of
significant interest in tumour development. However, inflamma-
tion was previously shown to increase CYP1B1 expression in brain
cells (Malaplate-Armand et al, 2003). In a recent study, IL6 was
shown to induce CYP1B1 but not CYP1A1 gene expression in
human hepatocellular carcinoma cell line HepG2 in an AhR-
independent manner (Kurzawski et al, 2012). This is in line with
our results, where IL6 induced CYP1B1 but not CYP1A1 in CRC
cells and only CYP1B1 levels were significantly elevated in tumour
tissue where IL6 expression was also increased. While Kurzawski
et al (2012) did not establish a specific mechanism for the
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induction of CYP1B1 by IL6, here we show that CYP1B1 is post-
transcriptionally regulated by IL6 through miR27b, an miRNA
reported to directly target CYP1B1 mRNA (Tsuchiya et al, 2006).
Furthermore, our data suggest that DNA methylation has a role in
IL6-mediated downregulation of miR27b. Yan et al (2011) reported
a CpG island located near miR27b that is methylated in CRC cells
and can regulate miR27b expression, thus supporting our findings.
MiR27b has been shown to have various roles in the inflammatory
process. In neuroblastoma cells, inhibition of miR27b activated
NFkB signalling leading to increased expression of IL6 (Lee et al,
2011), whereas the opposite has been found in breast cancer cells
(Jin et al, 2013). Despite these conflicting reports, miR27b and IL6
appear to be involved in the same pathways and this is the first
account of IL6 directly regulating miR27b expression.
In summary, this study has shown that CYP450 enzymes expressed
in colon tissue are significantly influenced by disease as evidenced by
the increased expression of CYP2E1 and CYP1B1 in tumour tissue
samples. However, it is important to note that a sample size of 40
patients was used in this study, and while our data are in agreement
with previous reports of increased CYP1B1 expression, studies with
larger patient numbers are needed to validate these findings, in
particular for CYP2E1 expression. Furthermore, we noted the changes
in CYP450 expression observed in malignant tissue did not correlate
with sex or age. Interestingly, CYP450 expression was also not
associated with tumour grade, suggesting that these changes occur at
an early disease stage. We have previously shown these same
colorectal tumours (from the same patient cohort) have increased
levels of IL6 compared with adjacent normal tissues (Maihofner et al,
2003) and here we demonstrate for the first time that addition of IL6
can regulate CYP1B1 and CYP2E1 in colon tumour-derived cell lines.
We describe a transcriptional mechanism for IL6-mediated CYP2E1
induction via STAT3 (Figure 7). We also demonstrate an epigenetic
mechanism by which IL6 represses miR27b expression involving
DNA methylation resulting in CYP1B1 upregulation (Figure 7).
Taken together, our study provides further insight into the
mechanisms by which IL6 promotes tumour development and
progression. While altering CYP450 expression is only one of the
mechanisms by which IL6 exerts its pro-tumourigenic effects, this
pathway is of particular importance when it comes to designing
therapies. New CRC treatment strategies could exploit this novel
pathway potentially through the use of drugs that can only be
activated by CYP2E1 or CYP1B1, and avoiding treatments that may
be deactivated by these CYP450s. These findings also suggest that
preventive dietary measures are of particular importance for patients
with inflammatory bowel conditions to reduce their risk of CRC. By
manipulating CYP450 enzymes, IL6 can induce phenotypic changes
in colon tumour cells possibly rendering them drug resistant, or
encouraging the in situ metabolism of carcinogens, thus resulting in
DNA damage and potentially tumour promotion.
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Interleukin-6 promotes dietary carcinogen-
induced DNA damage in colorectal cancer cells
Saroor A. A. Patel and Nigel J. Gooderham*
Colorectal cancer (CRC) is the third most common cancer worldwide with 80% of cases being sporadic,
arising following a series of environment-induced gene mutations. DNA damaging pro-carcinogens such
as benzo[a]pyrene (BaP) and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) contained in red
or processed meats are a potential risk factor for disease. These dietary pro-carcinogens require meta-
bolic activation to their genotoxic agents by cytochrome P450 (CYP) family 1 enzymes. We have pre-
viously demonstrated that the pro-inﬂammatory cytokine interleukin-6 (IL6) promotes CYP1B1 expression
in CRC cells grown as 2D monolayers and that these two proteins are overexpressed in malignant tissue
resected from CRC patients, indicating that inﬂammation inﬂuences metabolic competency in CRC cells.
To determine whether IL6 can inﬂuence BaP and PhIP activation, we investigated IL6 eﬀect on BaP- and
PhIP-induced DNA damage in CRC cell lines grown as 2D monolayers and as 3D spheroids using the
in vitro micronucleus (MN) assay. We also investigated the involvement of p53 and CYPs in the observed
eﬀects. MN formation was increased dose-dependently following treatment with BaP and PhIP while pre-
treatment with IL6 further enhanced DNA damage. We conﬁrmed that IL6-mediated eﬀects were not
caused by p53 expression changes but rather by CYP1B1 expression induction through miR27b down-
regulation. Taken together, these data demonstrate that inﬂammatory cytokines can promote dietary pro-
carcinogen activation and DNA damage in CRC cells.
Introduction
As the colon is part of the digestive system, it is particularly
susceptible to carcinogens present in the diet. Epidemiological
studies have reported a significant correlation between high
consumption of red and processed meats, known sources of
dietary carcinogens, to increased incidence of CRC.1
Commonly occurring dietary carcinogens include benzo[a]-
pyrene (BaP) and 2-amino-1-methyl-6-phenylimidazo[4,5-b]-
pyridine (PhIP).2–4 BaP is a five-ring polycyclic aromatic hydro-
carbon generated during the combustion of organic com-
pounds and is commonly found in motor fumes, cigarette
smoke and cooked meats.5,6 It is thought to be involved in
tobacco- and diet-associated cancers due to its mutagenic
potential. PhIP is the most abundant heterocyclic amine found
primarily in meats cooked at high temperatures, particularly
fish, chicken and beef.7 Studies have found correlations
between meat consumption, PhIP intake and colon, breast
and prostate cancers,1,8–10 and PhIP-DNA adducts have been
detected in these tissues,11–13 supporting its role as a mutagen
in these tissue types.
Like many carcinogens, BaP and PhIP are activated into
their genotoxic derivatives, 7,8-diol-9,10-epoxy BaP and
N-hydroxy PhIP respectively, by CYP1 A1, A2 and B1
enzymes.6,14,15 The activated molecules covalently bind DNA
disrupting the double-helical structure resulting in DNA
damage including double-strand breaks, deletions and points
mutations.6,16–19
CYP1B1 and CYP1A1 are found extra-hepatically and are
expressed in CRC tissue,20–22 suggesting a potential for in situ
metabolism and increased susceptibility to dietary carcinogen-
induced mutations. However, mechanisms that regulate carci-
nogen activation in the colon are not yet well understood.
Overexpression of pro-inflammatory cytokine interleukin-6
(IL6) occurs at the tumour site in CRC patients23,24 and we
recently determined that CYP1B1 expression was epigenetically
regulated by IL6 through miR27b in CRC cells grown as 2D
monolayers.20 Given our previous findings, IL6 may be
involved in promoting activation of dietary pro-carcinogens in
colonic cells.
In vitro techniques commonly use cells cultured as 2D
monolayers. However, when cultured in this manner, cells are
flattened onto the culture surface thus changing their struc-
ture, and parameters such as cell-to-cell interaction and tissue
architecture are lost. In vitro 3D cell culture systems, in which
cells are grown as spheroids, constitute a better model of
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in vivo tissue without the use of animal models. Previous
studies comparing 2D and 3D cell culture systems have shown
3D cell morphology and growth rate more accurately represent
in vivo tumours.25 Thus, 3D cell culture has become increas-
ingly popular replacing standard cell culture techniques as a
means of increasing in vivo relevance of in vitro experimental
results.
In this study, we have adapted current in vitro techniques
for use with 3D cultures and have compared results with that
obtained with cells grown as 2D cultures. We have used this
novel technique to investigate the mechanisms involved in
diet-associated CRC by studying the eﬀect of IL6 on BaP- and
PhIP-induced DNA damage as well as underlying mechanisms
for observed eﬀects using in vitro models. Exploring
these mechanisms is important to further understand the role
of IL6 in diet-associated colorectal carcinogenesis and could
potentially identify a novel regulator of dietary carcinogen
activation.
Materials and methods
Cell culture
The human colorectal adenocarcinoma cell lines HCT116 and
SW480 were obtained from ATCC (LGC Prochem, Middlesex,
UK). HCT116 p53−/− cells were kindly provided by Professor
Bert Vogelstein (John Hopkins University, Baltimore, MD,
USA). Cells were routinely cultured in RPMI1640 medium
(GIBCO, Life technologies, Paisley, UK) supplemented with
10% foetal bovine serum (FBS), 100 units per ml penicillin,
100 μg ml−1 streptomycin and 2 mM L-glutamine (GIBCO, Life
technologies). All cells were incubated at 37 °C in a humidified
incubator (5% CO2). Cells between passages 3–7 were used for
experiments.
For 3D cell culture, cells were seeded at a density of 5 × 105
cells per well in a 24-well Algimatrix system (Invitrogen, Life
technologies) according to the manufacturer’s protocol. Cells
were monitored and culture medium was routinely changed.
Spheroids cultured for 7–10 days were used in all experiments.
To isolate spheroids from the matrix, matrix-dissolving buﬀer
(Invitrogen, Life technologies) was used according to manufac-
turer’s protocol.
Cell treatments
Prior to treatment, HCT116 and SW480 were maintained in
culture medium supplemented with 5% dextran-coated char-
coal-stripped FBS for at least 72 hours. Cells were seeded at a
density of 1 × 105 cells per well of a 6-well plate (for 2D cell
culture). HCT116 and SW480 do not express IL6 so human
recombinant IL6 (HumanKine, Sigma-Aldrich, Dorset, UK) dis-
solved in PBS containing 0.1% human serum albumin (Sigma-
Aldrich) was added to the cells for 24 and 48 hours at doses of
0–5000 pg ml−1 (chosen within the range secreted by stromal
cells in the colon26).
For treatment with dietary carcinogens, cells were pre-
treated with IL6 as described above, washed with PBS and
treated with a dose-range of BaP (0–10 μM, Sigma-Aldrich) and
PhIP (0–100 μM, Toronto Research Chemicals Inc., Toronto,
Canada). Both chemicals were dissolved in DMSO and final
vehicle control concentration of 0.2% was used.
Cytotoxicity and micronucleus assay
Micronucleus (MN) assay was performed according to OECD
guidelines with modifications. Briefly, cells were seeded at a
density of 5 × 104 cells per well of a 24-well plate for 2D cell
culture. Spheroids grown for 10 days were used for 3D culture.
Cells were treated with IL6, BaP or PhIP as detailed previously,
washed with PBS and cultured for a further 72 hours prior to
harvest. Etoposide (Sigma-Aldrich) was used as a positive
control in all assays at a concentration of 125 nM. Cells were
then harvested, resuspended in culture medium containing
2% pluronic (GIBCO, Life technologies) and cytotoxicity was
determined by counting cells in a haemocytometer with Trypan-
Blue exclusion (GIBCO, Life technologies). Cells were fixed
with 100% methanol onto microscope slides at a density of 2 ×
104 cells per slide and stained for 60 seconds with acridine
orange (0.1 mg ml−1 dissolved in PBS, Sigma-Aldrich). Fre-
quency of MN was scored blind in 1000 cells per sample and
three biological replicates were performed per treatment.
RNA extraction
Total RNA was isolated from cells using TRIzol reagent (Invi-
trogen, Life technologies) according to the manufacturer’s pro-
tocol. RNA extracts were quantified by UV spectroscopy
(UV-VIS Nano-spectrophotometer, Implen, Essex, UK) with
purity assessed from 260/280 nm and 260/230 nm ratios.
Extracts were stored at −80 °C until used.
Reverse transcription and qPCR
Reverse transcription and qPCR were performed as previously
described.20 Briefly, for mRNA reverse transcription, Super-
script II reverse transcription kit was used (Invitrogen, Life
technologies) and miRNA reverse transcription kit was used
for miRNA expression (Applied Biosystems, Life technologies).
QPCR was performed using pre-designed expression
assays (Taqman, Applied Biosystems, Life technologies) for
CYP1A1 (Hs01054797_g1), CYP1B1 (Hs00164383_m1), p53
(Hs01034249_m1), GAPDH (Hs99999905_m1), U6 (001973) and
miR27b (000409). FAST PCR master mix was used according to
the manufacturer’s protocol (Taqman, Applied Biosystems,
Life technologies).
Statistical analysis
Data were obtained from measurements made in at least three
biological replicates and presented as a mean ± standard error
(SEM). Significant diﬀerences (p < 0.05) were determined
using Student’s t-test, one-way analysis of variance (ANOVA)
followed by a Dunnett post-test. Pearson’s product-moment
correlation coeﬃcient test was used for correlation analysis
(GraphPad Prism 5, GraphPad Software Inc., La Jolla,
CA, USA).
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Results
IL6 eﬀect on chemical-induced DNA damage by food-derived
pro-carcinogens BaP and PhIP
The in vitro MN assay is a commonly used toxicological test for
detecting genotoxic potential of compounds due to its simpli-
city of scoring, accuracy and adaptability to diﬀerent cell types.
More importantly, studies in humans have shown strong
associations between micronuclei frequency and cancer risk.27
Formation of micronuclei, i.e. small membrane-bound DNA
fragments in the cytoplasm, occurs during cell division when a
whole chromosome or a chromosomal fragment is not incor-
porated into the nucleus of one of the daughter cells. Standard
MN assays utilise immature blood cells, but non-standard
versions of the assay have been developed using diﬀerent cell
types including epithelial cells. Here, we have adapted the
assay for use with human colorectal adenocarcinoma epithelial
cell lines grown as 2D and 3D cultures.
Cytotoxicity. Cytotoxicity was measured following IL6 and
carcinogen treatment to ensure cell viability post-treatment.
While some toxicity (around 30% drop in cell survival) was
observed particularly with IL6 + BaP treatment in both cell
lines, these diﬀerences were not statistically significant com-
pared to respective controls (Fig. 1).
Genotoxicity. A dose-dependent increase in BaP- and PhIP-
induced MN frequency was observed in HCT116 and SW480
cell lines cultured as 2D monolayers. Interestingly, pre-treat-
ment with IL6 significantly enhanced the pro-carcinogen-
induced DNA damage while treatment with IL6 on its own had
no eﬀect (Fig. 2). Etoposide, a topoisomerase II inhibitor
and potent inducer of MN formation, was used as a positive
control and does not require activation to induce DNA
damage. Pre-treatment with IL6 did not enhance etoposide-
induced DNA damage suggesting that IL6 may have an eﬀect
on the activation pathway of the pro-carcinogens rather than
on MN formation itself.
3D cell culture. The assay was repeated using HCT116 cells
grown as 3D spheroids. In general, results (Fig. 3) were in
agreement with that found in 2D: no significant cytotoxicity
was observed and pre-treatment with IL6 enhanced BaP and
PhIP induced DNA damage. However, the increase in DNA
damage observed with IL6 pre-treatment was not as pro-
nounced in 3D culture compared to 2D: MN frequency was
increased by 1.5 fold in 3D culture with IL6 pre-treatment
Fig. 1 Cytotoxicity of 2D HCT116 and SW480 induced by BaP and PhIP. HCT116 (A, B) and SW480 (C, D) cells grown as monolayers were pre-
treated with IL6 for 48 hours and 24 hours respectively, followed by 24 hour treatment with BaP or PhIP. Cells were harvested 72 hours post-treat-
ment. Cytotoxicity following treatment expressed as % of cell survival. Statistically signiﬁcant diﬀerences were calculated using one-way ANOVA with
a Dunnett post-test (GraphPad Prism 5). Error bars represent the SEM for independent cultures (n = 3).
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while in 2D culture it was increased by 2–3 fold (Fig. 2). Taken
together, these data demonstrate that presence of IL6 in colon
epithelial cells along with food-derived pro-carcinogen can
enhance induction of DNA damage. We therefore investigated
the mechanism by which IL6 exerts this eﬀect. IL6 is a pleio-
tropic cytokine with a multitude of functions; it has previously
been shown to regulate p53 gene expression28 and CYP1B1
expression,20 thus we investigated whether these two pathways
were responsible for IL6 mediated eﬀects.
Mechanisms underlying IL6 eﬀects
P53 involvement. The tumour suppressor protein p53
induces cell cycle arrest upon DNA damage recognition, acti-
vates DNA repair pathways or induces apoptosis in the com-
promised cell; p53 is thus crucial to maintain genomic
stability. IL6 has been reported to induce downregulation of
p53 gene expression by promoting methylation of its promoter
region.28 Both of the cell lines used in this study have p53
activity. To test whether inactivation of p53 may be responsible
Fig. 2 DNA damage measured by MN frequency in 2D HCT116 and SW480 induced by BaP and PhIP. HCT116 (A, B) and SW480 (C, D) cells grown
as 2D monolayers were pre-treated with IL6 for 24 hours followed by 24 hour treatment with BaP or PhIP. Cells were harvested 72 hours post-treat-
ment. Etoposide was used as a positive control. Micronuclei (MN) frequency per 1000 cells was measured following treatment. Statistically signiﬁ-
cant diﬀerences are shown for comparisons between carcinogen treated vs. IL6 pre-treated samples (***p < 0.001, **p < 0.01, *p < 0.05), IL6 alone
vs. IL6 pre-treated and carcinogen treated (†††p < 0.001, ††p < 0.01, †p < 0.05) and vehicle vs. carcinogen treated (‡‡‡p < 0.001, ‡‡p < 0.01, ‡p <
0.05). Signiﬁcance was calculated using one-way ANOVA with a Dunnett post-test (GraphPad Prism 5). Error bars represent the SEM for independent
cultures (n = 3).
Fig. 3 Cytotoxicity and DNA damage in HCT116 grown as 3D spheroids.
Cells grown as 3D spheroids on Algimatrix were pre-treated with IL6 for
24 hours followed by 24 hour treatment with BaP or PhIP. Cells were
harvested 72 hours post-treatment. Etoposide was used as a positive
control. (A) Cytotoxicity following treatment expressed as % of cell survi-
val. (B) Micronuclei frequency per 1000 cells following treatment. Stat-
istically signiﬁcant diﬀerences are shown for comparisons between
carcinogen treated vs. IL6 pre-treated samples (*p < 0.05). Signiﬁcance
was calculated using one-way ANOVA with a Dunnett post-test
(GraphPad Prism 5). Error bars represent the SEM for independent
cultures (n = 3).
Toxicology Research Paper
This journal is © The Royal Society of Chemistry 2015 Toxicol. Res., 2015, 4, 858–866 | 861
Appendix D 
	   -232- 
for the IL6 eﬀect observed, we performed a MN assay on
HCT116 p53−/− cells obtained from Professor Vogelstein’s
laboratory (John Hopkins University, Baltimore, MD, USA) and
looked at the eﬀect of IL6 treatment on p53 gene expression by
qPCR. No significant downregulation of p53 gene expression
was observed at the dose of IL6 used in this study (Fig. 4A–C).
Previous studies used supraphysiological doses of IL6 (10 ng
ml−1 (ref. 28)) and therefore, the dose used here (physiological
levels) are likely to be too low to inhibit p53 expression. In
addition, MN frequency was not increased in the p53-null
HCT116 cells when compared to wild-type HCT116, rather
total number of MN was decreased (Fig. 4D and E). This
demonstrates that the observed eﬀect of IL6 on MN induction
by BaP and PhIP is not caused by downregulation of p53,
further suggesting that IL6 may aﬀect the activation pathway
of the pro-carcinogens via induction of CYP1B1 expression as
previously described.20
CYP450 involvement. Previous studies in this laboratory
have demonstrated that IL6 can regulate CYP1B1 expression
via miR27b downregulation but not CYP1A1 in CRC cells
grown as 2D monolayers,20 indicating that IL6 may be associ-
ated with a change in metabolic competency. In the current
study, we examined the eﬀect of IL6 treatment on CYP450
expression in CRC cells grown as 3D spheroids to confirm our
previous findings. As expected, treatment with IL6 did not
alter CYP1A1 expression (Fig. 5A). Upregulation of CYP1B1 in
both HCT116 and SW480 3D spheroids following IL6 treat-
ment was observed along with downregulation of miR27b
(Fig. 5B and C), thus confirming our previous observations in
2D culture.20 Therefore IL6 regulates CYP1B1 expression by
downregulating miR27b.
Furthermore, we investigated the eﬀect of 24–48 hour pre-
treatment with IL6 followed by removal of the IL6 media then
24 hour BaP or PhIP treatment on CYP1A1, CYP1B1 and
miR27b expression. However, we found no significant changes
with IL6 pre-treatment followed by BaP or PhIP compared to
BaP or PhIP treatment alone (Fig. 6), likely due to the fact that
IL6 is removed prior to BaP and PhIP treatment. Therefore,
CYP1B1 induction is not sustained following IL6 removal.
These data suggest that the initial induction of CYP1B1
expression (in the first 24 to 48 hours) by IL6 treatment is
responsible for increased carcinogen activation and DNA
damage.
BaP (but not PhIP) is a known inducer of the AhR pathway
that controls CYP1A1 and CYP1B1 expression and here as
expected, BaP significantly induced expression of both CYP1B1
and CYP1A1. Furthermore, miR27b expression is not altered
following BaP and PhIP treatment, indicating that unlike IL6,
Fig. 4 Involvement of p53 in IL6-mediated induction of BaP- or PhIP-mediated DNA damage. HCT116 and SW480 cells grown as 2D monolayers
(A, B) and 3D spheroids (C) were treated with IL6 and p53 expression was measured by RT-qPCR. Data were normalised to expression of GAPDH and
are show relative to control. (D–E) HCT116 p53−/− and HCT116 wild-type (WT) cells were grown as monolayers and treated for 24 hours with BaP
or PhIP. Cells were taken 72 hours post-treatment and micronuclei frequency per 1000 cells were determined following treatment. Signiﬁcance was
calculated using one-way ANOVA with Dunnett post-test comparing treated group to vehicle control (GraphPad Prism 5, ***p < 0.001). Error bars
represent the SEM for independent cultures (n = 3).
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BaP regulates CYP1B1 expression via the AhR pathway and not
miR27b.
Discussion
In the current study, IL6 was shown for the first time to
promote DNA damage induced by BaP and PhIP, two carcino-
gens present in meats cooked at high temperatures. Umannová
et al. previously reported that TNFα, another pro-inflammatory
cytokine, increased BaP-induced genotoxic damage in alveolar
epithelial type II cells,29 suggesting that other inflammatory
cytokines may have a similar eﬀect, however specific mecha-
nisms were not presented. TNFα is a known inducer of IL6 and
therefore, IL6 may have been involved in the eﬀect reported by
Umammova et al.29 Here, we suggest that IL6 promotes BaP-
and PhIP-induced genotoxicity through induction of CYP1B1
expression.
Previous studies on IL6 regulation of CYP450 enzymes
present conflicting reports. Generally IL6 is thought to have an
inhibitory eﬀect in hepatic cells,30–33 however a few studies in
other cell types have shown increased expression of CYP450 in
response to IL6,20,34–36 which are in agreement with the data
presented here in CRC cells grown as 3D spheroids. As pre-
viously shown in 2D cultures,20 we found that IL6 downregu-
lated miR27b expression resulting in increased CYP1B1
expression in 3D cultured CRC cells. Furthermore, we also
determine that IL6 mediated regulation of CYP1B1 was not
sustained following IL6 removal and determined that the
higher levels of CYP1B1 in the cells caused by IL6 pre-treat-
ment were likely to be responsible for the increased activation
of BaP and PhIP. Moreover, we determined that BaP and PhIP
do not regulate miR27b expression.
BaP and PhIP are also prevalent in other environmental
factors such as pollution or smoking. In addition, CYP1B1 can
also activate other environmental carcinogens,37–41 and
smokers have been shown to have higher plasma levels of IL6
compared to non-smokers.42 Thus this novel IL6-mediated car-
cinogen activation pathway could also be important in other
environment-associated cancers such as lung, and preventing
IL6-mediated expression of CYP450 s could potentially be an
eﬀective disease prevention strategy. Regular intake of NSAIDs
has been associated with lower cancer risk including CRC,
breast and lung, however the specific underlying mechanisms
remain unclear43–45 and prevention of IL6-mediated induction
of CYP1B1 expression may be responsible, at least in part, for
this eﬀect.
CYP450 enzymes are also involved in metabolising a wide
array of drugs, thus identifying mechanisms of their regulation
in tumours could have significant implications in cancer
therapies. High levels of IL6 at the tumour site has been
associated with multiple drug resistance in a variety of cancer
types.46,47 IL6-mediated induction of local CYP450 expression
could be involved in this eﬀect as these enzymes could be in-
activating chemotherapeutic drugs, thus administrating
selected drugs that are not inactivated by these enzymes or
combining drugs with an anti-IL6 adjuvant therapy could
potentially attenuate drug resistance.
The IL6-mediated eﬀects were observed in diﬀerent in vitro
culture systems (2D and 3D) as well as in two distinct CRC cell
lines (HCT116 and SW480), thus providing further validation
of the current findings. When comparing diﬀerent cell culture
methods, we observed that IL6-mediated eﬀects on promoting
BaP- and PhIP-induced DNA damage were not as pronounced
in 3D cultures as compared to 2D cultures. Furthermore, for
SW480 cells, higher doses of IL6 were required in 3D culture
in order to reproduce responses observed in 2D culture. It has
generally been shown that a decrease in drug sensitivity is
Fig. 5 IL6 eﬀect on CYP1A1, CYP1B1 and miR27b expression in 3D cul-
tures. HCT116 and SW480 cells grown as 3D spheroids were treated
with 0, 1000 or 5000 pg ml−1 IL6 for 24 hours. CYP1A1 (A), CYP1B1 (B)
and miR27b (C) expression were measured by RT-qPCR. Data were nor-
malised to expression of GAPDH for gene expression or U6 RNA for
miRNA expression and are shown relative to control. Signiﬁcance was
assessed using Student’s t-test comparing the treated group to vehicle
control (GraphPad Prism 5, **p < 0.01, *p < 0.05). Error bars represent
the SEM for independent cultures (n = 3).
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observed in cells cultured in 3D compared to 2D48,49 likely due
to the diﬀerences in level of exposure caused by the architec-
ture of the spheroid, thus 3D culture better recapitulates
in vivo responses.
Conclusion
In the current study, we investigated the eﬀect of IL6 on DNA
damage caused by dietary pro-carcinogens BaP and PhIP in
CRC cells grown as 2D monolayers and 3D spheroids. Pre-treat-
ment with IL6 enhanced BaP- and PhIP-induced DNA damage
by promoting the activation of the carcinogens through
CYP1B1 expression induction. Increased levels of CYP1B1 in
the cell along with presence of dietary carcinogens would lead
to increased quantities of genotoxic metabolites, thus result-
ing in DNA damage. Discovery of this novel pathway provides
further understanding of the mechanisms regulating dietary
carcinogen activation in colonic cells and provides a mechanis-
tic basis for the established chemopreventive activity of non-
steroidal anti-inflammatory drugs in chemical-mediated
colorectal carcinogenesis.50
Fig. 6 CYP1A1, CYP1B1 and miR27b expression following IL6 pre-treatment and BaP or PhIP treatment in 2D cultured HCT116 and SW480 cells.
Cells grown as monolayers were pre-treated with 1000 pg ml−1 IL6 for 24 hours (SW480) or 48 hours (HCT116) followed by 24 hour treatment with
BaP or PhIP. CYP1A1 (A, C), CYP1B1 (B, D) and miR27b (E, F) expression were measured by RT-qPCR. Data were normalised to expression of GAPDH
for gene expression or U6 RNA for miRNA expression and are shown relative to control. Statistically signiﬁcant diﬀerences were calculated using
one-way ANOVA with a Dunnett post-test (GraphPad Prism 5) and are shown for comparisons between vehicle vs. carcinogen treated samples
(***p < 0.001, **p < 0.01, *p < 0.05) and IL6 alone vs. IL6 pre-treated and carcinogen treated (†††p < 0.001, ††p < 0.01, †p < 0.05). Error bars
represent the SEM for independent cultures (n = 3).
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